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ABSTRACT
The mechanism by which the adenosine A2A receptor mediates the actions of multiple 
drugs of abuse is thought to be partly attributable to interactions with dopamine D2 
receptors in the striatum; a key structure in drug-related reward, reinforcement and 
motor responses. Evidence now suggests that this interaction could be further 
influenced by actions of the metabotropic glutamate receptor, mGlus, which is co­
expressed with striatal A2A and D2 receptors.
This work aimed to identify the role of A2A receptors in mediating the locomotor and 
stereotypic responses to chronic administration of cocaine, morphine and 
methamphetamine with the use of wild-type (WT) and adenosine A2A receptor knockout 
(KO) mice. Further, via quantitative autoradiography in WT and A2A KO mice, the 
experiments described in this thesis also investigated whether the A2A receptor was 
involved in the regulation of D2 and mGlus receptor binding, both under physiological 
conditions and following chronic cocaine, morphine and methamphetamine 
administration.
A significant reduction of mGlus, but not D2 receptor density was observed in the 
ventral striatum of treatment-naive A2A KO mice, giving further evidence for the 
presence of a striatal A2A-mGlu$ interaction at the receptor level. Chronic administration 
of methamphetamine, but not cocaine or morphine, caused a significant upregulation of 
striatal mGlug receptors in WT mice. This was accompanied by the manifestation of a 
stereotypic rearing behaviour in methamphetamine-treated WT mice, both of which 
were completely abolished in A2A KO mice, suggesting a drug-specific role of an A2A- 
mGlus receptor interaction in the methamphetamine-induced rearing response.
Furthermore, the combination of sub-threshold doses o f A2A and mGlus receptor 
antagonists significantly attenuated methamphetamine-induced rearing in WT mice, 
confirming that a striatal A2A-mGlug interaction was specifically involved in the 
mediation of this response.
Chronic morphine treatment caused an upregulation of thalamic mGlug receptors in A2A 
KO mice, indicating that an A2A-mGlu$ interaction may also be o f relevance in the 
mediation of morphine-induced antinociceptive tolerance. No changes in D2 receptor 
binding were observed in either treatment-naive WT or A2A KO mice, or those mice 
treated chronically with cocaine, morphine or methamphetamine, suggesting that the 
A2A receptor is not involved in modulating the receptor density o f D2 receptors either 
physiologically, or following chronic drug administration.
Collectively, the results described in this thesis show that the contribution of the A2A 
receptor in mediating the locomotor and stereotypic responses to chronic drug 
administration is drug-dependent, as is the ability of A2A to regulate mGlug receptor 
binding. Specifically, the therapeutic relevance o f the novel A2A-mGlu5 interaction 
identified following chronic methamphetamine administration merits further 
investigation, as it adds to a growing body o f evidence which suggest simultaneous 
targeting of A2A and mGlus receptors has implications for the improved efficacy of 
treatments of basal ganglia disorders and drug addiction.
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CHAPTER 1
General Introduction
1.1 The problem of drug addiction
1.1.1 Drug addiction in the UK
Drug addiction is a recognised mental health disorder, hallmarked by chronic relapse to 
drug taking. As defined by the Diagnostic and Statistical Manual of Mental Disorders, 
(DSM), substance dependence is characterised by three distinct criteria: (1) compulsion 
to seek and take the drug, (2 ) loss of control over drug intake and (3 ) the emergence of a 
negative emotional state upon drug cessation (Ameriean Psyehiatric Association., 
1994).
Clinically, the oceasional and limited use of an addictive drug is very distinct from the 
escalated drug use leading to substance dependenee. Drug use in the UK is most 
prevalent in the youth population (1 5 -2 4  year old) and it was reported that around 1 in 
5 youths in the UK had used an illicit substance in the last year (Smith and Flatley,
2011), however, the abuse of Class A substances such as cocaine, heroin or injectable 
amphetamines in this population was estimated at 3% (Smith and Flatley, 2011). 
Although a seemingly small pereentage. Class A drugs are the most addictive and 
harmful illicit substances and give rise to the most ‘problem’ drug users - those unable 
to control drug intake. In England, there are an estimated one third o f a million 
‘problem’ drug users, which has resulted in an annual government spend of around £ 1.2 
billion in implementing anti-drug use strategy (National Audit Office., 2010). In 
addition to this, the annual socioeconomic cost o f ‘problem’ drug users of heroin and 
crack cocaine is estimated at approximately £15 billion, primarily attributable to drug- 
related crime such as theft and burglary (Smith and Flatley, 2011). Moreover, drug 
users place a financial strain on the health service; in 2 0 1 0 -2 0 1 1 , drug-related mental 
health and behavioural disorders accounted for 6,640 hospital admissions in England
and almost 13,000 admissions were made for drug poisoning, the primary cause of 
drug-related death (Office o f National Statistics., 2011). In fact, the cost of healthcare 
services over the lifespan of just one ‘problem’ drug user is estimated at £3 5 ,0 0 0 , and 
when the cost o f crime is added it is approximated that the total life-time cost to the 
economy for each ‘problem’ drug user is around £480,000 (National Institute for Health 
and Clinical Excellence., 2009). Even so, these figures neglect the cost to society, loss 
of produetivity and the financial strain on the welfare system due to relianee of 
‘problem’ drug users on state benefits.
1.1.2 Current pharmacotherapeutic treatment strategies in drug addiction
By definition, ‘problem’ drug users/drug addicts are likely to relapse to drug seeking 
despite treatment interventions. The National Treatment Agency for Substance Misuse 
(2011) estimates that only 49-60% of opioid or coeaine users entering treatment for 
substance abuse during 2011 were still abstinent following 6  months rehabilitation. It 
must be noted however, that many ‘problem’ drug users are not motivated or obliged to 
enter substance abuse treatment programmes, so this figure may largely underestimate 
the relapse problem. Furthermore, there are notoriously few pharmaeotherapies for 
illicit (i.e. illegal) drug addiction (several exist for alcohol and nicotine addiction) and 
those that do exist are met with limited degrees of success (see Pieree et a l ,  2012). The 
focus of this current work will concern only the psychostimulants cocaine and 
methamphetamine (MAP), and the narcotic opioid, morphine. At present, the only 
available pharmaeological treatment strategy for opioid addietion is substitution therapy 
using opioid agonists, such as methadone and buprenorphine. Methadone is 
preferentially used due to its longer half-life and increased oral bioavailability; 
however, both drugs pose substantial addiction liability. As such, their availability is
controlled which can result in redueed compliance. Despite many years o f research, no 
pharmacotherapy currently exists for addiction to psychostimulant drugs such as 
cocaine, MAP or amphetamine (see Kampman, 2005). Recent focus on addiction 
therapeutics has seen the development o f anti-addiction vaccines for heroin, eocaine, 
MAP and nieotine addictions, many of which are in clinieal trials (see Shen et a l,
2012). Although these vaccines appear to have promising efficacy in reducing drug- 
seeking behaviour, particularly in cocaine addiction (Martell et a l ,  2009), legal and 
ethical implications may prevent these drugs reaching manufacture (see Harwood, 
2004).
1.1.3 The addiction cycle
Upon administration, all drugs of abuse activate the reward pathway in the brain to 
produce feelings of euphoria (see Section 1.3.3) and this positively reinforces the user to 
engage in repeated drug use. Repeated drug administration however, causes 
neuroadaptive tolerance to the drug’s rewarding effeets (see Koob and Le Moal, 2001), 
meaning increased amounts o f drug are required in an attempt to replicate the initial 
high. During this period, the positive reinforcement (euphoria) assoeiated with drug 
administration is gradually replaeed with negative reinforcement to prevent the 
emergence of a displeasurable withdrawal syndrome upon drug cessation. The loss of 
control over drug intake has been hypothesised to represent a transition from impulsive 
(positive reinforcement) to compulsive (negative reinforcement) motivated behaviour, 
whieh drives the eyclic nature of drug addiction. This ‘addiction cycle’ eomprises three 
stages: preoccupation, binge/intoxication and withdrawal/negative affect (see Koob and 
Le Moal, 2001).
The vulnerability to drug addiction is hypothesised to involve a complex interplay 
between genetics and environmental influences, in partieular stress and environmental 
contextual assoeiations. Predisposition to addiction is thought to have a genetic 
component in the region of 40 -  60% (Uhl, 2004), risks not just attributable to gene 
function alone, but how the environment may impaet on how these genes are regulated 
or expressed. Understanding the neurobiological mechanisms in driving vulnerability to 
drug addiction, and the transition from occasional drug use to substance dependence, 
are key aims of drug addiction research.
1.1.4 Maladaptive learning in addiction
In 1993, Robinson and Berridge proposed that the transition from casual (impulsive) to 
compulsive drug use eould be modelled by the ‘incentive sensitisation’ theory of 
addiction. This theory suggested that repeated administration of addictive drugs, under 
certain conditions, could result in a persistent hypersensitisation of brain cells and 
circuitry involved in motivated behaviour and therefore pathologically alter the 
incentive salience, the eue-induced psychological ‘wanting’, to drug-related stimuli 
(Robinson and Berridge, 1993). These detrimental alterations are hypothesised to 
represent the human manifestation of drug ‘wanting’ and drug craving which provide a 
motivational basis for drug seeking. Indeed, prolonged and persistent drug use causes 
profound dysfunctional behavioural changes in the drug user. Charaeteristieally, this is 
exhibited as eontinued drug use despite serious negative eonsequences such as job loss, 
relationship breakdowns, and pursuit o f criminal activity to attempt to finance the 
addiction. Additionally, there may be failed attempts at abstinence, a narrow 
behavioural focus on drug-seeking, impaired social functioning and emergence of 
cognitive defieits. It has been shown that prolonged drug taking can result in poor
decision making ability (Bechara and Martin, 2004), decreased working memory 
(Bechara and Martin, 2004, George et ah, 2008) and problems with attention and 
perception (Tomasi et a l ,  2007). The development, progression and persistence of these 
behavioural changes may be due to alterations in synaptic transmission in brain areas 
affected by addiction, including the learning and memory circuitry. Synapses here 
exhibit various types o f long-term plasticity, which occur as a result o f recurrent and 
continued drug use (Section 1.6.2). One form of maladaptive learning in drug addiction 
is the classical ‘Pavlovian’ conditioning between drug-related experiences (e.g. 
euphoria, withdrawal) and the surrounding environmental cues and contexts in which 
the drug was administered (see Robbins and Everitt, 2002). This means that when such 
associated stimuli are present in the absence o f the drug they can elicit expectation of 
drug availability, or evoke positive (euphoric) or negative (withdrawal) memories 
(London et a l ,  1996), arousal of which can lead to drug craving or drug-seeking 
behaviour, which when acted upon causes relapse to drug taking.
1.1.5 Behavioural paradigms commonly used in addiction research
Most of the recent progress in understanding addiction neurobiology has been derived 
from animal models of drug addiction, an invaluable resouree in assessing addiction- 
related behaviours. Although no single animal model can fully emulate the human 
condition, many different aspeets of addiction can be investigated in vivo.
Administration of psychostimulant drugs such as cocaine and MAP, and also morphine 
in rodents (see Raeagni et a l,  1979), produce a characteristie elevation of motor 
responses and as such, a common measure of the efficacy of drugs for anti-addiction 
potential is to assess their ability to reduce this hyperlocomotor phenotype. Locomotor 
behaviour is routinely assessed via use of specially-designed motility chambers which
utilise infra-red beam-break technology to calculate movements in horizontal and 
vertical planes.
Psychostimulant administration can also induce stereotypie behaviours (see Gold et a l,  
1989, Ridley, 1994), which are eategorised as repetitions of single or multiple 
movements with purposeless function, and commonly manifest in humans as repeated 
nail-biting, scratehing, pacing or circling. Psychostimulant-induced stereotypic 
behaviours in rodents were first characterised by Creese and Iversen (1972) and 
included head swaying or bobbing, stereotyped sniffing and grooming, rearing (standing 
on hind-limbs to produce vertieal movement) and oral stereotypies, such as licking and 
nibbling. Due to strain-, dose- and drug-specific stereotypic responses however, 
modified forms of this scale also exist (e.g. Schlussman et a l,  2003, Bailey et a l, 
2010). The manifestation of the psychostimulant-indueed stereotypic response disrupts 
normal goal-directed behaviours such as feeding, and patterns of stereotypic behaviour 
are similar to those exhibited in neuropsychiatrie disorders such as autism, 
schizophrenia, and obsessive-compulsive disorder (OCD). With the exception of 
vertical activity, which can be automated with beam-break apparatus, it is notoriously 
difficult to objectively categorise and record much other stereotypic behaviour in animal 
models. Although beam-break technology exists with greater temporal resolution in 
order to ‘record’ smaller movements, it has not been widely embraced, possibly due to 
concerns over misinterpretations in detailing the complexity of stereotypic behaviours. 
Much stereotypic behaviour can only be recorded by manual observation, whieh is time- 
consuming and prone to human error, and eonsequently means that stereotypie 
responses and their interpretation is quite an understudied phenomenon. As such, the 
majority of psychostimulant-induced behavioural studies tend to rely on automated 
locomotor data as an indicator o f psychomotor response (horizontal activity) and in far
fewer studies, stereotypy (e.g. vertical activity). The underlying neurobiological 
mechanisms o f locomotor and stereotypic responses will be further discussed in Section 
1.3.3.
In animals, the incentive-sensitisation theory of addiction can be modelled as 
behavioural sensitisation, which refers to an increase o f a drug-indueed effect upon 
repeat administration of that drug (Robinson and Becker, 1986). Traditionally, this is 
measured in terms of locomotor or stereotypic activity, although it is thought that 
locomotor sensitisation may only represent indirect evidence o f hypersensitivity of the 
motivation circuit, as it is sensitisation of this, and not the locomotor circuit, which 
contributes to the addictive ‘wanting’ for drugs (see Robinson and Berridge, 2008). 
Behavioural sensitisation occurs in two distinct temporal domains: initiation, 
comprising the immediate neural events that induce behavioural sensitisation and 
expression, the long-term consequences of these initial events (Pierce and Kalivas, 
1997). Often, expression of behavioural sensitisation is persistent even following long­
term abstinence from drug administration, as demonstrated by low dose ‘challenge’ 
drug injections following drug withdrawal (see Pierce and Kalivas, 1997). More 
specifically, direct evidence of ineentive salienee comes from studies designed to assess 
drug-induced changes in the reward-directed behaviour based on habit-leaming using 
the Pavlovian conditioned-stimulus approach (Di Ciano et a l ,  2007).
One such method used to study drug reward is the conditioned place preference (CPP) 
paradigm. The CPP apparatus usually consists of 3 chambers -  two larger tactilely, 
olfactorily or visually distinct compartments separated by a small connecting 
antechamber. During drug eonditioning, animals are placed into one of the larger 
distinct compartments and receive drug injections, allowing the animal to associate the
experience o f a drug with a specific environmental cue (see Tzsehentke, 2007). These 
drug conditioning sessions are alternated with saline conditioning sessions in the other 
large chamber, whieh is distinct from the drug-paired environment. Repeated 
conditioning in this way produces contextual associative learning between the euphoric 
and physiological effects of the drug with the environment in which it was received. 
Following this ‘conditioning phase’ the animal is placed in the antechamber and given 
the opportunity to explore both drug- and saline-paired compartments. In this ‘test 
phase’, CPP to the drug is observed if  the animal demonstrates an increased amount of 
time in the drug-paired compartment versus the saline-paired compartment. The CPP 
paradigm can be further divided into the acquisition and expression phases. 
Experimental manipulations, such as administration of receptor agonists or antagonists 
that are performed prior to drug-conditioning sessions give information about CPP 
acquisition, i.e. the effect on contextual learning. Manipulations immediately prior to 
the test session determine effects on the expression of CPP, the behavioural 
manifestation of the contextual learning.
The effect of drug reinforcement can be modelled in the self-administration paradigm 
(de Wit and Stewart, 1981), hypothesised to be a reliable predictor o f drug abuse 
liability in humans as it closely represents the human pattern of drug taking (Collins et 
a l,  1984). In this model, animals are catheterised to receive drugs intravenously upon 
operant responding, such as lever pressing, nose-poking or wheel-turning. Progressive 
ratio schedules of drug self-administration can directly evaluate the reinforcing effects 
o f the self-administered drug by increasing the response requirements for each 
successive dose. This allows the determination of a ‘break-point’, a response 
requirement level at which the animal stops responding for the drug as the effort to 
obtain it exceeds its reward value (Bedford et a l,  1978, Griffiths et a l,  1978).
Given the fundamental problem of relapse to drug taking in humans, understanding this 
phenomena is vital to the development of addiction pharmacotherapies. In animals, 
relapse to drug seeking can be modelled in the reinstatement paradigm. Following 
achievement of stable self-administration, animals undergo extinction training whereby 
the operant task previously associated with drug administration (e.g. lever press, wheel- 
tum or nose-poke) is disabled. This induces a forced abstinence which eventually 
extinguishes the frequency of operant behaviour. Following a withdrawal period, 
operant responding can be reinstated via presentation of one o f three stimuli: drug- 
paired cues (usually a conditioned visual or auditory stimulus), a stressor (such as foot- 
shock) or brief re-exposure to the drug, referred to as drug priming (see Shaham et a l, 
2003).
The use o f in vivo models of drug addiction has greatly enhanced our understanding of 
the various neurochemieal adaptations that occur in the brain as a result o f drug 
administration. In particular, they have identified a crucial role of dopamine (DA) and 
the dopaminergic (DAergic) system, especially in the rewarding and reinforcing aspects 
of addiction (Section 1.3). They have also highlighted an important role for the 
neurotransmitter glutamate in mediating drug-induced neural alterations (see Section 
1.6). In order to understand the signifieance o f these neurotransmitters in relation to 
addiction, a brief overview of the role of the basal ganglia and striatal neuroeircuitry in 
mediating drug-induced behaviours will be discussed (see Section 1.2).
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1.2 The basal ganglia and striatum as components of addiction 
neuroeircuitry
The basal ganglia are a group o f nuclei in the brain associated with functions such as 
motor control (Obeso et a l,  2008), habit formation (Yin and Knowlton, 2006), 
motivation (Shohamy, 2011) and learning (Graybiel et a l,  1994, Graybiel, 2005). Given 
these functions, it is not surprising that drug addiction causes complex alterations in the 
basal ganglia circuitry. As shown in Figure 1.1, the nuclei of the dorsal basal ganglia 
comprise the dorsal striatum (caudate putamen, CPu), the globus pallidus (GP), the 
substantia nigra pars compacta (SNc) and pars recticulata (SNr) and the subthalamic 
nucleus (STN). The ventral basal ganglia incorporates limbic structures such as the 
ventral component of the striatum , the nucleus accumbens (Acb), the ventral pallidum 
(VP) and the ventral tegmental area (VTA).
The main input structure of the basal ganglia is the striatum, which is anatomically and 
functionally divided into the dorsal and ventral areas, corresponding to the parts 
receiving motor and limbic information, respectively. The dorsal striatum is involved in 
the learning o f complex motor acts (Graybiel, 1995) and as shown in Figure 1.1, 
receives glutamatergic inputs from sensorimotor- and association- cortical areas and 
DAergic input from the SNe (Parent and Hazrati, 1995). In addition to the Acb, the 
ventral striatum also comprises the olfactory tubercle (Tu). In non-human primates, the 
sub-regions o f the striatum have been shown to be organised in a series of parallel 
circuits which are linked in an ascending spiral (Haber et a l ,  2000). This serial 
connectivity between the ventral and dorsal sub-regions of the striatum supports current 
theories which propose that the transition from impulsive to eompulsive drug seeking 
underlies the development of addiction (see Everitt et a l, 2008).
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Figure 1.1: Representation of the motor components of the basal ganglia 
circuitry including the dorsal and ventral striatum. Main structures and connections 
of the basal ganglia are highlighted, in particular the ascending dopaminergic pathways: 
nigrostriatal (blue), mesolimbic (green) and mesocortical (red). The GABAergic striatopallidal 
(enkephalin-containing) and striatonigral (dynorphin-containing) neurons are further 
distinguished by the presence of either dopamine D] and adenosine A2A receptors or dopamine 
Di and adenosine Ai receptors respectively. Acb, nucleus accumbens; CPu, caudate putamen; 
DA, dopamine; GABA, y-aminobutyric acid; GLU, glutamate; GP, globus pallidus; mPFC, 
medial pre-frontal cortex; PMC, premotor cortex; SNc, substantia nigra pars compacta', SNr, 
substantia nigra pars reticulata', STN, subthalamic nucleus; Th, thalamus; VP, ventral pallidum; 
VTA, ventral tegmental area. Adapted from Ferre et al (1997) and Muller and Ferre (2007).
Over 90% of neurons originating in the striatum are GABA (y-aminobutyric acid) -ergic 
medium spiny neurons (MSNs), so-called due to their large number of dendritic 
branches or ‘spines’. Dendritic spines are highly plastic, physically adaptive structures 
and this plasticity is primarily regulated by glutamatergic transmission (see Section 1.6).
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Long-lasting alterations in spine number have been reported in many neuropsychiatrie 
disorders, including drug addiction (see Kalivas et a l,  2009, Grueter et a l ,  2011). The 
synaptic architecture of the dendritic spines o f the striatopallidal GABAergic neurons 
involves midbrain (either mesolimbic or nigrostriatal) DAergic innervation at the neck 
of the dendritic spine and cortical glutamatergic input at the spine head (Figure 1.2). 
This framework suggests that DA, acting at DA receptors, can modulate corticostriatal 
glutamate transmission in these neurons (Bamford et a l ,  2004) with potential to 
regulate these plastic changes.
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Figure 1.2: Schematic representation of a dendritic spine in the GABAergic 
striatopallidal neuron. Cortical glutamatergic transmission makes contaet at the head of 
the spine, whereas dopaminergic input from the midbrain converges on the spine neek. This 
anatomical framework allows dopamine and adenosine to play a modulatory role in the 
excitatory effects of glutamate at this location. Receptors of interest are shown: Ai, adenosine 
Ai receptor; A2A, adenosine A ja reeeptor; D2, dopamine D2 receptor; mOlus, metabotropie 
glutamate reeeptor subtype 5; NMDA, A-methyl-D-aspartic aeid ionotropie glutamate receptor. 
More detail about the function and localisation of these receptors, ineluding the proposed 
presynaptic localisation of mGlug receptors in striatal glutamatergic terminals (as indieated by 
‘?’ symbol. Section 1.7.2) is provided in the text. DA, dopamine; GABA; y-aminobutyric acid; 
GLU, glutamate. Adapted from Ferre et al. (2004), and Fuxe et al. (2007a).
Striatal GABAergic MSNs form two neurochemically and anatomically distinct 
populations which, in the dorsal striatum, have opposing actions on motor control to 
allow fine tuning of motor regulation. Striatonigral neurons, connecting the striatum to 
the SN, contain the peptides dynorphin and substance P and are also referred to as the 
direct motor pathway. Stimulation of the direct pathway increases exeitatory thalamic
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input to the motor cortex, thereby increasing motor activity. Conversely, the 
striatopallidal neurons, connecting the striatum to the GP, contain the peptide 
enkephalin (Gerfen and Young, 1988) and are referred to as the indirect motor pathway. 
Stimulation o f these neurons results in increased inhibition of the thalamic neurons and 
therefore reduces motor activity (Alexander and Cruteher, 1990). Both pathways are 
modulated by DA, whieh is synthesised in the SNc and VTA and released as a 
consequence of neuronal firing. DA acts on two families o f G-protein coupled DA 
receptors: the Di-like family, comprising Di and D5 receptors, and the D2-like family, 
comprising D2, D3 and D4 receptors. These receptors will be further discussed in Section 
1.3.2. The striatonigral neurons in the direet pathway contain a large density of 
stimulatory Gs/oirprotein coupled Di receptors; whereas the striatopallidal neurons of 
the indirect pathway contain a large number o f inhibitory Gj/o-protein coupled D2 
receptors. As such, increases of extracellular DA in the striatum, such as those induced 
by administration of addictive drugs (see Section 1.3.3), causes amplified motor 
activity. This is due to the stimulatory action of DA at Di receptors in the direct 
pathway and the disinhibition of motor activity via DAergic activation o f inhibitory D2 
receptors in the indirect pathway (Alexander & Crutcher, 1990).
In contrast, the ventral striatum appears to have a larger role in mediating motivational 
and reward based behaviours due to its large connectivity to the limbie system. The 
ventral striatum mainly receives input from allocortical regions such as the amygdala 
and hippocampus, and also from neocortical areas involved in emotional expression 
such as the prefrontal eortex (see Meredith et a l,  2008). The Acb, a major part o f the 
ventral striatum, is a heterogeneous structure composed of two anatomically distinct 
sub-regions: the ‘core’ and the ‘shell’, whieh are thought to differentially mediate the 
reinforcing effects of drugs of abuse (see Di Chiara, 2002). The Acb shell (AcbSh) is
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classified as part of the limbic system and receives glutamatergie innervation primarily 
from the amygdala and DAergic input from the VTA. The AcbSh is implicated in the 
primary rewarding effects of drugs of abuse (Shin et a l, 2008), and is thought to have a 
general role in mediating unconditioned behavioural responses such as spontaneous 
locomotion (Ito et a l, 2004). The Acb core (AcbC) however, is considered part of the 
basal ganglia and receives glutamatergie input from the hippocampus and DAergic 
input from both the VTA and SN. The AcbC has a more prominent role in modulating 
goal-directed exploratory activity, new instrumental learning and behavioural responses 
to conditioned stimuli, such as cue-conditioned responses to cocaine seeking (Fuchs et 
a l, 2004, Ito et a l,  2004). As a whole, the Acb can therefore function as an interface 
between limbic and motor systems, processing affective and motivational information 
from the limbic system and integrating it with the basal ganglia to produce appropriate 
behavioural responses. As such, ventral striatopallidal neurons are important in the 
conversion of motivation to action, and form a common pathway for the rewarding 
effects of psychostimulants (see Koob, 1996, 1999).
1.3 Dopamine and D% receptors
13.1 The basal ganglia dopaminergic circuitry
In addition to its role in regulating physiological motor function, DA signalling in the 
basal ganglia also modulates motivated behaviours and natural rewards (see Kelley and 
Berridge, 2002, Berridge, 2007). As can be seen in Figure 1.1, DA comprises three 
ascending systems in the basal ganglia, namely the mesolimbic, mesocortical and 
nigrostriatal pathways. DA neurons arising from the SNc ascend to the CPu to form the 
nigrostriatal pathway, degeneration of which is observed in Parkinson’s disease 
resulting in the profound motor function deficits characteristic of this disorder (see
16
Obeso et a l ,  2000). The two ascending DAergic pathways arising from the VTA project 
to either various limbic structures (Acb, hippocampus, lateral septum, VP, amygdala) or 
to cortical areas (prefrontal cortex (PFC), orbitofrontal cortex and anterior cingulate) 
forming the mesolimbic and mesocortical pathways, respectively. These systems, 
sometimes together termed the mesocorticolimbic pathway, operate in parallel and have 
been shown to be central to the drug addiction process, partieularly drug reward (see Le 
Moal and Simon, 1991, Wise, 1996).
1.3.2 The dopamine D2 receptor and vulnerability to addiction
As mentioned earlier (Section 1.2), DAergic signalling is mediated by five distinet G- 
protein coupled receptors divided into two receptor families: the Gs/oirprotein coupled 
Di-like family (Di and D 5) and the Gj/o-protein coupled Di-like family (D2 , D3 and D4 ) 
(Alexander et a l,  2011). This classification is generally based on biochemieal evidence 
relating to the opposite modulation of adenylyl cyclase (AC) activity. It is commonly 
agreed that the Di-family activate Gj/oif coupled proteins to stimulate cyclic AMP 
(cAMP) production, whereas the D2-like family couple to Gi/o proteins to inhibit AC 
formation (see Beaulieu and Gainetdinov, 2011).
The striatal GABAergic MSNs possess a high density of both Di and D2 receptors, 
which are located on striatonigral and striatopallidal neurons respectively (see Figure 
1.1). There is a distinct role of the Di receptor in drug addiction, particularly in cocaine 
addietion, however, detailed discussion of the action of the Di receptor in drug 
addiction is largely beyond the scope of this thesis. The reader is directed to reviews on 
this subject (see Hummel and Unterwald, 2002, Caine et a l ,  2007). The focus of the 
current thesis coneems the DA D2 receptor, which has a prominent role in addiction 
processes, particularly in the vulnerability to drug use (see Nader and Czoty, 2005),
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drug reward (Maldonado et a l ,  1997) and motor activation associated with drug 
administration (Kelly et a l,  1998). D% receptors are most highly expressed in the 
striatopallidal neurons, where they are found pre-, post- and peri-synaptically at the 
DAergie synapse, but also pre- and postsynaptically around the glutamatergic synapse 
(Yung et a l ,  1995, Delle Donne et a l,  1997) where they can exert modulatory effects 
on glutamatergic transmission (Bamford et a l,  2004) (Figure 1.2). Two isoforms of the 
D2 receptor have been identified; namely the D2L (long) and D2S (short), which occur 
as a consequence o f splicing of the D2 receptor gene, DRD2 (Dal Toso et a l,  1989, 
Giros et a l, 1989, Monsma et a l,  1989). Generally, the D2L form is more abundantly 
expressed in mouse brain as approximately 90% of total D2 in the striatum is 
attributable to D2L mRNA (Mack et a l,  1991). It has been shown that D2L reeeptors are 
mainly postsynaptic, whereas D2S receptors serve as presynaptic autoreceptors (Usiello 
et a l,  2 0 0 0 ).
A large body o f evidence supports a link between polymorphisms in the DRD2 gene 
and alcoholism (see Noble, 2000), but this also extends to opioid (Chen et a/., 2011) and 
cocaine (Noble et a l ,  1993) addictions and methamphetamine-induced psychosis (Ujike 
et a l,  2009). Further to this, positron emission tomography (PET) studies in humans 
have consistently demonstrated decreased striatal D2 receptor number in cocaine, 
heroin, methamphetamine and alcohol addicts (Voikow et a l,  1996, Voikow et a l,  
1997, Wang et a l ,  1997, Voikow et a l,  2001), a finding which has been shown to 
persist following drug detoxification (see Voikow et a l,  2004b). Also, decreased D2 
receptor levels are observed following chronie cocaine self-administration in monkeys 
(Moore et a l ,  1998, Nader et a l ,  2002) and low D2/D3 number in the ventral striatum of 
impulsive rats predicts their vulnerability to escalate cocaine intake (Dailey et a l,
2007). It is thought that escalated drug intake may lead to further neuroadaptations.
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including D2 receptor down-regulation at the protein level in the dorsal striatum, which 
can lead to rapid consolidation of drug-seeking habits. These habits become compulsive 
and difficult to abandon, and as such are readily reinstated following drug abstinence. 
This ventral to dorsal striatal shift, supported by anatomical evidence of linked circuitry 
(Haber et a l ,  2000), is another important hypothesis which may underlie the transition 
from voluntary to habitual drug seeking (see Everitt et a l,  2008).
Moreover, eocaine addicts show decreased DA cell activity as measured by PET which, 
in addition to the reduced striatal D2 receptor density, may indicate a decreased output 
of DA circuitry (Voikow et a l ,  1997). Interestingly, it was also shown that D2 receptor 
number in alcoholic individuals were significantly decreased versus their non-addicted 
familial counterparts suggesting that, in line with the above data, high D2 reeeptor levels 
may protect against drug self-administration (Volkow et a l ,  2006). This is further 
supported by preclinical evidence showing that mice overexpressing the D2 receptor 
exhibit reduced alcohol self-administration (Thanos et a l,  2001). Although this implies 
role for decreased D2 receptors following drug administration, it is not clear whether an 
inherently lower number of D2 receptors contributes to, or is the cause of, addiction 
predisposition.
1.3.3 Dopamine and the D2 receptor in drug addiction
Classically, most research in the drug addiction field has foeussed on DAergic systems 
because both natural rewards, and the ‘reward’ obtained by taking drugs o f abuse, 
acutely increases DA release in the Acb (Hernandez and Hoebel, 1988, Carboni et a l, 
1989, Mifsud et a l ,  1989, Rada et a l,  1991). The reward produced by addictive drugs is 
invariably larger and more robust than those produced by natural reinforcers such as 
food (see Di Chiara and Bassareo, 2007) and is hypothesised to drive the positive
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reinforcement for drug re-administration. The mechanism by which this increase occurs 
varies between drug type, although it tends to involve actions directly at the Acb (e.g. 
cocaine and amphetamines) or indirectly at the VTA (e.g. opioids), thereby heavily 
implicating a role for the mesolimbic pathway in drug reward and reinforcement (see 
Pieree and Kumaresan, 2006). This is further confirmed by evidence of attenuated 
heroin and cocaine self-administration, a model of drug reinforcement, upon lesions of 
the Acb, VTA or VP (Roberts et a l,  1980, Roberts and Koob, 1982, Hubner and Koob, 
1990). Additionally, microdialysis studies have reliably shown that extracellular DA 
concentrations in the Acb are increased during morphine, cocaine and amphetamine 
self-administration (Pettit and Justice, 1989, Di Ciano et a l ,  1995, Pontieri et a l ,  1995) 
and self-administration of a number of drugs of abuse is attenuated upon administration 
of DA receptor antagonists (Woolverton, 1986, Rassnick et a l ,  1992, Richardson et a l,  
1994) or neurotoxic 6 -hydroxydopamine (6 -OHDA) lesioning of the aecumbal DAergic 
pathways (Roberts et a l,  1980, Pettit et a l,  1984, Zito et a l,  1985).
The motor stimulant effect of psychostimulant drugs are reported to result in part from 
drug-induced elevations in DA concentrations in the DA mesocorticolimbie system 
(Kalivas and Stewart, 1991, Kalivas and Duffy, 1993, Robinson and Berridge, 1993, 
Neisewander et a l ,  1995) in particular, DAergic transmission in the mPFC. It has been 
shown that repeated electrical kindling o f the mPFC in rats produced an augmented 
response to cocaine challenge (Schenk and Snow, 1994). Moreover, 6 -OHDA lesions of 
the mPFC have been demonstrated to enhance locomotor sensitisation to amphetamine 
(Banks and Gratton, 1995) and also both the motor-stimulant response to coeaine and 
cocaine-induced DA concentrations in the Acb (Beyer and Steketee, 1999). 
Furthermore, direct injection of the Dz receptor agonist quinpirole into the mPFC dose- 
dependently blocked both cocaine-induced DA overflow in the Acb and the acute and
2 0
sensitisation motor-stimulant responses to cocaine (Beyer and Steketee, 1999, 2002), 
which suggests that mPFC D2 reeeptors are important in mediating the locomotor 
activating effects of psychostimulants. As discussed in Section 1.1.5, administration of 
psychostimulants also causes the emergence of stereotypic behaviours. Less is known 
about the neuroanatomical and neurochemieal regulation o f stereotypic-like responses 
to psychostimulants, although dysregulation of the basal ganglia and frontal cortex is 
implied (see Ridley, 1994). Early evidence indieated a role for striatal DAergic 
involvement, as psychostimulant-induced motor stereotypies were abolished by 6 - 
OHDA lesions of the striatum (Fibiger et a l,  1973, Creese and Iversen, 1973). 
Moreover, administration of Di and D2 reeeptor agonists enhanced stereotyped 
behaviours in amphetamine-primed animals (Kuezenski and Segal, 1999) which was 
thought to be attributable to stimulation of Di and D2 receptors in the CPu (Staton and 
Solomon, 1984). In fact, microinjections of amphetamine into the CPu increased 
stereotypy without having effect on locomotor behaviour, whereas amphetamine 
microinjected into the Acb produced the opposite response -  increased locomotion 
without effect on stereotypy (Staton and Solomon, 1984). This suggests a role for 
DAergic transmission in discrete subregions of the striatum in mediating 
psychostimulant-induced locomotor and stereotypic behaviours.
Further to its role in drug-induced locomotor responses, systemie pharmaeological 
antagonism of the D2 receptor has also been shown to prevent cocaine-, amphetamine- 
(Amit and Smith, 1992, Fletcher, 1998) and morphine- (David et a l ,  2002) self­
administration, indicating a prominent role of D2 receptors in drug reinforcement. In 
the 1990’s, however, the high sequence homology between the D2-like family of 
receptors led to uncertainty o f the pharmacological selectivity o f DAergic ligands 
between their receptor subtypes (Burris et a l, 1995), which led to the development of
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the D2 receptor knockout (KO) mouse (Baik et a l,  1995). Studies using D2 KO mice 
showed a role for the D2 receptor in the rewarding effects of morphine as these mice 
failed to develop morphine-induced CPP (Maldonado et a l,  1997), an effect which was 
later found to be attributable to D2L receptor function (Smith et a l,  2002). This was in 
agreement with studies showing that pharmacological antagonism of D2 receptors 
disrupted amphetamine-induced CPP (Liao et a l, 1998), however, CPP to cocaine was 
unaffected (Cervo and Samanin, 1995, Liao et a l ,  1998). Similarly, despite increased 
extracellular striatal DA release upon administration of either eoeaine or morphine 
(Rouge-Pont et a l ,  2002), D2 KO mice readily self-administered cocaine (Caine et a l, 
2002), but not morphine (Elmer et a l,  2002). These studies suggest that the 
neurobiological mechanisms underlying reward and reinforcement differ between 
psychostimulant and opioid addictions.
Despite evidence implicating a beneficial role for D2 antagonists in reducing drug 
reward and reinforeement, the serious extrapyramidal side effeets associated with their 
use have prevented them being a clinically successful addiction pharmacotherapy. 
Recently however, use o f D2 receptor partial agonists, such as aripiprazole, have shown 
some preelinical benefit in reducing both cocaine reinstatement (Feltenstein et a l,  2007) 
and MAP self-administration (Wee et a l,  2007). Partial agonists bind to a receptor site 
in the same way as a full receptor agonist, but elieit intermediate efficacy. This means 
that in states of high DAergic tone, such as drug administration, a D2 partial agonist can 
act as a D2 antagonist (Clark et a l,  1991). Unfortunately, due to small sample size, the 
clinical efficacy of aripiprazole in treating drug addiction is currently unclear (Meini et 
a l,  2011, Haney et a l ,  2011).
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As direct D2 receptor blockade appears not to be a viable option in addiction 
pharmacotherapy, approaches are now focusing on regulation of D2 receptor function. 
One such hypothesis is that D2 receptor function can be manipulated via its physical 
interactions with other endogenous receptor subtypes, such as the adenosine A2A 
receptor. This interaction has been explored in great detail over the last 15 years, both in 
physiological and pathological states, and its role in drug addiction will be discussed in 
Section 1.5.2.
1.4 Adenosine and adenosine A%A receptors
1.4.1 General properties o f  adenosine
Adenosine is an endogenous purine nucleoside which is formed by the breakdown of 
intra- or extracellular adenine nucleotides (see Zimmermann, 2000). Under normal 
physiological conditions, intracellular adenosine triphosphate (ATP) is broken down to 
adenosine diphosphate (ADP) releasing energy for cell metabolism (Figure 1.3). ATP is 
then regenerated from ADP molecules via oxidative phosphorylation to provide a 
balance of energy. In the absence o f oxygen however, ATP cannot be renewed, 
resulting in intracellular ATP depletion and ADP accumulation. In these conditions, the 
enzyme adenylate kinase phosphorylates and dephosphorylates ADP molecules to 
produce both ATP and adenosine monophosphate, respectively (Newby, 1984). 
Adenosine monophosphate (AMP) is metabolised by 5’-nucleotidase to produce 
adenosine which, once exported out of the cell via adenosine transporters (see 
Zimmermann et a l,  1998), acts on cell-surface receptors to increase blood flow and 
therefore oxygen levels. As such, adenosine is generally formed in conditions of 
oxidative stress, such as hypoxia (Fowler, 1989) and ischemia (Pedata et a l,  2001).
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Figure 1.3: Intracellular and extracellular formation of adenosine in the 
brain. A simplified representation of the formation of adenosine by enzymatic degradation of 
adenine nucleotides, both inside and outside of the cell. AMP, adenosine monophosphate; ADP, 
adenosine diphosphate; ATP, adenosine triphosphate; NT, neurotransmitter. Adapted from 
Dunwiddie and Masino (2001).
In the brain, adenosine is more commonly produced as a result o f ATP co-release with 
neurotransmitters, such as glutamate or DA, as a consequence o f neuronal firing (see 
Sperlagh and Vizi, 1996) (Figure 1.3). Once outside the cell, ATP is then 
dephosphorylated by ecto-nucleotidases to form adenosine. Extracellular adenosine 
exerts its action via four cell-surface G-protein coupled adenosine receptors, A%, A2A, 
A2B and A3 (Fredholm et a i,  1994). As can be seen in Table 1.1, adenosine Ai and A3 
receptors are primarily coupled to Gi/o proteins, which upon activation inhibit the 
activity of AC. Conversely, activation o f adenosine A2 receptor subtypes, A2A and A2B,
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stimulate AC due to their Gg-protein coupling. The differential coupling, localisation 
and affinity of these receptors for adenosine (see Table 1.1) allow adenosine to regulate 
brain functions in both physiological and pathological conditions, and allow a high 
degree of complexity in modulating other neurotransmitter systems (see Boison, 2008).
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1.4.2 Striatal adenosine receptors
It is well known that structures o f the basal ganglia, such as the striatum, play an 
important role in the pathogenesis of drug addiction (see Section 1.2). The adenosine Ai 
receptor is widely expressed in the brain, including a significant density in the striatum 
(Fastbom et a l ,  1987). In particular, Ai receptors are expressed in GABAergic 
striatonigral neurons where they are co-localised and functionally interact with DA Di 
receptors (see Figure 1.1) to regulate motor responses (Ferre et a l ,  1994b, Ferre et a l, 
1996a, 1996b). Additionally, Ai receptors are also found presynaptically in striatal 
glutamatergic nerve terminals where they are co-localised (see Figure 1.2) and 
functionally interact with adenosine A%A receptors to modulate glutamatergic 
neurotransmission (Ciruela et a l,  2006). Unlike Ai receptors, A2A receptors are almost 
exclusively restricted to the striatum, specifically the GABAergic striatopallidal neurons 
(Svenningsson et a l,  1999), although small numbers of high-affmity extrastriatal A2A 
receptors have also been identified autoradiographically in the hippocampus and 
cerebral cortex (Cunha et a l,  1996) and immuohistochemically in the extended 
amygdala, thalamus, cerebellum and hindbrain (Rosin et a l, 1998). A2A receptors on 
GABAergic striatopallidal neurons have also been identified postsynaptically around 
the DAergic synapse (Hettinger et a l, 2001). However, the highest expression of A2A 
receptors are found postsynaptically in the glutamatergic synapse o f the striatopallidal 
dendritic spines (Figure 1.2) (Schiffmann et #7,1991, Hettinger et a l ,  2001).
Polymorphisms of the gene encoding the A2A receptor, AD0RA2A, are linked to a 
number of pathological disorders associated with striatal dysfunction such as 
Parkinson’s disease (Hong et a l,  2005, Popat et a l, 2011), panic disorder (Alsene et a l,  
2003, Hamilton et a l ,  2004, Marchand et a l, 2009, Hohoff et a l ,  2010) and autism (Di
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Martino et a l ,  2009, Freitag et a l,  2010). The A2A receptor is also involved in the 
arousal effect of caffeine (Huang et a l, 2005, Lazarus et a l ,  2011); the world’s most 
widely used psychostimulant. Unsurprisingly, AD0RA2A  polymorphisms have been 
linked to caffeine sensitivity and sleep quality (Retey et a l ,  2007) and also caffeine- 
induced anxiety (Alsene et a l ,  2003, Childs et a l,  2008). Additionally, a role for the 
A2A receptor has been widely implicated in schizophrenia (see Ferre, 1997, Wardas,
2008), where AD0RA2A  polymorphisms have also been observed (Hong et a l,  2005, 
Jagannathan et a l ,  2010). Interestingly, schizophrenic-like symptoms such as 
stereotypy, impaired cognition and psychosis are often observed following chronic 
psychostimulant administration. Moreover, methamphetamine-induced psychosis was 
recently linked to ADORA2A polymorphisms in the Japanese population (Kobayashi et 
a l, 2010). Imbalances in AD0RA2A  expression are also observed in sufferers of Lesch- 
Nyhan disease (Garcia et al., 2012), a neurological condition which manifests as severe 
obsessive-compulsive self-injurious behaviour. These types o f repetitive stereotypic 
behaviours are also evident following chronic psychostimulant administration (see 
Langen et a l, 2011) and which may occur as a result of dysregulation of the dorsal 
striatum in mediating habit-forming behaviours.
1.4.3 The adenosine A 2A receptor knockout mouse
In 1997, the adenosine A2A receptor was the first adenosine receptor subtype to be 
genetically deleted in mice and was created on the outbred CD-I background (Ledent et 
a l, 1997). The global deletion of the A2A receptor in these mice was intended to further 
clarify the role the A2A receptor without concerns over the pharmacological specificity 
of adenosinergic ligands. Following this, other A2A KO lines were developed on 
different genetic backgrounds, which included the pure inbred 129-Steel (Chen et a l .
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1999) and 129-Steel x C57BL/6J hybrid strains (Chen et a l ,  2000). Combined, these 
models provide a valuable in vivo approach to investigate A2A receptor function.
Initial characterisation of the A2A KO phenotype mainly focused on behavioural 
parameters associated with basal ganglia function due the prominent localisation of A2A 
receptors in the striatum. In agreement with much of the human literature, results 
showed that A2A KO mice had a more anxious phenotype, displayed reduced 
exploratory activity and had a depressed motor response to caffeine (Ledent et a l,  
1997). Additionally, in vivo microdialysis revealed that in comparison to their intact 
wild-type controls, A2A KO mice had reduced DAergic, but increased glutamatergic 
release in the striatum (Dassesse et a l,  2001), emphasising the role o f A2A receptors in 
striatal neuromodulation. Furthermore, A2A KO mice had reduced sensorimotor gating 
as measured by pre-pulse inhibition (PPI), and reduced startle habituation responses 
(Wang et a l ,  2003), parameters that are both attenuated in human schizophrenics (see 
Braff et a l ,  2001). A2A (and Ai) receptor KO mice have also shown to display fewer 
involuntary movements in models of Parkinson’s disease (Xiao et a l ,  2011). Finally, 
striatal-specific A2A KO mice (str-KO) displayed impaired habit formation (Yu et a l,
2009), which may be linked to the phenotypic obsessive-compulsive behaviours 
observed in Lesch-Nyhan disease (Garcia et a l ,  2012), suggesting that striatal A2A 
receptors are important for instrumental learning. These results suggest that due to both 
their prominent striatal density and neuromodulatory roles, dysregulation of A2A 
function is key to many disorders of the basal ganglia.
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1.5 The A2A-D2 receptor interaction and its role in drug addiction
1.5.1 The A 2A-D2 receptor interaction
As mentioned previously, both adenosine A%A and DA D2 receptors are found on 
GABAergic striatopallidal neurons (Schiffmann et a l ,  1991, Hettinger et a l,  2001), 
where they are co-localised and hypothesised to exist as a functional receptor 
heterodimer (Fink et a l ,  1992, Hillion et a l,  2002, Canals et a l ,  2003). Early studies 
suggested a link between adenosinergic and dopaminergic systems when it was 
observed that in rat models of Parkinson’s disease (6 -OHDA lesion of the SN), 
administration of the non-selective Ai and A2A receptor antagonists, theophylline and 
caffeine, increased contralateral turning behaviour induced by DA receptor agonists 
(Fuxe and Ungerstedt, 1974). Subsequent development o f selective A2A receptor 
ligands showed that the A2A agonist, CGS 21680 (4-[2-[[6-amino-9-(N-ethyl-b-D- 
ribofuranuronamidosyl)-9H-purin-2-yl] amino] ethyl] benzenepropanoic acid), reduced 
the binding affinity o f D2 receptors for DA agonists in both rat striatal membranes and 
transfected cell lines (Ferre et a l,  1991, Ferre et a l, 1993b, Dasgupta et a l ,  1996). 
Later, it was discovered that A2A activation also counteracted D2-receptor mediated 
intracellular calcium reduction (Salim et a l,  2000), a main mechanism in D2-receptor 
mediated suppression of striatopallidal neuronal activity (Figure 1.4) (Hernandez-Lopez 
et a l, 2000). These studies were the first to suggest a close localisation o f A2A and D2 
receptors in the striatum and a functional ability of A2A receptor activation to 
conformationally change the D2 receptor binding site to prevent D2-receptor mediated 
effects.
Conversely, a reciprocal D2-A2A receptor interaction has been shown to exist at the AC 
level. Activation of the D2 receptor inhibits A2A receptor-mediated activation of AC and
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consequently prevents accumulation of cAMP, phosphorylation of cAMP response 
binding element protein (CREB) and expression of the intermediate early gene, c-fos 
(Kull et a l ,  1999). Similar effects were observed in striatal slices whereby activation of 
Di receptors completely antagonised AzA-receptor mediated phosphorylation of 
dopamine- and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) (Svermingsson et 
a l,  1998), an intracellular signalling phosphoprotein highly abundant in the striatum 
(Walaas et a l, 1983, Ouimet et a l, 1984) which is associated with both modulation of 
the actions of drugs of abuse (see Svenningsson et a l ,  2005) and the regulation of 
neural plasticity (Valjent et a l, 2005).
Studies utilising in vivo microdialysis showed that administration of A2A agonists into 
either the ventral or dorsal striatum reversed the D2-mediated decrease in extracellular 
pallidal G ABA concentrations, indicating A2A receptors can control the inhibitory role 
of D2 receptors on neuronal excitability (Ferre et a l,  1993a, Ferre et a l ,  1994a). 
Further, administration o f A2A agonists counteracted D2-agonist induced motor 
activation in vivo, both physiologically (Rimondini et al., 1998) and in a model of 
Parkinson’s disease (Stromberg et a l, 2000). Given the therapeutic benefit o f DA 
agonists in improving striatal DAergic transmission in Parkinson’s disease, A2A 
antagonists have been proposed as novel anti-Parkinsonian therapy based on the 
antagonistic A2A-D2 receptor interaction (see Fuxe et a l, 2007b). In fact, the novel A2A 
antagonist SCH 420814 (Preladenent) is currently in Phase III clinical trials for 
treatment o f motor impairments in Parkinson’s disease (see Salamone, 2010, Hauser et 
#7,2011).
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Figure 1.4: Mechanisms involved in the biochemical reactions between 
adenosine A%A receptors and dopamine D% receptors. The antagonistic D2-A2A 
receptor interaction at the AC level means that D2 receptor activation inhibits A2A receptor 
mediated cAMP accumulation and PKA activation leading to DARPP-32 and CREB 
phosphorylation. Additionally, D2 receptor stimulation activates PLC which activates 
caicineurin to inactivate L-type VDCCs and reduce neuronal excitability. The reciprocal A2A-D2 
receptor interaction occurs at the receptor binding level, whereby administration of A2A receptor 
antagonists cause a conformational change in the D2 receptor binding site for dopamine 
agonists. AC, adenylyl cyclase; ADE, adenosine; ATP, adenosine triphosphate; Ca^ ,^ calcium; 
cAMP, cyclic adenosine monophosphate; CREB, cAMP-response element binding protein; DA, 
dopamine; DARPP-32, dopamine and cAMP regulated phosphoprotein molecular weight 
32kDa; PKA, protein kinase A; PLC, phospholipase C; MAPK, mitogen-activated protein 
kinases; L-type VDCC, long-lasting voltage-dependant calcium channel. Adapted from 
Svenningsson et al. (1999) and Ferre et al. (2004).
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1.5.2 The Â 2A receptor in drug addiction
In both the glutamatergic and DA synapses of GABAergic striatopallidal neurons, A2A 
receptors are shown to be co-expressed with and functionally interact with DA D2 
receptors (Schiffmarm et a l,  1991, Fink et a l ,  1992, Fuxe et a l ,  2007a). The co- 
localisation and functional interaction between the A2A and D2 receptors in the dendritic 
spines of GABAergic striatopallidal neurons (see Figure 1.2) allows adenosine and DA 
to modulate the excitatory effects of glutamate at this location (Tozzi et a l ,  2007). A 
growing body o f evidence has shown that the A2A receptor is implicated in addiction- 
related behaviours such as locomotor responses, reinforcement, reward, withdrawal and 
reinstatement (Tables 1.2 and 1.3). As the focus of this thesis involves cocaine, opioid 
and methamphetamine addictions, the role of the A2A receptor in alcohol and nicotine 
addictions is not discussed. The reader is directed to reviews on this literature by 
Brown and Short (2008) and Filip et a l (2012).
In agreement with the well-known antagonistic A2A-D2 interaction, pharmacological 
activation of the A2A receptor was shown to counteract the D2-mediated hyperactivity 
induced by acute psychostimulant administration (Poleszak and Malec, 2002b, Filip et 
a l, 2006) and to also attenuate behavioural sensitisation to MAP (Shimazoe et a l,
2000), cocaine (Filip et a l,  2006) and morphine (Listos et a l,  2008). These findings 
however, were in contrast to evidence from global C57BL/6J A2A KO mice models, 
where both acute cocaine and amphetamine-induced hyperactivity (Chen et a l ,  2000) 
and behavioural sensitisation to amphetamine (Chen et a l ,  2003) were significantly 
attenuated in comparison to wild-type controls. The reduction of amphetamine-induced 
behavioural sensitisation observed in global A2A KO mice (Chen et a l,  2003) was 
mirrored in mice with a specific deletion o f forebrain (striatum, cerebral cortex and
33
hippocampus) A%A receptors, suggesting a role o f forebrain A2A receptors in mediating 
this response (Bastia et a l ,  2005). This finding led to the hypothesis that in terms of 
psychomotor activity, extra-striatal A2A receptors may oppose postsynaptic striatal A2A 
function. This was confirmed in a pivotal study by Shen and colleagues (2008), who 
used the aforementioned forebrain-specific A2A receptor KO mice (fb-KO) in addition 
to striatal-specific A2A receptor KO mice (str-KO), to assess the differences in 
locomotor response to cocaine administration. In line with previous findings in global 
and fb-KO mice, decreased cocaine-induced hyperactivity was observed in fb-KO mice 
(Shen et a l,  2008). Conversely, cocaine-induced locomotor activity in str-KO mice was 
increased; a finding that was consistent with pharmacological inactivation of A2A 
receptors and in line with an antagonistic A2A-D2 interaction (Filip et a l ,  2006). This 
evidence suggested that due to high postsynaptic density of A2A receptors in the 
striatum, as opposed to lower-density presynaptic extrastriatal A2A receptors, A2A 
antagonists produce a primarily striatal-mediated behavioural response to cocaine. 
Administration of an A2A antagonist in str-KO mice essentially means blockade of 
extra-striatal receptors only. Interestingly, when str-KO animals were given both 
cocaine and an A2A receptor antagonist a reduction in cocaine-induced locomotor 
activity was observed, suggesting for the first time a crucial role o f extra-striatal A2A 
receptors in modulating psychomotor responses. These results suggested that, despite 
having a much lower expression density, activation of forebrain A2A receptors, which 
have consequently been suggested to be presynaptic A2A receptors in cortical neurons 
which connect with the striatum (Quiroz et a l, 2009), provided a prominent excitatory 
effect that was able to counteract the inhibitory striatal A2A-mediated effect seen 
pharmacologically. This suggests targeting extra-striatal (presynaptic), as opposed to 
striatal (postsynaptic), A2A receptors via the use of A2A ligands acting preferentially at a
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presynaptic site (see Orru et a l, 2011), may be more beneficial in controlling 
psychomotor activity.
Yet, it must be mentioned that in contrast to the above data, which were conducted on 
inbred strains of A2A KO mice, in the outbred CD-I A2A KO mouse strain the acute 
locomotor response to cocaine and cocaine-induced sensitisation were unaltered (Soria 
et a l ,  2006). The reason for the differences between these two studies is not clear, 
however, it is most likely attributable to differences in genetic background, as 
background strain has been shown to result in a variable sensitivity to the effects of 
drugs of abuse (see Roberts et a l, 1992, He and Shippenberg, 2000, Orsini et a l,  2005, 
Bailey et a l ,  2010, Conversi et a l, 2011).
In contrast to psychostimulants, the acute locomotor response to morphine does not 
appear to be mediated by the A2A receptor (Castahé et al., 2008, Brown et al., 2009), 
indicating that A2A, like D2, differentially mediates the mechanism of locomotor control 
between opioid and psychostimulant drugs. This may be due to a more prominent role 
of Di receptor (Becker et a l ,  2001), as opposed to D2 receptor signalling in mediating 
morphine-induced locomotion (Maldonado et a l,  1997). Additionally, Ai, but not A2A 
receptors appear to be necessary for the development and expression of behavioural 
sensitisation to morphine (Weisberg and Kaplan, 1999, Brown et a l, 2009). The A2A 
receptor does however, appear to be involved in the development of morphine 
locomotor tolerance, as this is abolished in A2A KO mice (Brown et a l ,  2009). Although 
the reason for this is not fully understood, it may be due to dysregulation in cellular and 
molecular signalling as a result of A2A receptor deletion. Long-term morphine exposure 
can increase extracellular adenosine in the striatum by upregulating adenosine 
transporter binding sites (Kaplan and Leite-Morris, 1997). Additionally, opioid
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tolerance as a consequence of chronic morphine administration is thought to be partly 
attributable to upregulation of the striatal AC/cAMP/PKA pathway (see Nestler et a l,  
1996, Chao and Nestler, 2004). Therefore, although repeated morphine administration 
may increase adenosine levels, the absence of A2A receptors in KO mice for it to act 
upon could result in reduced cAMP accumulation and consequently the absence of 
morphine tolerance.
As can be seen from Tables 1.2 and 1.3, there is clear evidence to indicate involvement 
of the A2A receptor in drug reinforcement and reward. However, conflicting evidence 
from genetic deletion and pharmacological studies and differences in drug-specific 
effects, make it difficult to speculate on its exact role. It has been shown that following 
cocaine self-administration A2A receptors are upregulated (Marcellino et a l ,  2007), and 
that cocaine self-administration is inhibited by A2A activation (Knapp et a l ,  2001) and 
exacerbated by A2A antagonism (Weerts and Griffiths, 2003). Conversely, A2A KO mice 
display reduced self-administration of not only cocaine (Soria et a l ,  2006), but also the 
amphetamine derivative MDMA (3,4-methylenedioxy-A-methylamphetamine) (Ruiz- 
Medina et a l ,  2011) and morphine (Brown et a l ,  2009). Reduced morphine self­
administration in A2A KO mice however, does agree with pharmacological data as this 
behaviour was initiated upon A2A receptor activation (Sahraei et a l, 1999) and is 
hypothesised to reflect a decreased reward value o f morphine in these animals, as they 
also fail to develop morphine-induced GPP (Brown et a l ,  2009), yet GPP to cocaine is 
unaltered (Soria et a l,  2006). However, pharmacologically, it is A2A receptor activation, 
rather than antagonism, which has been shown to attenuate stimulation-derived reward 
(Baldo et a l ,  1999). Nevertheless, A2A antagonism does prevent the expression, but not 
acquisition, of cocaine-induced GPP, yet this finding is further confounded by the
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observation o f the same effect at low doses of A2A agonist, CGS 21680 (Poleszak and 
Malec, 2002a). Moreover, amphetamine-induced CPP appears to be preferentially 
modulated by the Ai, rather than A2A receptor (Poleszak and Malec, 2003). Like A2A 
receptor KO mice (Castahe et al., 2008, Brown et al., 2009), D2 receptor KO mice also 
fail to develop morphine CPP (Maldonado et a l,  1997), which suggests a necessary role 
of both A2A and D2 receptors in mediating opioid reward. The above evidence indicates 
that the role of A2A receptors in mediating drug reward and reinforcement may be drug 
specific. However, the discrepancies in the studies outlined, which are likely 
attributable to factors such as strain, protocol and perhaps the discernible roles of 
striatal versus extrastriatal A2A receptors, mean that a definitive role for A2A receptors in 
the mediation of drug reward and reinforcement remains to be further elucidated.
The A2A receptor has also been shown to have a role in morphine withdrawal and 
reinstatement, as it has been shown that morphine withdrawal symptoms are reduced via 
A2A activation, and exacerbated by A2A antagonism (Kaplan and Sears, 1996, Salem and 
Hope, 1997). In agreement, global A2A KO mice display augmented physical morphine 
withdrawal symptoms, such as paw tremor and jumping (Berrendero et a l,  2003, Bailey 
et a l,  2004). Interestingly, in these animals, the aversive dysphoric effects associated 
with morphine withdrawal were abolished, suggesting a differential role of the A2A 
receptor in mediating motivational versus somatic opioid withdrawal symptoms 
(Castahe et al., 2008). Following morphine withdrawal, cue-induced morphine-seeking 
behaviour was not altered in global A2A KO mice, suggesting that absence of this 
receptor does not prevent the development of drug-seeking behaviour in morphine 
abstinence (Brown et a l,  2009). Heroin-primed reinstatement however, was reduced 
upon administration (either intra-accumbal or systemically) o f an A2A antagonist (Yao
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et a l,  2005). These apparently conflicting results may be due to the involvement of 
differential brain circuits in mediating cue- versus drug-primed reinstatement (see 
Shaham et a l ,  2003). Interestingly, the result from Yao et a l  (2005) fits well with 
emerging evidence which shows that, under certain conditions, a synergistic rather than 
antagonistic A2A-D2 receptor interaction exists (see Ferre et a l,  2008) which appears to 
be dependent on the presence of an activator of G-protein signalling, AGS3 (Yao et a l,  
2002, Kudlacek et a l ,  2003). Indeed, upregulation of AGS3 has been observed in the 
later stages o f addiction, such as cocaine (Bowers et a l, 2004) and morphine 
withdrawal (Fan et a l ,  2009) and knock-down of AGS3 in the PFC and AcbC has been 
shown to prevent cocaine and heroin reinstatement (Bowers et a l ,  2004, Yao et a l,  
2005).
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1.5.3 A summary o f  the A 2A receptor in drug addiction
The above evidence indicates that although the A2A receptor is implicated in many 
different aspects of drug addiction, there are clear discrepancies between findings from 
pharmacological and genetic investigations, particularly in psychostimulant 
administration. As discussed above, some locomotor differences may be explained by 
the recent discovery o f a crucial role of extra-striatal A2A receptors in overriding the 
inhibitory action facilitated by striatal A2A activation (Shen et a l ,  2008, Quiroz et a l, 
2009). However, the specific role of extrastriatal/presynaptic A2A receptors has not been 
fully examined in other drug paradigms. This implies a more complex mechanism of 
action of the A2A receptor which extends beyond the established postsynaptic A2A-D2 
receptor interaction and could have important implications in furthering the 
understanding of the role of A2A receptor function in other stages of addiction and also 
with regard to the type of drug administered. Indeed, there are clear differences in the 
role of A2A receptors in regulating psychostimulant and opioid responses, indicating 
there may be a drug-selective specificity in the therapeutic benefit o f A2A ligands. 
Overall, the role o f the A2A receptor in addiction is yet to be fully elucidated, both in 
terms of drug paradigm and drug class. Further work is required to characterise both 
molecular mechanisms and neuronal circuitry associated with A2A receptors to allow a 
greater understanding o f its role and potential therapeutic benefit for drug addiction. 
One such avenue of exploration is the involvement of an A2A receptor interaction with 
the metabotropic glutamate receptor mGlus, which will be discussed further in Section 
1.7.
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1.6 The metabotropic mGlus glutamate receptor
1.6.1 Physiological role o f  glutamate
Glutamate is the most prevalent excitatory neurotransmitter in the CNS, mediating up to 
70% of synaptic transmission. Upon release, glutamate binds to one of three ligand- 
gated ionotropic glutamate receptors, the a-amino-3-hydroxy-5 -methyl-D-aspartate 
(AMPA) receptor, the A-methyl-D-aspartate (NMDA) receptor or the kainic acid 
receptor. Ionotropic glutamate receptors mediate fast excitatory glutamate transmission 
and play important roles in drug addiction which are largely beyond the scope of this 
thesis (see Kalivas et ah, 2009). In addition to ionotropic receptors, glutamate also binds 
to G protein-coupled metabotropic receptors (mGlu) which mediate slower modulatory 
neurotransmission. Eight different mGlu receptor subtypes have been identified to date 
and are classified into three main groups based on sequence homology, pharmacology 
and intracellular coupling, as detailed in Table 1.4.
Glutamate is the primary mediator of synaptic plasticity, a neuroadaptive process 
underlying learning and memory functions (Bear, 1996). Synaptic plasticity refers to the 
ability o f a synapse to change in strength and is classified into two broad categories: the 
strengthening of synapses, known as long-term potentiation (LTP), and synaptic 
strength weakening, referred to as long term depression (LTD), processes which involve 
both NMDA and AMP A receptors (see Rao and Finkbeiner, 2007). Synaptic plasticity 
was first demonstrated in hippocampal synapses (Bliss and Lomo, 1973) and therefore 
was initially hypothesised to reflect a cellular process exclusive to learning and 
memory. However, it is now apparent that LTP and LTD are basic properties of most 
synapses throughout the CNS which allow the brain to adapt to environmental stimuli 
(see Malenka and Bear, 2004).
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There is much evidence to show that drugs of abuse can induce or modulate forms of 
synaptic plasticity in areas of the brain associated with addiction, such as the VTA 
(Jones et a l ,  2000, Borgland et a l,  2004, Ungless et a l ,  2001, Sarti et a l, 2007, Chen 
et a l, 2008, Schumann et a l,  2009), Acb (Thomas et a l, 2001), hippocampus 
(Thompson et a l ,  2004, Bao et a l,  2007) and amygdala (Goussakov et a l,  2006, 
Grueter et a l ,  2006). In particular, the role of glutamate in behavioural sensitisation, a 
form of drug-dependent neural plasticity, has been well established in the mesolimbic 
DAergic pathway. As mentioned previously, behavioural sensitisation refers to the 
augmentation of locomotor and stereotypic responses in response to repeat drug 
administration (Robinson and Berridge, 1993) which occurs in two distinct temporal 
domains: initiation and expression (Pierce and Kalivas, 1997). Initially, it was shown 
that blockade of NMD A receptors in the VTA prevented the development of 
behavioural sensitisation to psychostimulant administration (Karler et a l,  1989, Kalivas 
and Alesdatter, 1993). Later, microdialysis studies showed that glutamate transmission 
in the VTA was elevated in response to both acute (Zhang et a l,  2001) and chronic 
cocaine administration (Kalivas and Duffy, 1998), indicating a role for glutamate 
transmission in the VTA in the development of the sensitisation response. In 2001, it 
was demonstrated that a single cocaine injection caused glutamate-dependent LTP in 
DAergic cells of the VTA (Ungless et a l,  2001), a finding since widely replicated (Sarti 
et a l,  2007, Chen et a l,  2008, Schumann et a l,  2009). As such, alterations in synaptic 
strength in the VTA are linked to the initiation of behavioural sensitisation, whereas 
synaptic plasticity in the Acb appears to mediate its long term maintenance and 
expression (Thomas et a l,  2001). This was based on the finding that a cocaine priming 
injection increased glutamate release in the AcbC, which arises from prefrontal 
glutamate afferents (McFarland et a l,  2003). This produced a LTD-like reduction in
49
AMP A receptors to cause expression of sensitised behaviour (Brebner et a l,  2005). In 
support, blockade of AMP A receptors in the AcbC has been shown to prevent the 
expression of locomotor sensitisation in rats (Pierce et a l,  1996) and can also prevent 
cue- or drug-induced reinstatement (Cornish and Kalivas, 2000, Di Ciano and Everitt,
2001). Taken together, these results suggest glutamatergic regulation of synaptic 
plasticity may have functional consequences in the management of drug-induced 
behaviours.
1.6.2 The mGlus receptor and synaptic plasticity
Group I metabotropic receptors are well known to play a pivotal role in the induction 
and maintenance of synaptic plasticity (Bellone et a l,  2008, Anwyl, 2009, Gladding et 
a l, 2009). Attention turned to the mGlus receptor as a modulator of synaptic plasticity 
partly due to its physical link to (Ehlers, 1999) and positive reciprocal interaction with 
the NMDA receptor (Alagarsamy et a l,  1999, Awad et a l,  2000). Indeed, transgenic 
mGlus receptor knockout mice show a significant reduction of LTP in NMDA receptor- 
dependant pathways such as the CAl region in the hippocampus (Jia et a l ,  1998), and 
also display an impaired learning phenotype manifested as delayed responses in both 
the Morris water-maze and fear-conditioning tests (Lu et a l,  1997). With the 
development of selective mGlus receptor ligands such as the negative allosteric 
modulators 2-methyl-6-(phenylethynyl)pyridine (MPEP) and 3-[(2-methyl-l,3-thiazol- 
4-yl)ethynyl]piperidine (MTEP), the role of mGlug in synaptic plasticity has been 
further elucidated. Negative allosteric modulators (NAMs) indirectly decrease the 
activity of a receptor at an allosteric site in order to prevent the binding o f an 
endogenous ligand. Selective antagonism of mGlug receptors in rats via NAMs results 
in significant impairment o f both the induction and maintenance of LTP and LTD,
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which is paired with various learning behavioural deficits (Balschun and Wetzel, 2002, 
Naie and Manahan-Vaughan, 2004, Popkirov and Manahan-Vaughan, 2011), and is 
consistent with mGlug receptor mediation o f LTP and LTD observed in hippocampal 
slices in vitro (Harney et a l ,  2006, Neyman and Manahan-Vaughan, 2008). Conversely, 
activation of mGlus receptors, therefore augmentation of NMDA receptor function, has 
shown to enhance synaptic plasticity (Ayala et a l,  2009, Rosenbrock et a l, 2010), 
improve learning and memory (Balschun et a l, 2006, Uslaner et a l ,  2009) and reverse 
cognitive deficits produced by NMDA receptor antagonist administration (Stefani and 
Moghaddam, 2010).
The mGlus receptor is widely expressed in the brain, with highest densities in the 
olfactory bulb, Acb, CPu, lateral septum, cortex and hippocampus (Shigemoto et a l, 
1993, Romano et a l,  1995). In the striatum, mGlug receptors are predominantly 
expressed postsynaptically in both types of GABAergic neuron (Mitrano and Smith, 
2007) and show a similar postsynaptic localisation to the A2A receptor (Paquet and 
Smith, 2003, Bogenpohl et a l, 2012) (Figure 1.2). Moreover, mGlug receptors have also 
been shown to exist presynaptically in the glutamatergic terminals of the striatum, 
where they are also co-localised with A%A receptors (Rodrigues et a l ,  2005). In addition 
to important roles in memory and learning, the mGlug receptor has also been implicated 
in a wide variety of CNS disorders which, aside from Fragile X syndrome (Dolen and 
Bear, 2008), bear resemblance to disorders linked with A2A and D2 dysfunction, such as 
autism (Dolen and Bear, 2008, Sokol et a l,  2011), Parkinson’s disease (see Blandini 
and Armentero, 2012), anxiety (Brodkin et a l, 2002a, Brodkin et al., 2002b, Spooren et 
a l, 2002, Klodzinska et a l ,  2000) and drug addiction. The role of mGlus receptors in 
drug addiction will be discussed in Section 1.6.3.
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1.6.3 The mGlus receptor in drug addiction
A  pivotal study by Chiamulera et al. (2001) demonstrated that genetic deletion of the 
mGlus receptor in mice prevented acquisition of cocaine self-administration and 
abolished cocaine-induced hyperlocomotion evident in wild-type controls. Moreover, 
deficits in cocaine self-administration were shown not to be attributable to alterations in 
learning ability, as these mice showed unaltered lever-pressing for food (Chiamulera et 
al., 2001). In addition, DA release in the Acb following acute cocaine administration 
was unaltered in mGlus receptor KG mice, as were levels of Di and D] receptor binding 
in comparison to wild-type mice, suggesting these mice had normal mesolimbic DA 
function (Chiamulera et a l, 2001). As such, it was hypothesised that mGlug receptor 
inhibition may be useful in the treatment of cocaine addiction. These findings have 
since been widely replicated in both rats and mice, whereby pharmacological 
antagonism of the mGlus receptor reduced cocaine and amphetamine-induced 
hyperlocomotion (Pietraszek et a l,  2004, Herzig and Schmidt, 2004, McGeehan et a l, 
2004, Kinney et a l,  2005, Rodriguez et a l,  2010), and se lf  administration o f cocaine 
(Kenny et a l ,  2003, Tessari et a l, 2004), heroin (van der Kam et a l ,  2007) and MAP 
(Osborne and Olive, 2008). The ability of MPEP to reduce drug-self administration may 
be attributable to its ability to elevate intra-cranial s e lf  stimulation thresholds and 
therefore decrease reward value in both cocaine and vehicle treated rats (Kenny et a l,
2005).
Despite its efficacy in reducing acute drug-induced hyperlocomotion, antagonism of 
mGlus receptors does not reduce the hyperactivity induced by repeated administration of 
amphetamine (Yap et a l,  2005, Gill et a l, 2012), nor the expression of behavioural 
sensitisation in response to repeat cocaine administration (Herzig and Schmidt, 2004, 
Dravolina et a l ,  2006). mGlug receptor antagonism however, does inhibit expression of
52
behavioural sensitisation to morphine (Kotlinska and Bochenski, 2007), which suggests 
that the repeated administration of psychostimulants and opioids differentially affect the 
role of mGlus receptors in modulating locomotor sensitisation, much like the discernible 
roles of A2A and D2 receptors in addiction-related behaviours.
Additionally, mGlus receptors appear to play drug-specific roles in mediating 
conditioned reward. McGeehan and Olive (2003) demonstrated that administration of 
MPEP reduced cocaine-induced acquisition of GPP, but had no effect on this acquisition 
for amphetamine, nicotine, morphine or ethanol. Interestingly, MPEP administration did 
prevent the expression of amphetamine (Herzig et a l,  2005), ethanol (Lominac et a l,
2006) and morphine (Popik and Wrobel, 2002, Aoki et a l,  2004) GPP, but had no effect 
on cocaine (Herzig and Schmidt, 2004). This evidence shows that, with the exception of 
cocaine, the mGlug receptor is not involved in the contextual learning as demonstrated 
by GPP acquisition, but has a more prominent role in the behavioural manifestation of 
learning as shown by expression of GPP.
A role for the mGlus receptors exists also in drug withdrawal and reinstatement, as it 
has been shown that mGlug receptor antagonism reduced the severity o f morphine 
withdrawal symptoms in both rats (Rasmussen et a l,  2005) and mice (Palucha et a l,  
2004). Furthermore, mGlus receptor antagonism has also been shown to be important in 
preventing cue- and priming-induced reinstatement o f drug seeking of MAP (Gass et 
a l, 2009), morphine (Brown et a l, 2011) and cocaine (Backstrom and Hyytia, 2007, 
Kumaresan et a l,  2009, Novak et a l, 2010) and also stress-induced reinstatement to 
cocaine (Martin-Fardon and Weiss, 2012), indicating it may be a potential target for 
prevention o f relapse.
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In summary, the above evidence indicates blockade of mGlug receptors results in 
reduced drug reward, reinforcement, withdrawal symptoms and reinstatement of drug 
seeking behaviour. Recently however, positive allosteric modulation of mGlug receptors 
has also been shown to be beneficial in other aspects o f addiction. Use of the positive 
allosteric modulator (PAM), 3-cyano-N-[2,5-di(phenyl)pyrazol-3-yl]benzamide 
(CDPPB) reduced cocaine-seeking in rats following cocaine self-administration (Cleva 
et a l, 2011) and facilitated the extinction of drug-seeking behaviour as assessed by GPP 
for cocaine (Gass and Olive, 2009), but not MAP (Widholm et a l,  2011). However, 
mGlus PAMs have shown to be beneficial in reversing MAP-induced cognitive defects 
(Reichel et a l ,  2011). These findings help explain the lack of manifestation of cocaine 
GPP expression as mentioned above (Herzig and Schmidt, 2004) and also identifies 
discernible roles o f mGlug receptor targeting within the psychostimulant class of drugs.
Gollectively, these data suggest a distinct role of the mGlus receptor in many 
behavioural aspects o f drug addiction, likely attributable partly to its ability to mediate 
mesolimbic and hippocampal synaptic plasticity. The differential behavioural effects 
exhibited by positive or negative allosteric modulation of mGlug receptors suggests that 
the type of modulation required is dependent on addiction stage, in addition to drug 
type. A better understanding of the neural circuitry and molecular mechanisms involved 
in the behaviours elicited by both PAMs and NAMs of mGlus receptors may help 
pinpoint a more specific role of this receptor for therapeutic benefit. One such 
mechanism by which this could occur may involve interactions with other receptors 
similar to the well-documented functional mGlug-NMDA receptor interaction 
(Alagarsamy et a l,  1999, Awad et a l, 2000).
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1.7 The AzA-mGlug receptor interaction
1.7.1 Co-localisation o f  A 2A cmd mGlus receptors
Over the last decade, attention has turned to the existence of a functional interaction 
between the A2A and mOlug receptors. As mentioned in Section 1.4.2, A2A receptors are 
localized mainly peri- and postsynaptically at glutamatergic synapses in the dendritic 
spines of striatal GABAergic neurons (Hettinger et a l,  2001), however, presynaptic A2A 
immunoreactivity has also been observed in the glutamatergic terminals of the striatum 
(Ciruela et a l ,  2006). Similarly, mGlug receptors are densely expressed in the striatum, 
and in primates they show a similar postsynaptic localisation to A2A receptors (Paquet 
and Smith, 2003). It has recently been shown that A2A and mGlus are co-expressed 
postsynaptically in up to 70% of dendritic spines in monkey striatum (Bogenpohl et a l, 
2012). Such strikingly similar localisation provided a morphological basis for a receptor 
co-localisation hypothesis (Figure 1.2). Indeed, in an AiA-mGlug receptor co-transfected 
cell line, these receptors were not only co-localised, but were also co- 
immunoprecipitated in cell membranes, indicating a physical link between these 
receptors (Ferre et a l ,  2002). Importantly, this finding was also observed in native rat 
striatal membrane preparations (Ferre et a l, 2002). More recently, experiments have 
shown that not only do mGlug receptors also heterodimerise with D2 receptors, but it is 
suggested that these receptors exist as postsynaptically in striatopallidal neurons as an 
mGlu5-A2A-D2 receptor oligomer (Cabello et a l,  2009). Moreover, A2A and mGlus, but 
not D2 receptors have also been demonstrated to co-exist presynaptically in the 
glutamatergic terminals o f the striatum (Rodrigues et a l, 2005). Although it is thought 
that these are preferentially located in cortical glutamatergic terminals which connect 
with the direct striatonigral pathway (Quiroz et a l ,  2009, see Figure 1.2), further work
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is required to elucidate their anatomical specificity. In light o f the well-known 
functional A2A-D2 receptor interaction, it was postulated that the mGlus receptor may 
also have a role in striatal modulation due to its physical association and co-localisation 
with these receptors.
1.7.2 Functional interactions between A 2A cmd mGlus receptors
One of the first studies to examine functional interactions between mGlus, A2A and D2 
receptors was by Popoli and colleagues in 2001. This group showed that the selective 
mGlus receptor agonist, 2-amino-2-(2-chloro-5-hydroxyphenyl)acetic acid (CHPG), 
reduced the binding affinity of D2 receptors for DA in the same manner as was 
demonstrated for A2A receptors (Ferre et a l ,  1991). Additionally, using 6-OHDA 
lesioned rats, they observed that administration of CHPG decreased DA-induced 
contralateral turning and reduced spontaneous motor activity in intact rats, suggesting 
that mGlus exerted anti-DAergic effects; however, this was shown to be independent of 
striatal DA release. Reductions in contralateral turning elicited by CHPG were 
preferentially reduced by administration of the D2 agonist quinpirole than with a Di 
receptor agonist and, when co-administered with CGS 21680, the ability o f CHPG to 
reduce quinpirole-induced turning was significantly potentiated, an effect blocked by 
administration o f the A2A antagonist, SCH 58261. This study demonstrated for the first 
time interactions between mGlus, D2 and A2A receptors in the regulation o f striatal 
functioning.
To examine this relationship more closely, dual probe in vivo microdialysis was 
employed to study the effect of mGlug-mediation on the ventral striatopallidal pathway. 
Diaz-Cabiale and colleagues (2002) demonstrated that intraccumbal perfusion o f CGS 
21680 or CHPG caused a 30% - 50% increase in ipsilateral ventral pallidal GABA
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release respectively, but when co-perfused together, basal pallidal levels were 
potentiated by 200%. These increases were all reduced by co-administration of 
quinpirole, which, when administered alone, had no effect on pallidal GABA levels. 
Therefore, it was hypothesised that A%A and mGlu$ receptors could act synergistically to 
overcome Dz-mediated inhibition o f GABA release in the VP. Additionally, centrally 
co-administered CGS 21680 and CHPG significantly reduced the motor-activating 
effects of NMDA receptor antagonist, phencyclidine (PCP), an effect neither ligand was 
able to achieve when administered alone, further demonstrating evidence for this 
interaction in vivo (Ferre et a l ,  2002).
Given the significance of the A2A-D2 interaction in Parkinson’s disease (see Fuxe et a l, 
2007b), the nature of mGlug receptor involvement has been o f great interest to this field 
of research. In Parkinson’s disease, degeneration of nigrostriatal neurons causes 
upregulation o f the striatopallidal GABAergic pathway, which in turn causes 
disinhibiton of the SNr and STN to reduce thalamocortical activity (Albin et a l ,  1989). 
Therefore, it is hypothesised that co-antagonism of mGlus and A2A receptors together in 
the striatum may dampen over-activity of the striatopallidal pathway and thereby 
stimulate thalamic projections to the cortex (see Figure 1.1) to alleviate motor 
dysfunction. Indeed, in a rodent model of Parkinson’s disease, simultaneous blockade of 
A2A and mGlus receptors promoted full recovery of akinesia at doses which when given 
singularly were inefficient (Coccurello et a l, 2004). Similarly, administration of an A2A 
antagonist potentiated the effect of the mGlus receptor antagonist, MPEP, to stimulate 
locomotor activity in both normal and resperpinised mice - mice treated with reserpine 
to induce Parkinson’s-like tremor and bradykinesia (Kachroo et a l,  2005). In addition, 
this study showed that in A2A, D2 or double A2A-D2 KG mice, administration o f MPEP
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produced distinctly reduced locomotor responses, further suggesting a functional 
interdependence o f these receptors (Kachroo et a l ,  2005).
Although the molecular mechanisms underpinning the mGlu5-A2A-D2 receptor 
interactions are yet to be elucidated, it may involve communication at the second- 
messenger level. Co-activation of A2A and mGlug receptors causes synergism in 
signalling pathways by increasing phosphorylation of both DARPP-32, a signal 
transduction molecule enriched in striatal MSNs (Nishi et a l ,  2003) and MAPK (Ferre 
et a l, 2002). Additionally, mGlug receptor stimulation potentiated A2A-mediated 
increases in striatal c-Fos, which is only induced when D2 signalling is interrupted 
(Pinna et a l ,  1999), thus providing further evidence that concomitant stimulation of A2A 
and mGlus receptors can overcome D2-mediated effects.
Generally, this evidence supports the presence of functional receptor interactions 
postsynaptically in GABAergic striatopallidal neurons, however, low levels of 
presynaptic mGlug receptors have been observed in monkey striatum (Paquet and 
Smith, 2003) where it is known A2A receptors also exist (Ciruela et a l ,  2006). A2A and 
mGlus receptors are, in fact, co-localised in approximately 50% of presynaptic 
glutamatergic nerve terminals in rat striatum where they functionally interact to 
facilitate striatal glutamate release (Rodrigues et a l,  2005). This indicates a further 
mechanism by which an A2A-mGlu5 interaction can regulate striatal function. It has 
been shown that presynaptic A2A receptors are located in the cortical glutamatergic 
terminals of the direct pathway (Quiroz et a l,  2009), although, whether this includes 
mGlus receptors is as yet unknown (Figure 1.2).
It has been suggested that the apparent interdependent nature o f the A2A-mGlu5 receptor 
interaction may actually be reflecting a permissive role of A2A on mGlug function. In
58
order to assess this hypothesis, Domenici and colleagues (2004) investigated whether 
the state o f activation of A2A receptors influenced the ability o f mGlus to potentiate 
NMDA-like effects in the striatum. Indeed, administration of A2A receptor antagonists 
prevented CHPG-induced effects on NMDA function and these effects were potentiated 
in the presence of an A2A receptor agonist. The authors therefore hypothesised that the 
state of activation of A2A receptors may regulate mGlus effects in terms of synaptic 
plasticity. Additionally, this effect was also observed in the hippocampus, showing for 
the first time co-localisation and functional effects of these receptors outside of the 
striatum (Tebano et a l ,  2005).
1.7.3 The A 2A-mGlu5 receptor interaction in drug addiction
Despite numerous evidence of this interaction in the striatum, a key brain structure in 
movement and reward, very little research has been conducted to explore how this 
interaction may be important in drug addiction. Initially, it was demonstrated that co­
administration o f A2A and mGlus receptor agonists reduced the locomotor effect 
induced by PCP at doses ineffective to produce this response when administered 
singularly (Ferre et a l ,  2002). Conversely, in 2008, Adams and colleagues 
demonstrated that sub-threshold doses of mGlug and A2A receptor antagonists given in 
combination, reduced both self-administration of and cue-induced reinstatement to 
alcohol seeking in alcohol-preferring rats (Adams et a l,  2008). More recently, this 
group demonstrated that MTEP administration failed to abolish cocaine-induced CPP in 
A2A KO mice as it did in WT mice, suggesting that A2A receptors are required for mGlug 
to regulate this behaviour (Brown et a l, 2011). However, MTEP similarly attenuated 
cocaine-induced hyperactivity in both WT and A2A KO mice indicating that A2A 
receptors are not required for the action of MTEP on regulating the acute locomotor
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inducing properties of cocaine. Additionally, this study found that autoradiographic 
striatal binding of the A2A receptor was reduced in wild-type brain slices pre-incubated 
with MTEP, a finding hypothesised to reflect a decrease in A2A receptor binding 
affinity; a likely result o f changes in the conformation of a proposed A2A-mGlu5 
heterodimer caused by mGlus receptor blockade (Brown et a l ,  2011). This study, which 
was the first o f its kind to use both pharmacological and genetic inactivation of the 
mGlus and A2A receptors respectively, showed a necessary role for the A2A receptor in 
mediating the effects of MTEP on cocaine conditioning, but not on acute cocaine- 
stimulated locomotor activity. To date, these are the only studies which have 
investigated an A2A-mGlu5 interaction in models of drug addiction. Although they 
provide evidence for a role of this receptor interaction in aspects drug addiction, further 
work is required to understand at what stage and in what types of addiction in which 
targeting this interaction may be beneficial.
1.7.4 A summary o f  the A 2a-^GIus receptor interaction
In summary, A2A and mGlus receptors have been shown to be predominantly co­
localised postsynaptically in striatopallidal GABAergic neurons, where they can 
functionally interact to synergistically overcome D2-mediated effects, both at the 
behavioural and at the molecular level (Ferre et a l,  2002, Coccurello et a l,  2004, 
Kachroo et a l ,  2005). Additionally, there is some evidence to support the existence of 
an A2A-mGlu5 receptor interaction at the presynaptic level to influence glutamate 
release in the striatum (Rodrigues et a l,  2005). It is hypothesised that the nature of this 
interaction is based on a permissive role of A2A on mGlug function, such as 
enhancement of NMDA-mediated effects, which has been demonstrated both in the 
striatum and hippocampus of rats (Domenici et a l ,  2004, Tebano et a l,  2005) and
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which may have important implications in the regulation of synaptic plasticity. Yet to 
be fully elucidated, the molecular basis of this interaction may also involve cross-talk 
between independent signalling pathways; however, it is unknown if  such cross-talk is 
responsible for the behavioural effects observed.
Blockade o f the A2A-mGlu5 receptor heterodimer is already showing therapeutic benefit 
in preclinical models of Parkinson’s disease (Coccurello et a l,  2004, Kachroo et a l,  
2005); however, research into how it may be useful in drug addiction has been very 
limited. Drug addiction studies so far implicate a role of a functional A2A and mGlug 
receptor interaction in alcohol self-administration and cue-reinstatement of alcohol 
seeking (Adams et a l,  2008), cocaine-conditioning (Brown et a/., 2011) and the acute 
locomotor-activating effects of PCP (Ferre et a l,  2002), but not cocaine (Brown et a l ,  
2011). These studies provide initial evidence that co-targeting o f A2A and mGlug 
receptors may be o f therapeutic potential in drug addiction; however, study in this area 
is evidently still in infancy. To clarify a role for the A2A-mGlu$ receptor interaction and 
its possible regulation of D2-receptor effects in other classes of drug addictions and drug 
addiction paradigms, further investigation is needed.
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1.8 Thesis hypothesis and aims
The role of the A2A receptor in the behavioural responses to drugs of abuse is currently 
unclear, partly due to conflicting evidence from pharmacological and genetic knockout 
models. There is emerging evidence that in addition to a functional A2A-D2 interaction 
in the striatum, an interaction between A2A and mGlus receptors exists to regulate D2 
receptor mediated effects. This has been demonstrated both in native tissues and models 
of basal ganglia disorders, such as Parkinson’s disease and drug addiction; however, its 
contribution to drug addiction is relatively unexplored.
The research within this thesis tests the hypothesis that adenosine A2A receptors 
modulate the behavioural and neurochemical responses to chronic administration of 
addictive drugs via interactions with D2 and mGlus receptors. The hypothesis is 
evaluated using CD-I adenosine A2A knockout (KG) mice and wild-type (WT) controls 
in a number of experiments including autoradiographic and behavioural paradigms. The 
specific objectives o f each chapter are as follows:
Chapter 2; The effect of chronic ‘binge’ cocaine administration on locomotor 
behaviour and autoradiographic binding of the D2 and mGlug receptors in wild- 
type and A2A receptor knockout mice
• To investigate the presence of an interaction of A2A with mGlus and D2 
receptors in native brain tissue by quantitative autoradiography of these 
receptors in WT and A2A KO mice
• To determine the role of the A2A receptor in the modulation of locomotor and 
stereotypic responses to chronic ‘binge’ cocaine administration by analysis of 
horizontal and vertical activity via infra-red beam-break analysis in WT and 
A2A KO mice
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• To identify if  the A2A receptor plays a role in the regulation of D2 and mGlug 
receptor binding following chronic ‘binge’ cocaine administration by 
quantitative autoradiography of these receptors in WT and A2A KG mice
Chapter 3: The effect of chronic morphine administration and naloxone- 
precipitated withdrawal on locomotor behaviour and autoradiographic binding of 
the D2 and mGlug receptors in wild-type and A2A receptor knockout mice
• To determine the role of the A2A receptor in the modulation of locomotor 
responses to chronic, escalating-dose morphine administration by analysis of 
horizontal and vertical activity via infra-red beam-break analysis in WT and A2A 
KG mice
• To investigate the role o f the A2A receptor in the modulation of somatic 
naloxone-precipitated morphine withdrawal symptoms in WT and A2A KG 
mice
• To elucidate if  the A2A receptor plays a role in the regulation o f D2 and 
mGlus receptor binding of chronic, escalating-dose morphine administration 
or naloxone-precipitated morphine withdrawal by quantitative 
autoradiography o f these receptors in WT and A2A KG mice
Chapter 4: The effect of chronic methamphetamine administration on locomotor 
behaviour and autoradiographic binding of the D2 and mGlug receptors in wild- 
type and A2A receptor knockout mice
• To assess the role o f the A2A receptor in the modulation of locomotor and 
stereotypic responses to chronic methamphetamine administration by 
analysis of horizontal and vertical activity via infra-red beam-break analysis 
in WT and A2A KG mice
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• To identify if  the A2A receptor plays a role in the regulation of D2 and mGlug 
receptor binding during chronic methamphetamine administration by 
quantitative autoradiography of these receptors in WT and A2A KG mice
• To confirm the role of A2A in the modulation of locomotor and stereotypic 
responses to methamphetamine by investigating the effect of A2A antagonist 
pre-treatment on methamphetamine-induced horizontal and vertical activity 
in WT mice
• To determine if an A2A—mGlus receptor interaction was involved in the 
locomotor and stereotypic effects of methamphetamine administration by 
investigating the effect of sub-threshold doses o f A2A and mGlug receptor 
antagonists on methamphetamine-induced horizontal and vertical activity in 
WT mice
Chapter 5; In vivo dopamine release following chronic ‘binge’ cocaine 
administration in wild-type and adenosine A2A receptor knockout mice
To evaluate the role of the A2A receptor in the modulation of extracellular 
dopamine release in the striatum following chronic ‘binge’ cocaine 
administration in WT and A2A KG mice by utilising freely-moving 
microdialysis with HPLC-EC detection
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CHAPTER 2
The effect of chronic ‘binge’ cocaine 
administration on locomotor behaviour and 
autoradiographic binding of the D2 and 
mGlus receptors in wild-type and A2A 
receptor knockout mice
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2.1 Introduction
Cocaine is a widely abused Class A psychostimulant drug which acts in the brain as a 
non-selective monoamine transporter inhibitor. Cocaine acts as a reuptake blocker of 
DA, serotonin (5-HT) and noradrenaline (NA) with greatest affinity for 5-HT 
transporters, followed by DA and NA transporters respectively. The blockade of the DA 
transporter (DAT) in VTA mesolimbic neurons causes an increase in DA synaptic 
concentration at the Acb, causing euphoria and thereby cocaine reinforcement (Hall et 
ah, 2009b, Thomsen et ah, 2009). Cocaine is rapidly absorbed and delivered to the 
brain where it has a relatively short half-life of approximately 30 minutes. This means 
that in order to maintain its euphoric effects, cocaine users often engage in a ‘binge’ 
pattern of administration, using multiple doses of cocaine over a relatively short period 
of time. Usually, this ‘binge’ pattern of cocaine administration is not well reflected in 
animal models of cocaine addiction, as many paradigms tend to use either acute or 
chronic single daily doses of cocaine. As such, the human relevance o f single daily dose 
cocaine administration in animals has been questioned. Consequently, the Kreek 
laboratory (Maisonneuve and Kreek, 1994, Maisonneuve et a l, 1995) developed the 
‘binge’ cocaine administration paradigm to more closely resemble the human pattern of 
chronic cocaine abuse. In order to mimic ‘binge’ cocaine taking as observed in humans, 
rodents were administered 3 x 1 5  mg/kg cocaine injections at 1 hour intervals over a 14 
day period (Maisonneuve, 1994, Maisonneuve et a l,  1995). This administration 
paradigm has been shown to acutely maintain increased DAergic transmission in the 
striatum, which may contribute to sustaining initial cocaine reward (Maisonneuve and 
Kreek, 1994).
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As discussed in Section 1.1.5 and 1.3.3, administration of psychostimulants such as 
cocaine results in elevated motor responses and the emergence o f stereotypic-like 
behaviours, thought to be mediated by DAergic transmission in the mesocorticolimbic 
system (see Kalivas and Stewart, 1991, Kalivas and Duffy, 1993, Robinson and 
Berridge, 1993). Stereotypic responses to psychostimulants have been associated with 
increased DAergic transmission in the dorsal striatum (Staton and Solomon, 1984) and 
it has been shown that persistent vertical activity (rearing), a characteristic high-level 
stereotypic response to cocaine observed in C57BL/6J mice (Schlussman et a l,  2003, 
Bailey et a l,  2008), was correlated with high DAergic stimulation of the CPu (al-Khatib 
et a l, 1995). Both horizontal and vertical behavioural responses to the chronic ‘binge’ 
cocaine paradigm have been established in C57BL/6J mouse strain (Schlussman et a l,  
2003, Bailey et a l,  2008), however, behavioural responses to this method of cocaine 
administration in the outbred CD-I mouse strain has not yet been investigated.
It is thought that some of the behavioural effects observed as a consequence of A2A 
receptor manipulation (see Tables 1.2 and 1.3) may involve D2 receptor modulation, due 
to the functional interaction between postsynaptic A2A and D2 receptors in the striatum 
(Section 1.5). As discussed in Section 1.5.2, the role of the A2A receptor in mediating 
cocaine-induced locomotor behaviours is unclear. In agreement with the antagonistic 
A2A-D2 interaction, pharmacological studies have shown that systemic A2A receptor 
activation decreased acute cocaine-induced hyperactivity in both mice (Poleszak and 
Malec, 2002b) and rats (Filip et a l,  2006). However, it was demonstrated that the acute 
locomotor responses to cocaine were attenuated in the C57BL/6J A2A KO mouse in 
comparison with WT littermates (Chen et a l,  2000), thus suggesting that the A2A 
receptor was necessary in mediating this response. As mentioned in Section 1.5.2, the 
discrepancies between pharmacological and genetic inactivation studies were partly
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explained by a differential role of striatal versus extrastriatal A2A receptors in mediating 
cocaine-induced locomotor behaviour (Shen et a l,  2008). Despite this, the outbred 
strain o f CD-I A2A KO mice showed no alterations in acute cocaine-induced 
hyperactivity (Soria et a l,  2006, Brown et a l,  2011). In agreement, locomotor 
sensitisation to chronic cocaine administration (10 mg/kg, i.p., 12 days) in CD-I A2A 
KO mice was unaltered (Soria et al., 2006), yet the locomotor sensitisation response 
observed following a similar pattern of cocaine administration in rats was decreased 
when combined with daily A2A receptor agonism (Filip et al., 2006). Although this is 
likely an effect o f strain difference, it appears the role of the A2A receptor in cocaine- 
induced locomotor activity, in particular following chronic administration, is still 
unclear.
As discussed in Section 1.7, in addition to an A2A-D2 receptor interaction, there is a 
growing body of literature which suggests that A2A and mGlus receptors are co­
expressed and can functionally interact to regulate D2-mediated effects at the 
behavioural, transmission and molecular levels. Localisation of the mGlus and A2A 
receptors are very similar in the striatum (Paquet and Smith, 2003) and here is where 
the majority of evidence documenting an A2A-mGlu5 receptor interaction exists. 
Furthermore, an mGlus-A2A-D2 receptor oligomer has been demonstrated in both HEK- 
293 cells and rat striatal homogenate (Cabello et a l ,  2009). In addition, a role of mGlus 
receptors in modulating cocaine addiction has been established. As mentioned 
previously, genetic deletion of the mGlus receptor prevented acquisition o f cocaine self­
administration and abolished cocaine-induced hyperlocomotion (Chiamulera et a l,  
2 0 0 1 ), which was supported by findings showing that pharmacological antagonism of 
the mGlus receptor reduced both cocaine-induced hyperlocomotion and self­
administration (Kenny et a l ,  2003, Herzig and Schmidt, 2004, McGeehan et a l ,  2004,
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Tessari et a l ,  2004, Kinney et a l,  2005, Rodriguez et a l ,  2010). This points towards a 
beneficial role of mGlug receptor antagonism in aspects of cocaine addiction.
Because of the growing evidence supporting a role for both A2A ^ d  mGlug receptors in 
addiction, and the existence of a functionally active A2A-111GIU5 receptor interaction 
which can mediate D2 receptor function, recent attention has focused on how this could 
be exploited in models o f drug addiction. It has been shown that co-administration of 
A2A and mGlus receptor antagonists at a sub-threshold dose synergistically reduced both 
alcohol self-administration and cue-induced reinstatement of alcohol seeking in rats 
(Adams et a l ,  2008). In addition, use o f the mGlus receptor antagonist, MTEP, 
abolished the conditioning effect of cocaine in WT, but not in global A2A KG mice 
(Brown et a l ,  2011), further demonstrating a functional interaction between A2A and 
mGlug receptors. Interestingly, administration of MTEP induced a similar attenuation of 
acute cocaine-induced locomotor activity in both genotypes (Brown et a l ,  2011), which 
suggests perhaps differential roles for the A2A-mGlu5 receptor interaction in cocaine- 
induced behaviours. However, the mechanism underlying the A2A-IÏ1GIU5 interaction 
and its possible regulation of Ü2-mediated effects are currently unclear. Understanding 
whether the regulation o f these receptors is co-dependent and/or affected by drugs of 
abuse could have implications for the development of new pharmacotherapeutic ligands 
designed to target receptor heterodimers (e.g. Soriano et a l, 2009).
The aim of the current study was firstly to investigate whether an interaction of A2A 
with mGlus or D2 receptors in native brain tissue existed at the receptor level by 
quantitative autoradiography of these receptors in WT and A2A KO mice. Secondly the 
role of the A2A receptor in the modulation of locomotor and stereotypic responses to 
chronic ‘binge’ cocaine in WT and A2A KO mice was determined. Lastly, to identify i f
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AiA receptors play a role in the regulation of D2 and mGlug receptor binding during 
chronic ‘binge’ cocaine administration, quantitative autoradiography of these receptors 
in WT and A2A KG mice was undertaken.
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2.2 Methods
2.2.1 Maintenance and genotyping o f  the adenosine A 2A receptor knockout mouse 
colony
The CD-I adenosine A2A knockout mice were originally created by Ledent et al. (1997) 
and generously supplied in order to maintain a breeding colony within the University of 
Surrey which has been maintained at the University of Surrey Experimental Biology 
Unit for approximately 14 years. In brief, the generation of the A2A receptor knockout 
mice involved cloning of the A2A receptor gene and interruption of the coding region by 
a single intron at a position corresponding to the second intracellular loop of the 
receptor. The deduced amino acid sequence was 410 amino acids long. The A2A 
receptor gene was inactivated in R1 embryonic stem cells by replacement of part of 
exon 1 with a neomycin-resistance cassette (Figure 2.1). Three neomycin-resistant 
clones were identified as bearing a recombinant allele o f the A2A receptor gene. The 
correct integration was identified by Southern blotting and one o f the clones was used to 
generate chimaeric mice. Two chimaeras bred with CD-I mice transmitted the mutant 
allele and bred for four generations on a CD-I background.
. The mice forming the breeding colony were bred from heterozygote breeding pairs 
which originated from the original crossing of a number of heterozygote males from the 
existing colony each with a wild-type female from an external supplier (Charles River, 
Margate, Kent, UK). The male and female heterozygotes from the litters of the newly 
created breeding pairs were paired and these formed the main breeding colonies which 
were maintained for approximately one year before new breeding pairs were created. 
The mice were housed in groups of approximately 4-5 mice per cage in a temperature- 
controlled environment on a 12 hour light-dark cycle (lights on 07:00) and were fed a
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standard pellet diet with water available ad libitum. All experimental procedures were 
conducted in accordance with the UK Animal Scientific Procedures Act (1986).
A polymerase chain reaction (PCR) based method was used to genotype the mice at 
weaning (three weeks old). Tail tip samples o f no more than 5 mm were taken from 
each mouse and transferred to a DNase-free microcentrifuge tube and DNA was 
extracted using the DNeasy tissue kit (Qiagen, Hilden, Germany) following the 
manufacturer’s protocol. In brief, all samples were incubated in a water bath at 55°C 
with proteinase K (Sigma-Aldrich, Dorset, UK) and left overnight. The following day 
cells in the sample were lysed with ethanol and transferred to individual spin columns, 
composed o f a silica-gel membrane allowing DNA to selectively bind. Two 
centrifugation steps with washes followed, removing any contaminants and binding the 
DNA to the column. The spin columns were transferred to collection tubes and the 
DNA extracted upon the addition of a buffer, releasing the DNA from the membrane. 
The extracted DNA was then subjected to PCR amplification using puReTaq Ready-To- 
Go PCR beads (GE Healthcare, Buckinghamshire, UK) and three custom primers 
(Sigma-Genosys, Suffolk, UK):
1) The common forward primer: AGTCATGGTTTCGGGAGATG
2 ) The wild-type reverse primer: ACCATGATGTACACCGAGGAG
3) Adenosine A%A receptor knockout primer: A AGG A AGGGT G AG A AC AG AG
These were used to selectively amplify fragments of different sizes from the wild-type 
and adenosine A2A knockout alleles. Primers 1 and 2 amplified a 229 base pair band 
from the wild-type allele, whereas primers 1 and 3 amplified a 572 base pair from the 
mutated allele. Heterozygous mice carrying a copy of both alleles resulted in 2 bands, 
enabling the identification of the 3 genotypes (Figure 2. IB). A total volume of 25 pi per
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reaction was made up of 2 pi of each primer, 6  pi of DNA sample and 13 pi of double- 
autoclaved MilliQ water. The cycle parameters for the PCR were as follows:
1) Pre-cycle 2 minutes 94°C
2) Dénaturation 30 seconds 94°C
3) Annealing 1 minute 15 seconds 72°C
4) Elongation 1 minute 72°C
5) Post-cycle 5 minutes 72°C
This process was repeated for 40 cycles.
The PCR products were separated by gel electrophoresis using 2% agarose double comb 
e-gels (Invitrogen, Carlsbad, CA, USA) allowing the identification of the genotypes by 
comparison to the HyperLadder I DNA ladder (Bioline, London, UK; Figure 2. IB).
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Figure 2.1: Generation of A2A knockout mice. (A) Organization of the mouse A2A receptor 
gene, the targeting construct, and the allele resulting from homologous recombination. Coding sequences 
of first (El) and second (E2) exons are represented by boxes. Taken from Ledent et al. (1997). (B) 
Representative sample showing the separation of the PCR products of the genotyping reaction visualised 
by gel electrophoresis. Lane 1; +/+ wild-type allele, 229 base-pairs (bp), Lane 2: +/- heterozygote, 229 
and 572 bp. Lane 3: DNA Ladder, Lane 4: -/- A2A receptor knockout allele, 572 bp.
2.2.2 Animals and treatments
Male, 12-15 week old wild-type (WT) and A2A receptor knoekout (KO) mice were 
singularly housed in home cages throughout the whole duration of the study. Mice were 
habituated to the home cages and to experimenter handling for a period o f 7 days prior 
to the start of experiment. The home cages were in a temperature-eontrolled 
environment on a 12-hour light-dark eycle (lights on 07:00). Whilst in home cages, 
mice had access to food and water ad libitum.
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Prior to experimental procedure on each day, mice were removed from their home cage 
at 10:00 am and allowed to habituate in the motility chambers for 1 hour. Following 
this, mice were treated with a chronic steady-dose ‘binge’ cocaine administration 
paradigm as first described by Maisonneuve et a l  (1994). This consisted of 3 injections 
per day at 1-hourly intervals (at 11.00, 12.00 and 13.00 hours) of either cocaine (15 
mg/kg, S.C., Sigma-Aldrich, UK) or saline (4 ml/kg, s.c.) for 14 days. Horizontal and 
vertical (rearing) activity behaviours were recorded for each mouse throughout the 
duration o f the study. All experimentation was carried out in a temperature-controlled 
environment and in dim light.
2.2.3 Motor activity measurements
Mice were habituated in motility chambers (40 cm length x 20 cm width x 20 cm 
height; Linton Instrumentation, Norfolk, UK) for 1 hour prior to experimental procedure 
to assess basal (pre-injection) activity every day throughout the duration of the study. 
Each cage had two sets of 16 photocells located at right angles to each other projecting 
horizontal beams 2.5 cm apart at 1 cm and 6  cm above the cage floor. Horizontal and 
vertical activity (rearing) was defined by the measurement o f either sequential 
horizontal or vertical infrared beam-breaks. For the habituation (pre-injection) period, 
beam-breaks were recorded every 5 minutes (5 minute bins) for 60 minutes, beginning 
immediately after placing the animals in the motility chamber. Beam-breaks were also 
recorded every 5 minutes (5 minute bin) for 60 minutes immediately following each 
injection (saline or cocaine). Mice were returned to their home cages each day 
following completion of the locomotor test.
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2.2.4 General autoradiographic procedures
2.2.4.1 Cleaning and subbing o f  microscope slides
Slides were left to soak overnight in Decon, a water-based detergent. Slides were then 
rinsed in hot running water for 15 minutes followed by a rinse in cold distilled water for 
a further 15 minutes. The slides were then soaked in a 10% HCl/90% ethanol solution 
for 20 minutes followed by another 15 minute rinse in distilled water. Slides were 
coated by a 2  minute immersion in 1% gelatine/chrom-alum solution and left to dry 
before use.
2.2.4.2 Tissue preparation
All mice were killed 1 hour post final treatment injection via cervical dislocation, whole 
brains removed, snap-frozen in -25°C isopentane and immediately stored at -80°C. Prior 
to sectioning, brains were removed from -80°C storage and placed into a -21°C cryostat 
(Zeiss Hyrax C25, Hertfordshire, UK) and coronally aligned by fixing the cerebellum 
onto a mounting stage using a plastic embedding liquid (O.C.T compound, BDH 
chemicals, Dorset, UK). 20 pm coronal brain sections spanning the whole brain were 
cut at 300 pm distances at -21°C and thaw mounted onto gelatine-coated ice-cold 
microscope slides. Adjacent slides were cut for determination of total and non-specific 
binding (NSB). Slides were dried using anhydrous calcium sulphate (Drierite-BDH 
Chemicals, Dorset, UK) at 4°C for 2 hours to prevent the formation of ice crystals and 
then stored at -20°C for a minimum of 1 week.
2.2.4.3 Autoradiographic binding o f  the dopamine D2 receptor
Autoradiography was performed as detailed by Lena et al. (2004). Slides were defrosted 
thoroughly for 30 minutes then pre-incubated for 20 minutes at room temperature in a
76
50 mM Tris-HCl assay buffer containing 120 mM NaCl, 5 mM KCl, 2 mM CaCb and 
ImM MgCl2 (pH 7.4). The DA D2 receptor antagonist [^HJraclopride (Perkin Elmer 
Ltd, Belgium) was used to label DA D2 receptors at a 4 nM concentration, 3-4 times Kd 
of ligand as previously described in the literature (Kohler et a l,  1985). The incubation 
buffer was made up of the radioligand in the assay buffer as stated above for both total 
and non-specific binding. 10 pM of DA D2 antagonist sulpiride (Tocris Biosciences, 
Bristol, UK) was added to the assay buffer containing 4 nM [^HJraclopride to determine 
non-specific binding.
1 ml of incubation buffer for total and non-specific binding was pipetted over the 
appropriate slides, ensuring all sections were completely covered, for 60 minutes at 
room temperature. The slides were then washed 6  times for 1 minute in ice-cold rinse 
buffer (50 mM Tris-HCl, pH 7.4) followed by a 1 minute rinse in ice-cold distilled 
water. The slides were dried under a cold stream of air for 2 hours and stored in an 
airtight box with anhydrous calcium sulphate for 7 days at room temperature for further 
drying.
2.2.4.4 Autoradiographic binding o f  the glutamate mGlus receptor
Slides were defrosted thoroughly for 30 minutes then pre-incubated for 20 minutes in a 
50 mM Tris-HCl assay buffer containing 50 mM Tris, 5 mM KCl, 120 mM NaCl, 2 mM 
CaCb and 1 mM MgCb (pH 7.4) at room temperature. The mGlug receptor negative 
allosteric modulator [^H]2-methyl-6-(phenylethynyl)pyridine (MPEP; American 
Radiolabelled Chemicals, USA) was used to label mGlug receptors at a 10 nM 
concentration, 3-4 times Kd of ligand (as determined in our laboratory). The incubation 
buffer was made up of the radioligand in 50 mM Tris-HCl buffer (pH 7.4) for both total 
and non-specific binding. 10 pM of the mGlug receptor antagonist fenobam (Tocris
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Biosciences, Bristol, UK) was added to the assay buffer containing 10 nM [^H]MPEP to 
determine non-specific binding.
1 ml of incubation buffer for total and non-specific binding was pipetted over the 
appropriate slides, ensuring all sections were completely covered, for 60 minutes at 4°C 
(on ice). The slides were then washed twice for 1 minute in ice-cold rinse buffer (50 
mM Tris-HCl, pH 7.4) followed by a 1 minute rinse in ice-cold distilled water. The 
slides were dried under a cold stream of air for 2  hours and stored in an airtight box 
with anhydrous calcium sulphate for 7 days at room temperature for further drying.
2.2.4.5 Autoradiographic binding o f  the adenosine A 2A receptor
In order to confirm the genotype of mice used in each study had been correctly 
identified by PCR, autoradiographic binding of the adenosine A2A receptor was 
undertaken in all experimental mice used.
Sections were only taken from the striatal area of the brain and the adjacent non-specific 
binding slides were not required to conduct qualitative confirmation of A2A receptor 
binding. Slides were defrosted thoroughly for 30 minutes then pre-incubated at room 
temperature for 30 minutes in a 170 mM Tris-HCl buffer (pH 7.4) containing 1 mM 
EDTA and 2U/ml adenosine deaminase (Sigma-Aldrich, Dorset, UK). The A%A receptor 
agonist [^HjCGS 21680 (Amersham International pic., Buckinghamshire, UK) was used 
to label A2A receptors at a 10 nM concentration, 3-4 times Kd of ligand as previously 
described in the literature (Johansson and Fredholm, 1995, Bailey et a l,  2002b). The 
incubation buffer was made up of the radioligand in 50 mM Tris-HCl buffer containing 
10 mM MgCb (pH 7.4) for total binding only.
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1 ml of incubation buffer for total binding was pipetted over the slides, ensuring all 
sections were completely covered, for 2 hours at room temperature. The slides were 
then washed 3 times for 5 minutes in ice-cold rinse buffer (170 mM Tris-HCl, pH 7.4) 
followed by a 5 minute rinse in ice-cold distilled water. The slides were dried under a 
cold stream of air for 2  hours and stored in an airtight box with anhydrous calcium 
sulphate for 7 days at room temperature for further drying.
2.2.4. 6  Autoradiographic film  preparation
The slides containing the sections were securely placed in Hypercassettes with 
[^H]microscales standards (Amersham International, Buckinghamshire, UK). Where 
treatment groups were compared, sections from each group of mice were apposed to the 
same film in a paired manner. Slides were apposed to Kodak BioMax MR-1 film 
(Kodak, UK) by placing emulsion side down onto the slides in a dark room under red 
filtered light. The Hypercassettes were sealed to prevent any light exposure and stored 
flat at room temperature for 3 weeks for A2A receptor binding, 5 weeks for mGlus 
receptor binding and 6  weeks for DA D2 receptor binding.
2.2.4.7 Film development
Film development was carried out in a dark room under red filtered light. The films 
were developed using an aqueous solution containing 50% Kodak D19 developer 
(Sigma-Aldrich, Dorset, UK) and 50% distilled water for 1 minute. The film was then 
placed in a solution of distilled water and glacial acetic acid for 1 minute to stop the 
reaction. The images were finally fixed in a Kodak rapid fix solution (Kodak, UK) for 3 
minutes, rinsed in cold running water for 2 0  minutes and left to dry in a fume hood.
79
2.2.4 . 8  Image analysis
A  video-based densitometry MCID image analyser (Imaging research, Ontario, Canada) 
was used to analyse quantitative receptor binding autoradiography. A computerised 
free-hand drawing tool was used to take measurements from the right and left 
hemispheres o f the brain, providing a duplicate representation of each structure 
analysed. For central structures one measurement was taken. The regions of interest 
were identified using the mouse atlas of Franklin and Paxinos (1997).
Specific binding was calculated by subtracting the non-specific binding from the total 
binding in the images of the brain sections. With reference to the calibration standards 
laid dovm with the slides, specific binding was expressed in fmol/mg tissue equivalent 
against a 3*^  ^degree polynomial curve.
2.2.5 Radiolabelled ligands
[^H]racIopride: Specific activity 82.8 Ci/mmol. Purchased from Perkin Elmer 
(Belgium). Concentration used was 4 nM. Purity >99% as determined by HPLC 
analysis.
[^H]CGS 21860: Specific activity 60 Ci/mmol. Purchased from Amersham 
International pic. (Buckinghamshire, UK). Concentration used was 10 nM. Purity >99% 
as determined by HPLC analysis.
[^HJMPEP: Specific activity 60 Ci/mmol. Purchased from American Radiolabelled 
Chemicals (St Louis, Missouri, USA). Concentration used was 10 nM. Purity >99% as 
determined by HPLC analysis.
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2.2.6  Data analysis
All graphs were produced using GraphPad Prism V5.04 software (GraphPad Software 
Inc., USA). All statistical analysis was carried out using Statistica V I0 software 
(StatSoft Inc., USA).
2.2.6 .1 Motor activity measurement
Basal (treatment-naive) locomotor activity was represented as the mean ± SEM of the 
cumulative total horizontal or vertical (rearing) activity for 1 hour before any treatment 
on Day 1. Comparison o f these behaviours between WT and A2A KO mice was carried 
out using Student’s unpaired t-test. The mean ± SEM of the cumulative pre- (1 hour) 
and post-injection ( 3 x 1  hour) total horizontal or vertical activity was calculated for 
each experimental group every day throughout the duration of the study. Comparison of 
locomotor activities was carried out using three-way repeated measures ANOYA for 
factors genotype, treatment and time and significant factors were further analysed with 
Unequal n Tukey post-hoc test.
2.2.6.2 Autoradiography o f  dopamine D2 and glutamate mGlu 5 receptors
The mean ± SEM of each ligand binding measures (fmol o f radioligand bound/mg 
tissue equivalent) was calculated in each brain region for each experimental group. In 
treatment-naive animals, comparison of quantitative measures of autoradiographic 
binding for the ligand was carried out using two-way ANOYA for factors genotype and 
brain region followed by Duncan’s Multiple Range post-hoc test where appropriate. For 
the chronic cocaine administration experiment, comparison of quantitative measures of 
autoradiographic binding for the ligand was carried out using three-way ANOYA for
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factors genotype, treatment and brain region. Two-way ANOVA was used to assess 
differences in binding between genotype and treatment in each brain region, followed 
by Duncan’s Multiple Range post-hoc test where appropriate.
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2.3 Results
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Day 1 in WT and A 2A KO mice
Basal (treatment-naiVe) locomotion, defined as total number o f horizontal or vertical 
beam-breaks for 1 hour prior to either treatment injection on Day 1, showed there was 
no difference in either the horizontal or vertical activity o f WT and A2A KO mice 
(P>0.05, Figure 2.2A,B).
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Figure 2.2: Basal locomotor activity in wild-type and adenosine A2A receptor 
knockout mice prior to cocaine treatment. Basal horizontal (A) and vertical (rearing) (B) 
locomotor data of wild-type (WT) and adenosine A2A receptor knockout (KO) mice were collected in 5- 
minute bins for 1 hour prior to injection of saline or 15 mg/kg cocaine on day 1. The cumulative total of 
rearing activity during 1 hour prior injection is represented as mean ± SEM (n= 15-20).
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2.3.2 Horizontal locomotion pre- and post- chronic ‘binge ’ cocaine administration in 
WT and A 2A KO mice
Horizontal locomotor activity in WT and adenosine A%A KO mice was recorded in 5- 
minute bins for 1 hour prior to injections of either saline or cocaine (pre-injection 
activity) or for 1 hour post each injection (11:00, 12:00, 13:00) every day throughout 
the duration o f the study. Horizontal activity was measured as number of horizontal 
beam-breaks per bin and a cumulative total was calculated.
To assess cocaine-induced effects on basal horizontal activity (pre-injection), this was 
recorded for 1 hour prior to first daily injection on each day throughout the study 
(Figure 2.3A). All groups showed a decrease in basal activity over time (time effect, 
F(9,270) = 4.29, P<0.001) and post-hoc analysis for the factor of time revealed that in 
comparison to Day 2, this decrease was significantly different from Day 5 onwards in 
all treatment groups (P<0.001). No significant effects o f genotype (P>0.05) or treatment 
(P>0.05), nor interactions between any factors (P>0.05) were observed.
Three-way repeated measures ANOVA showed that treatment with chronic ‘binge’ 
cocaine increased horizontal locomotor activity compared to saline controls (treatment 
effect, F(i 3^0) = 22.88, P<0.001, Figure 2.3B). Compared to saline controls, cocaine- 
stimulated horizontal activity was significantly increased on most days in both WT 
(Day 1, P<0.001; Days 2, 3, 9, 11, P<0.01; Days 10, 12, 13, P<0.05) and A2A KO mice 
(Day 1, P<0.001; Days 2, 3, 11, 12, P<0.05; Days 9, 10, P<0.01). In addition, a 
significant effect o f time was observed (time effect, F(io,3oo) = 4.29, P<0.001). Over 
time, the ability of cocaine to stimulate locomotor activity decreased (time x treatment 
interaction, F(io,3oo) = 4.29, P<0.001). Post-hoc analysis revealed that in comparison to 
Day 1, cocaine-stimulated activity was significantly decreased on all days (Days 2, 3, 5,
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6, 8, 11, 13, P<0.01; Day 10, P<0.05) except Days 9 and 12 (P>0.05). Neither 
significant effect of genotype (P>0.05), nor any other interactions between genotype, 
time and treatment were observed (P>0.05).
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Figure 2.3: Effect of chronic ‘binge’ cocaine administration on pre- and post­
injection horizontal locomotor activity in wild-type and adenosine A2A receptor 
knockout mice. (A) Pre-injection horizontal locomotor activity in wild-type (WT) and adenosine A2A 
receptor knockout (KO) mice following saline or cocaine ‘binge’ administration throughout the duration 
of the study. Basal (pre-injection) locomotor data was collected daily in 5-minute bins for 1 hour prior to 
the first of 3 daily injections of saline or 15 mg/kg cocaine. The cumulative total of daily horizontal 
activity during 1 hour prior to injection is represented as mean ± SEM (n=7-l 1). A significant effect of 
time (P<0.001) was observed (3-way repeated measures ANOVA). ***P<0.001 vs. Day 2 over all 
treatment groups (Unequal n Tukey post-hoc test). Data for Day 1 is omitted as it is represented in Figure 
2.2. (B) Total horizontal locomotor activity in WT and KG mice following administration of saline or 
cocaine (15 mg/kg, s.c.) in a chronic ‘binge’ paradigm (3 x daily injections at 11:00, 12:00 and 13:00). 
Locomotor data was collected daily in 5-minute bins for 1 hour post each injection. The daily cumulative 
total of horizontal activity during each 1 hour period post each injection is represented as mean ± SEM (n 
= 7-11). Significant effects of time (P<0.001), treatment (f<0.001) and a treatment x time interaction 
(f<0.001) were identified (3-way repeated measures ANOVA). Cocaine-stimulated activity was 
significantly increased from saline controls on most days (P<0.05 - P<0.001) in WT and KO mice, 
however, significance is omitted from the graph for purpose of clarity. *P<0.05, ***P<0.001 vs. Day 1 
over all treatment groups (Unequal n Tukey post-hoc test). Data for days 4, 7 and 14 are absent due to 
irretrievable software failure.
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2.3.3 Vertical locomotion pre- and post- chronic ‘binge’ cocaine administration in 
WT and A 2A KO mice
Vertical (rearing) activity in WT and A2A KO mice was recorded in 5-minute bins for 1 
hour prior to injections of either saline or cocaine (pre-injection activity), or for 1 hour 
post each injection (11:00, 12:00, 13:00) every day throughout the duration of the study. 
Vertical activity was measured as number of vertical beam-breaks per 5 minute bin and 
a cumulative total was calculated.
To assess cocaine-induced effects on basal (pre-injection) vertical activity, this was
recorded for 1 hour prior to first daily injection on each day (Figure 2.4A). All groups
showed a decrease in basal activity over time (time effect, F(9 2^6i) = 17.40, P<0.001),
and post-hoc analysis in the factor of time revealed that in comparison to Day 2, this
decrease was significantly different from Day 5 onwards in all treatment groups
(P<0.001). No significant effects o f genotype (P>0.05) or treatment (F>0.05) were 
observed.
Three-way repeated measures ANOVA showed that treatment with chronic ‘binge’ 
cocaine increased vertical locomotor activity compared to saline controls (treatment 
effect, F(i,30) = 16.89, P<0.001). Compared to saline controls, cocaine-stimulated 
vertical activity was significantly increased in WT mice on Day 1 (P<0.01) and Day 2 
(P<0.05). In cocaine-treated A2A KO mice, vertical activity was significantly increased 
from saline controls on Day 1 (P<0.01) and Day 9 (P<0.05). In addition, a significant 
effect of time was observed (time effect, F(io,3oo) = 7.25, P<0.001).
Injections o f cocaine on Day 1 caused a significant increase in vertical activ ity , 
however, this effect was reduced over time (time x treatment interaction, F(io,32()) = 5 .4 4 , 
F<0.001, Figure 2.4B). Post-hoc analysis revealed that cocaine administration o n  all
8 7
other treatment days significantly reduced rearing behaviour in comparison to Day 1 
(P<0.001). Neither significant effect of genotype (P>0.05), nor any other interactions 
between genotype, time and treatment (F>0.05) were observed.
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Figure 2.4: Effect of chronic ‘binge’ cocaine administration on pre- and post­
injection vertical locomotor activity in wild-type and adenosine Aja receptor 
knockout mice. (A) Pre-injection vertical activity (rearing) in wild-type (WT) and adenosine À2a 
receptor knockout (KO) mice following saline or cocaine ‘binge’ administration throughout the duration 
of the study. Basal (pre-injection) locomotor data was collected daily in 5-minute bins for 1 hour prior to 
the first of 3 daily injections of saline or 15 mg/kg cocaine. The daily cumulative total of rearing activity 
during 1 hour prior injection is represented as mean ± SEM (n=7-ll). A significant effect of time 
(P<0.001) was observed (3-way repeated measures ANOVA). ***P<0.001 vs. Day 2 over all treatment 
groups (Unequal n Tukey post-hoc test). Data for Day 1 is omitted as it is represented in Figure 2.2. (B ) 
Total vertical activity in WT and KG mice following administration of saline or cocaine (15 mg/kg, s.c.) 
in a chronic ‘binge’ paradigm (3 x injections at 11:00, 12:00 and 13:00). Locomotor data was collected 
daily in 5-minute bins for 1 hour post each injection. The daily cumulative total of rearing activity during 
1 hour post each injection is represented as mean ± SEM (n=7-l 1). Significant effects of time (f<0.001), 
treatment (f< 0 .0 0 1 ) and a treatment x time interaction (f<0 .0 0 1 ) were identified (3 -way repeated 
measures ANOVA). <0.001 vs. Day 1 over all treatment groups. ^f<0.05, ^^ P<0.01 vs. WT Saline, 
^f<0.05, ^^f<0.01 vs. KO Saline (Unequal n Tukey post-hoc test). Data for days 4, 7 and 14 are absent 
due to irretrievable software failure.
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2.3.4 Autoradiographic binding o f  the adenosine Â 2a receptor fo r  genotype 
confirmation o f in treatment-naive and cocaine-treated WT and À 2a KO mice
Striatal sections from the brains of each experimental animal were bound with the 
radiolabelled A2A receptor agonist [^HjCGS 21f80 to confirm that the genotype 
determined by the PCR and DNA electrophoresis procedures was correct. 
Representative images showing the presence (WT) and absence (KO) of A2A receptors 
are shown in Figure 2.5.
W T KO
Figure 2.5: Receptor autoradiographic binding of the adenosine A%A receptor with 
[ H|CGS 21680 to confirm genotype in wi ld-type and adenosine A%A knockout mice.
Representative computer-enhanced pseudocolour autoradiograms of coronal brain sections from naïve 
wild-type (WT) and adenosine A?A receptor knockout (KO) mice are shown. The adjacent sections shown 
are from the level of the caudate (Bregma +1.10 mm).
The genotype of all mice used in the treatment-naive binding studies was confirmed as 
correct, however, approximately 15% of mice used in the chronic cocaine study were 
genotyped incorrectly as originally identified by PCR and DNA electrophoresis. Data 
obtained from these animals was re-assigned to the correct genotype treatment group.
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2.3.5 Quantitative autoradiographic binding o f  the dopamine D2 receptor in brains o f  
treatment-naive WT and A 2A KO mice
Quantitative autoradiography of the dopamine D2 receptor from coronal sections of the 
caudate showed extensive binding throughout (Figure 2.6). Binding of [^HJraclopride 
was observed in the Acb, Tu and CPu (region effect, F(3,40) = 27.88, P<0.001), where the 
highest level of binding was observed (mean specific binding 66.8 -  75.1 fmol/mg 
tissue equivalent). No significant genotype effect was observed (P>0.05).
2.3.6 Quantitative autoradiographic binding o f  the glutamate mGlus receptor in 
brains o f  treatment-naive WT and A 2A KO mice
Binding of 10 nM [^HJMPEP in coronal brain sections showed widespread localisation 
of the mGlus receptor (Figure 2.7). Two-way ANOVA showed a significant effect of 
region consistent with the localisation of mGlus receptors in the brain (F(i2,i2i) = 9.05, 
P<0.001). Levels o f [^HJMPEP binding were uniform in most of the regions analysed 
except the lateral septum (LS), where the highest density was observed (mean 95.4 -
109.3 fmol/mg tissue equivalent). In addition, thalamic regions had a lower density of 
[^HjMPEP binding (mean 39.1 -  42.4 fmol/mg tissue equivalent).
There was an effect of genotype (F(ij2i) = 9.90, P<0.01), but no genotype x region 
interaction (P>0.05). Binding density of [^HJMPEP was lower in the ventral striatum 
region of A2A KO versus WT mice. In comparison to WT, this decrease reached 
significance in the nucleus accumbens core (AcbC; P<0.01).
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Figure 2,6: Quanti tat ive autoradiography of 0% receptor binding in coronal  
brain sections from treatment-naïve wi ld-type or A2 A receptor knockout mice.
(A) Data are expressed as the mean specific binding (fmol/mg tissue equivalent) ± SEM (n=6) of 
fHjraclopride in brain regions of treatment-naive wild-type (WT) and adenosine A2A receptor 
knockout (KO) mice. Regional determinations were made from both left and right sides of the 
sections. Labelling of the sections was carried out in a completely paired protocol. No significant 
effect of genotype was observed in any brain region (f>0.05). AcbC, nucleus accumbens core; 
AcbSh, nucleus accumbens shell; CPu, caudate putamen; Tu, olfactory tubercule. (B) Representative 
computer-enhanced autoradiograms of total and non-specific (NSB) fHJraclopride binding in 
coronal brain sections from treatment-naïve WT and KO mice. The adjacent sections shown are 
from the level of the caudate (Bregma +1.10 mm). Specific binding was -80% of total binding in 
the majority of regions analysed. The colour bar represents a pseudo-colour interpretation of black 
and white film images in fmol/mg tissue equivalent.
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Figure 2.7: Quanti tat ive autoradiography of mGlug receptor binding in coronal  
brain sections from treatment-naive wi ld-type or adenosine A 2 A receptor  
knockout mice. (A) Data are expressed as the mean specific binding (fmol/mg tissue equivalent) 
± SEM (n=5-6) of [^HJMPEP in brain regions of treatment-naïve wild-type (WT) and adenosine A?A 
receptor knockout (KO) mice. Regional determinations were made from both left and right sides of 
the sections. Labelling of the sections was carried out in a completely paired protocol. A significant 
effect of genotype (P<0.01) was observed (2-way ANOVA). **f<0.01 vs. WT (Duncan’s Multiple 
Range post-hoc test). AcbC, nucleus accumbens core; AcbSh, nucleus accumbens shell; Amy, 
amygdala; Cg, cingulate cortex; CPu, caudate putamen; Hip, hippocampus; Hyp, hypothalamus; LS, 
lateral septum; Ml, M2, primary and secondary motor cortices; MS, medial septum; PrL, prelimbic 
cortex; Th, Thalamus; VDB, ventral limb of the diagonal band of Broca. (B) Representative 
computer-enhanced autoradiograms of total and non-specific (NSB) [^ EIJMPEP binding in coronal 
brain sections from treatment-naïve WT and KO mice. The adjacent sections shown are from the 
level of the caudate (Bregma +0.86 mm). The colour bar represents a pseudo-colour interpretation 
of black and white film images in fmol/mg tissue equivalent. Specific binding was -60% of total 
binding in the majority of regions analysed.
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2.5.7 Effect o f  chronic ‘binge’ cocaine administration on quantitative
autoradiographic binding o f  the dopamine D2 receptor in WT and A 2A KO mice
As can be seen in Figure 2.8, binding of [^HJraclopride in animals treated with chronic 
‘binge’ cocaine or saline showed a similar pattern of localisation to that observed in 
treatment-naive animals, whereby binding was observed in the Acb, Tu and CPu (region 
effect, F(3  ^71) = 34.16; P<0.001), where the highest density was observed (mean specific
binding 88.3 - 111.2 fmol/mg tissue equivalent). No significant effects o f genotype
(P>0.05) or treatment (P>0.05), nor interactions between those factors were observed 
(f>0.05).
2.3.8 Effect o f  chronic ‘binge’ cocaine administration on quantitative
autoradiographic binding o f  the glutamate mGlus receptor in WT and A 2a KO 
mice
Binding o f [^HJMPEP in animals treated with chronic ‘binge’ cocaine or saline (Figure 
2.9) showed a similar pattern of localisation to that observed in treatment-naïve animals, 
with highest binding observed in the LS (mean specific binding 131.8-166.1 fmol/mg 
tissue equivalent), and lower binding in the thalamus (mean specific binding 52.1 -7 7 .2  
fmol/mg tissue equivalent; region effect, F(i2,232) = 8.05; P<0.001). No effect of 
treatment (P>0.05), genotype (P>0.05) nor a treatment x genotype interaction were 
observed (P>0.05).
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Figure 2.8: Quanti tat ive autoradiography of receptor binding in coronal  
brain sections from chronically saline or cocaine ‘binge’ treated wi ld-type and 
adenosine A^ A receptor knockout mice. (A) Data are expressed as the mean specific 
binding (fmol/mg tissue equivalent) ± SEM (n= 4-8) of [^HJraclopride in brain regions of wild-type 
(WT) and adenosine Aja receptor knockout (KO) mice chronically treated with saline or a ‘binge’ 
cocaine administration protocol. Regional determinations were made from both left and right sides 
of the sections. Labelling of the sections was carried out in a completely paired protocol. No 
significant effect of genotype or treatment was observed in any brain region. (B) Representative 
computer-enhanced autoradiograms of total ["’HJraclopride binding in coronal brain sections from 
chronically cocaine or saline treated WT and KO mice. The adjacent sections shown are from the 
level of the caudate (Bregma +1.10 mm). The colour bar represents a pseudo-colour interpretation 
of black and white film images in fmol/mg tissue equivalent. Specific binding was -80% of total 
binding in the majority of regions analysed. AcbC, nucleus accumbens core; AcbSh, nucleus 
accumbens shell; CPu, caudate putamen; Tu, olfactory tubercule.
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2.4 Discussion
The aim of this chapter was firstly to investigate the presence of an interaction of A2A 
with mGlus and D2 receptors in brain tissue by quantitative autoradiography of these 
receptors in treatment-naïve WT and A2A KO mice. In addition, this study aimed to 
further investigate the role of the A2A receptor in mediating the locomotor and 
stereotypic effects of cocaine administration in WT and A2A KO mice and to identify if 
A2A plays a role in the regulation of D2 and m01u$ receptor binding following chronic 
‘binge’ cocaine administration.
The genotype o f all mice used in this study was confirmed ex vivo by radiolabelling 
striatal brain sections with [^H]CGS 21680 (Figure 2.5). Although all genotypes were 
confirmed as being correct for the treatment-naïve study, approximately 15% of the 
animals used in the chronic cocaine study were incorrectly genotyped by PCR. Where 
incorrect, data were reassigned to the correct genotype group. These discrepancies 
contributed to variability between the numbers of animals used in each experimental 
group and indicates that perhaps the PCR probes used to genotype the A2A receptor gene 
were not fully robust which, without ex vivo autoradiographical confirmation, could 
have led to the generation of false positives. This illustrates the great importance of 
confirming the genotype of transgenic animals with other techniques, in this case, 
autoradiographical binding.
2.4,1 Basal locomotor activity prior to treatment with saline or 'binge’ cocaine on 
Day 1 in WT and A 2A KO mice
Prior to any treatment on Day 1, the basal horizontal and vertical ‘rearing’ activity of 
WT and A2A KO mice was not significantly different (Figure 2.2). These data are in
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agreement with observations from both Soria et al. (2006) and Castané et a l  (2008) in 
CD-I A2A KO mice versus WT. Additionally, no difference in basal locomotion 
between A2A KO and WT mice bred on both 129-Steel and hybrid 129-Steel x 
C57BL/6J strains was observed (Chen et a l,  2000), suggesting that absence of the A2A 
receptor does not affect basal locomotor activity. However, these findings are in 
contrast with the original phenotyping study (Ledent et a l,  1997) using A2A KO mice 
bred on the same CD-I background as used in the present study. It is known that A2A 
KO mice have a more anxiogenic phenotype versus WT counterparts as they showed 
decreased open-arm time in the elevated plus-maze test (Ledent et a l,  1997). Animals 
that are anxious or fearful have reduced horizontal and vertical behaviours in novel 
environments, i.e. reduced exploratory activity (Holmes, 2003), and this behaviour may 
have contributed to the decreased activity originally observed by Ledent et a l  (1997). 
Importantly, anxiety responses in rodents are further affected by parameters such as 
environmental- and experimenter-habituation (Hurst and West, 2010) and social 
interaction (Ago et a l ,  2007). Mice used in the present study and by Soria et a l (2006) 
and Castané et a l  (2008) had either repeated exposure to both the test environment 
(either experimental room or motility chamber), or received experimenter handling prior 
to experimental start. It is feasible that such habituation may have reduced the anxiety 
of these mice and therefore increased motor activity under test conditions.
2.4.2 Effect o f  chronic ‘binge' cocaine treatment on pre-injection locomotor activity 
in WT and A 2A KO mice
In order to determine if  chronic ‘binge’ cocaine administration had any effect on the 
basal (pre-injection) locomotor activity of WT or A2A KO mice, horizontal and vertical 
activity was recorded for one hour prior to beginning experimental procedure on each
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day throughout the experiment. Upon first exposure to a novel open-field environment, 
rodents display pronounced behavioural activation in the form of exploratory behaviour, 
which includes sniffing, walking/running and hind-limb rearing (Drai et a l,  2001). In 
agreement, the present data showed that during their initial experiences of the motility 
chamber, both horizontal and vertical activities of all mice were high (Figures 2.3 A and 
2.4A). However, over time all groups showed a significant decrease in their total daily 
basal horizontal and vertical activity (time effect). This is likely an effect of behavioural 
habituation, a basic form of learning (Thiel et a l,  1998), whereby repeat exposure to an 
environment renders it less novel and thus reduces exploratory behaviour. 
Familiarisation strongly attenuates such locomotor exploratory behaviours which are 
replaced by grooming/cleaning responses and eventually sleep. The lack of treatment 
effect in the present data indicates that pre-treatment with cocaine does not affect 
habitual learning and locomotor responses to novel environment when administered in a 
‘binge’ protocol in CD-I mice. Further, modulation of this behaviour does not involve 
A2A receptors, despite A2A receptors having a crucial role in arguably more complex 
learning environments leading to habit formation (Yu et a l,  2009).
2.4.3 Acute cocaine-stimulated locomotion in WT and A 2A KO mice
The chronic ‘binge’ administration paradigm was designed to more accurately reflect 
the human pattern of cocaine taking in comparison to administration of repeated daily 
single doses (Maisonneuve, 1994). Acute cocaine administration blocks accumbal DAT 
and therefore increases striatal extracellular DA concentrations, which, particularly in 
the Acb, contributes to the locomotor activating effects o f psychostimulants (see 
Amalric and Koob, 1993). The data showed that administration of chronic ‘binge’ 
cocaine on Day 1 increased horizontal activity of both WT and A2A KO mice to a
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similar degree and that this increase was, as expected, significantly different from saline 
controls (Figures 2.3B and 2.4B). Cocaine-induced vertical activity was also initially 
increased as compared to saline controls in both genotypes; however, this was less 
prominent following the second day of cocaine administration.
The lack of genotype effect on acute ‘binge’ cocaine-induced horizontal locomotion 
(i.e. total activity on Day 1) observed in this study is in agreement with data from acute 
single-dose cocaine (1 x 10 or 20 mg/kg i.p.) administration studies in CD-I A2A KO 
mice (Soria et a l ,  2006, Brown et a l,  2011). However, they are in contrast to the 
attenuated hyperlocomotor response to psychostimulants observed in inbred (C57BL/6J 
X 129-Steel hybrid and 129-Steel) global A2A KO mice (Chen et a l ,  2000, Chen et a l,  
2003). Evidence using conditional A2A KO mice (C57BL/6J x 129-Steel hybrid 
background) showed that the attenuation of cocaine-induced hyperactivity in these mice 
is attributable to suppression of extrastriatal A2A receptors (Shen et a l ,  2008). Although 
this finding helped explain the cocaine-induced locomotor discrepancies observed when 
comparing pharmacological antagonism of A2A receptors (Filip et a l ,  2006) and A2A 
genetic inactivation (Chen et a l, 2000), it does not explain the difference in cocaine- 
induced locomotor responses in global A2A KO mouse bred on different backgrounds. 
One of the reasons for this discrepancy may be attributable to the established strain 
difference in their ability to metabolise cocaine (McCarthy et a l,  2004), which is 
known to impact on behavioural response, as brain cocaine levels positively correlate 
with locomotor stimulation (Benuck et a l, 1987). Behavioural responses may be further 
affected by strain differences in either striatal neurotransmission or the density or 
functioning of associated receptors, which may also be further affected by unidentified 
compensatory or developmental alterations as a consequence of genetic deletion o f the
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AzA receptor. Indeed, the genetic background of mouse strain has been shown to 
influence phenotypic and neurochemical consequences of gene deletion, such as those 
observed in opioid-receptor knockout mice. For example, Hummel et al. (2004) 
demonstrated differential effects of cocaine-induced sensitisation in p-opioid receptor 
KO mice bred on a variety of genetic backgrounds. Similarly, neurochemical alterations 
were observed in DA Di receptor binding in triple-opioid receptor KO mice bred on 
different background strains (Yoo et a l,  2010a). As such, this suggests that background 
strain plays an important role in influencing phenotypic and neurochemical responses in 
KO mice.
2.4.4 Chronic cocaine-stimulated locomotion in WT and A 2A KO mice
The chronic ‘binge’ cocaine administration paradigm has so far only been studied in rats 
(Maisonneuve, 1994, Maisonneuve et a l, 1995) and the C57BL/6J and 129/J inbred 
strains of mice (Schlussman et a l,  2003, Zhang et a l,  2003, Bailey et a l ,  2008, 
Metaxas et a l,  2012), therefore the present data are the first to utilise this protocol in the 
outbred CD-I mouse strain. Chronic ‘binge’ cocaine administration in CD-I mice 
increased both horizontal and vertical activity (treatment effect), and this increase was 
significantly higher on Day 1 than on any other day in both genotypes (Figure 2.3B and 
2.4B). This suggests that CD-I mice develop rapid tolerance to the locomotor-activating 
effects of cocaine following acute ‘binge’ cocaine administration. In agreement, 
locomotor tolerance to chronic ‘binge’ cocaine administration in C57BL/6J mice was 
also observed over the study duration period (Schlussman et a l,  2003), perhaps due to a 
reduction of cocaine-induced elevations in extracellular striatal DA transmission 
compared to first cocaine exposure (Zhang et a l ,  2003). However, other studies using 
the same ‘binge’ cocaine administration paradigm in C57BL/6J mice have shown that.
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whilst showed no locomotor tolerance throughout the duration of the study (Day 1 vs. 
Day 13), a brief period o f locomotor sensitisation around Day 3 -  5 in comparison to 
Day 1 was observed (Bailey et a l,  2008, Metaxas et a l ,  2012). The present study used 
an identical protocol to Bailey et a l  (2008) and Metaxas et a l (2012), however, no 
evidence of sensitisation to cocaine was observed in the CD-I strain, suggesting a 
strain-specific behavioural response to this paradigm. Indeed, strain-specific effects in 
modulating behaviours induced by ethanol (Roberts et a l, 1992), heroin (Bailey et a l,
2010), morphine (Orsini et a l,  2005) and amphetamine (Conversi et a l ,  2011) have 
also been observed which suggests that, in agreement with others, genetic background 
has a significant role in modulating the behavioural responses to addictive drugs 
(Barbaccia et a l,  1981; Shoaib et a l,  1995; He and Shippenberg, 2000; Fadda et a l,  
2005).
Additionally, the general pattern of cocaine-induced rearing behaviour observed over 
time (Figure 2.4B) was dissimilar to the rearing pattern observed in C57BL/6J mice, 
which, in contrast with our observations, progressed toward high levels of rearing with 
repeat cocaine administration (Bailey et a l, 2008, Metaxas et a l,  2012). In fact, visual 
observation of the stereotypic responses to cocaine in CD-I mice throughout the 
duration of the study showed a completely different pattern to that observed in 
C57BL/6J mice, which most notably included a tendency for persistent circling/turning 
behaviour rather than rearing (data not shown). This implies that the stereotypic 
behaviours induced by cocaine are strain specific, which is in agreement with the strain- 
specific stereotypic responses to cocaine observed between C57BL/6J and 129/J mice 
by Schlussman et a l  (2003). The present data also suggest the modified Creese-Iversen
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stereotypic scale (Creese and Iversen, 1973, Schlussman et a l ,  2003, Bailey et a l,
2008) may not be appropriate for scoring cocaine-induced stereotypy in CD-I mice.
With the exception of Soria et a l  (2006), no other study has investigated the effect of 
chronic cocaine administration on locomotor effects in A2A KO mice. The present data 
are in agreement with Soria et a l  (2006) who also observed no difference in total 
locomotor activity between WT and A2A KO throughout the duration of chronic single­
dose cocaine administration. The data, however, are in contrast with Filip et a l  (2006), 
who demonstrated A2A receptor agonists protected against the development and 
expression of cocaine sensitisation in rats. This suggests that the role of A2A in the 
modulation of the locomotor effects of chronic cocaine administration is subject to both 
strain and species differences. In addition, the present data demonstrates that vertical 
activity, a proposed indicator o f cocaine-induced stereotypy, is also unaffected by 
deletion o f the A2A receptor in CD-I mice, although this may be attributable to a 
different pattern o f cocaine-stereotypic behaviours observed in these mice when 
compared to others (Creese and Iversen, 1972, Bailey et a l,  2008, Metaxas et a l,  
2012). Therefore, further study is warranted to elucidate the role of A2A receptors in 
cocaine-induced stereotypy in CD-I mice.
In short, these data add to existing evidence which shows that the genetic background of 
mice can alter behavioural responses, either as a consequence of genetic deletion (Yoo 
et a l,  2010a), in response to addictive drugs (McCarthy et a l ,  2004, Bailey et a l,  2010) 
or a combination of both (Hummel et a l,  2004). This further highlights the need for 
careful consideration regarding strain and experimental paradigm and the need for 
caution in both comparing and interpreting such data.
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2.4.5 Quantitative autoradiographic binding o f  the dopamine D2 receptor in 
treatment-naive WT and A 2A KO mice
As shown in Figure 2.6, the present data showed that, in accordance with the literature, 
D2 receptor binding levels were not affected by A2A receptor deletion in treatment-naive 
mice (Chen et a l ,  2000, Dassesse et a l,  2001, Bailey et a l,  2004, Al-Hasani et a l,
2011). Although this evidence suggests that D2 receptor density is unaltered in A2A KO 
mice, it does not necessarily rule out alterations in downstream D2 signal transduction 
events; especially given that the reciprocal D2-A2A interaction occurs at the second 
messenger level (see Section 1.5.1). In support of this, electrophysiological studies have 
shown that levels of D2 receptor desensitisation in the DAergic VTA neurons of A2A 
KO mice are increased in comparison to WT mice (Al-Hasani et a l,  2011), without 
changes in D2 receptor density. The authors speculate that this finding may contribute to 
the hypoDAergic state observed in A2A KO mice (Dassesse et a l, 2001) and may have 
implications on the regulation of DA transmission in response to drugs of abuse.
2.4.6 Effect o f  chronic ‘binge’ cocaine administration on quantitative 
autoradiographic binding o f  the dopamine D2 receptor in WT and A 2A KO mice
Chronic ‘binge’ cocaine treatment had no effect on D2 receptor binding levels when 
compared to saline controls (Figure 2.8), which was in agreement with the lack of D2 
receptor modulation observed following an identical administration paradigm in 
C57BL/6J mice (Bailey et a l,  2008). This suggests that chronic ‘binge’ cocaine 
administration does not alter D2 receptor binding density, regardless of strain. In 
addition, D2 receptor function as assessed by quinerolane-stimulated [^^S]GTPyS 
binding was also unchanged following this identical paradigm in C57BL/6J mice 
(Bailey et a l,  2008), indicating that D2 receptor mediated G-protein activity in these
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mice was also unaffected by cocaine treatment. The present data also showed that D2 
receptor binding levels following chronic ‘binge’ cocaine administration were 
unaffected by deletion of the A2A receptor. This indicates that surface levels of the D2 
receptor are not regulated by A2A receptors either in a physiological state (treatment- 
naive, Figure 2.6), or in response to chronic cocaine administration. As D2 receptors are 
thought to attribute to the motor-stimulant responses to cocaine (Beyer and Steketee, 
1999, 2002), lack o f D2 receptor mediated effect observed presently are in line with the 
absence of genotype effect on behaviour observed in both the basal data (treatment- 
naive, Figure 2.2), and following chronic cocaine administration (Figures 2.3B and 
2.4B).
2.4.7 Quantitative autoradiographic binding o f  the glutamate mGlus receptor in 
treatment-naive WT and A 2A KO mice
There is a growing body o f literature which suggests that A2A and mGlug receptors 
functionally interact, particularly in the striatum, to synergistically overcome D2- 
mediated effects both at the behavioural and molecular levels (Ferre et a l,  2002, 
Coccurello et a l ,  2004, Kachroo et a l, 2005). Although there is some evidence this 
interaction may reflect a permissive role o f A2A on mGlug mediated effects (Domenici 
et a l, 2004, Tebano et a l, 2005), the mechanisms underpinning this interaction are 
currently unknown. In order to understand if  this interaction existed at the receptor 
level, the present study aimed to elucidate whether the levels of the mGlug receptor, 
radiolabelled with [^HJMPEP, were altered in animals genetically lacking the A2A 
receptor.
In accordance with published immunohistochemical data (Shigemoto et a l ,  1993, 
Romano et a l , 1995), the present study showed widespread mGlus receptor binding
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throughout the brain, with particularly high density in the LS (Figure 2.7). Deletion of 
the A2A receptor caused an overall reduction of mGlug receptor binding in forebrain 
regions, and a significant decrease in the AcbC, suggesting that mGlug receptor 
expression in the AcbC is directly regulated by A2A receptors. Indeed, the ventral 
striatum shows high density of both A2A and mGlus receptors (Rosin et a l, 1998, 
Mitrano and Smith, 2007, Mitrano et a l, 2010) and striatal A2A and mGlug receptors 
have been shown to functionally interact (see Section 1.7.2). Although the present 
autoradiographical technique is unable to distinguish between pre- and postsynaptic 
receptors, these data are in line with evidence demonstrating co-localisation of A2A- 
mGlug receptors both presynaptically in corticostriatal glutamatergic terminals 
(Rodrigues et al., 2005), and also postsynaptically in striatopallidal neurons as indicated 
in vitro (Cabello et a l, 2009) and suggest that an A2A-mGlu5 interaction is at least partly 
disrupted by the removal of the A2A receptor. The exclusive existence of an A2A- 
mediated mGlug receptor regulation in the striatum may have specific behavioural 
implications for pathological diseases of the basal ganglia, such as Parkinson’s disease 
and drug addiction. Specific targeting of this receptor heterodimer, such as via the 
development o f a bivalent ligand (see Soriano et a l ,  2009) and not A2A or mGlu$ 
receptors located elsewhere, may minimise unwanted side effects observed as a 
consequence of pharmacological global targeting o f these receptors.
The mechanism underlying the A2A-IT1GIU5 receptor interaction observed presently is not 
clear, although it might reflect a compensatory downregulation of mGlu$ receptors in 
the striatum in response to high striatal glutamatergic transmission. In agreement, 
microdialysis experiments have shown that tonically, A2A KO mice had striatal levels of 
glutamate three-fold higher than those observed in their WT counterparts (Dassesse et
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a l, 2001). Alternatively, the present observation may be due to the disruption of a 
complex mGlus-AzA-Di receptor oligomer (Cabello et a l,  2009) and consequent 
alterations in downstream effects. A wealth of evidence exists which supports an 
interaction of mGlu$ receptors and the Homer 1 family of postsynaptic scaffolding 
proteins (see Brakeman et a l,  1997, Ribeiro et a l,  2010). These proteins act to regulate 
mGlus receptor signalling and trafficking via coupling to other glutamatergic receptors 
or intracellular signal transduction pathways (Tu et a l,  1999, de Bartolomeis and 
lasevoli, 2003). It has been shown that the presence o f Homer 1 protein subtype, Homer 
la, which is found in glutamatergic synapses in the hippocampus, striatum and cortex 
(Xiao et al., 1998) was necessary for expression of mGlug receptors in cultured neurons 
(Ango et a l,  2002). Moreover, although there is no evidence as yet providing a link 
between A2A receptors and Homer proteins, recent findings suggest that expression of 
Homer la  proteins is regulated by D2 receptor manipulation (lasevoli et a l ,  2009). This 
suggests that disruption o f the A2A-D2 complex, via A2A receptor deletion, may have 
downstream effects on D2-mediated regulation o f Homer la  and therefore mGlug 
receptor surface expression.
2.4.8 Effect o f  chronic ‘binge’ cocaine administration on quantitative 
autoradiographic binding o f  the glutamate mGlus receptor in WT and A 2A KO  
mice
The pattern o f mGlus binding following chronic ‘binge’ cocaine administration in WT 
and A2A KO mice (Figure 2.9) was consistent with that observed in treatment-naive WT 
mice (Figure 2.7). There was no genotype effect in either saline or cocaine treated 
groups, despite a decrease in mGlug binding observed in treatment-naive A2A KO mice 
(Figure 2.7). The lack of genotype effect on mGlus receptor binding in chronic saline
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animals may be due to receptor modulation in response to chronic injection stress. A2A 
KO mice have been shown to be more sensitive to the anxiolytic effects of alcohol 
(Houchi et a l ,  2008) which may indicate a vulnerability of these mice to other stressful 
or anxiolytic situations, such as injection stress. Moreover, it has been shown that 
mGlus receptors were upregulated in brains of intact mice as a consequence o f chronic 
saline injection stress (Brodkin et a l, 2002a). As a result, it is plausible that the lack of 
genotype effect on mGlus receptor binding in saline-treated when compared to 
treatment-naiVe A2A KO mice, may be due to alterations in mGlug receptor levels as a 
consequence of chronic injection stress.
The present data showed that mGlug receptor density following chronic ‘binge’ cocaine 
administration was unchanged from levels observed in saline controls. This is in 
accordance with data from our laboratory which observed no change in mGlug binding 
density in C57BL/6J mice identically treated with chronic ‘binge’ cocaine (Bailey et a l,
2009). This suggests that cocaine-induced behavioural responses are unlikely to be 
related to changes in mGlus receptor density. In addition, it has been shown that striatal 
mGlus receptor mRNA levels assessed 1 day post final cocaine injection were also 
unchanged versus saline controls (Ghasemzadeh et a l, 2009), however, following a 3- 
week period o f extended withdrawal, a significant elevation of mGlus receptor mRNA 
levels in the Acb was observed (Ghasemzadeh et a l,  1999, Ghasemzadeh et a l ,  2009). 
This implies that mGlu$ receptor regulation may be more important in the later stages of 
cocaine addiction, such as withdrawal. In agreement, alterations in both mGlus receptor 
and Homer 1 mRNA were also observed at 3 weeks, but not 24 hours, following final 
cocaine injection (Swanson et a l,  2001) and similar observations were observed during 
cocaine reinstatement (Wang et a l,  2012). These findings suggest that regulation o f
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mGlus receptors appears to be more prominent in cocaine withdrawal and reinstatement 
rather than cocaine-induced locomotor behaviours. This is in accordance with evidence 
showing that mGlug receptor antagonism does not prevent hyperactivity or sensitisation 
as a consequence of repeat psychostimulant administration (Herzig and Schmidt, 2004, 
Yap et ah, 2005, Dravolina et a l,  2006, Gill et a l,  2012), yet is effective in its ability to 
prevent reinstatement of drug-seeking to cocaine (Backstrom and Hyytia, 2007, 
Kumaresan et a l ,  2009, Martin-Fardon and Weiss, 2012). In short, chronic ‘binge’ 
cocaine administration does not induce neuroplastic changes in mGlug receptor density. 
These changes could occur in cocaine withdrawal and reinstatement, as they do at the 
mRNA level, however, effect of this at the receptor level is unknown.
In addition, the present data also shows that the binding density o f mGlug receptors 
following chronic ‘binge’ cocaine treatment was not dependent on the presence of the 
A%A receptor, as mGlug binding was unaltered from saline controls in cocaine-treated 
A2A KO mice. This finding, together with the lack of genotype effect in cocaine-induced 
locomotor behaviour in A2A KO mice (Figure 2.3B and 2.4B), suggests that A2A and 
mGlus receptors do not interact to mediate the locomotor effect of chronic ‘binge’ 
cocaine administration, at least at the receptor level. This finding is in agreement with 
recent data from Brown et a l (2011) which showed that although A2A and mGlus 
receptors functionally interacted to mediate cocaine-conditioned reward, deletion of the 
A2A receptor had no effect on the ability o f MTEP to attenuate cocaine-induced 
locomotion (Brown et a l ,  2011). This suggests that the mechanism by which mGlug 
antagonism can reduce cocaine-induced hyperactivity does not involve an A2A-mGlu5 
receptor interaction.
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2.4.9 Chapter summary
The present data showed for the first time that deletion of the A2A receptor directly 
reduced mGlus receptor binding density in forebrain regions, in particular the AcbC, 
providing initial evidence that a striatal A2A-mGlu5 receptor interaction occurs at the 
receptor level. Identification of an A2A-dependent regulation on the expression of mGlus 
receptors in areas of the brain where they are densely co-expressed could have 
implications for the development of more selective pharmacotherapies. In addition, it 
was observed that chronic ‘binge’ cocaine treatment in CD-I mice produced a persistent 
locomotor tolerance to cocaine-induced horizontal and vertical hyperactivity following 
the first day of administration and did not induce changes in receptor binding densities 
of either D2 or mGlug receptors. In agreement with findings from Soria et al. (2006), A2A 
receptor deletion had no effect on the locomotor response to chronic cocaine 
administration, despite being administered in a chronic ‘binge’ paradigm, and suggests 
that the A2A receptor is not involved in mediating cocaine-induced activity in CD-I 
mice (Soria et ah, 2006, Brown et ah, 2011). Although evidence is provided for an A ia - 
mGlus receptor interaction in treatment-naive mice, it appears not to be involved in 
mediating the locomotor responses to chronic ‘binge’ cocaine administration, as A2A 
receptor deletion did not alter the binding density of mGlug receptors following chronic 
cocaine treatment. This suggests that the A2A-IÏ1GIU5 receptor interaction is probably not 
involved in mediating cocaine-induced locomotor responses; however, its potential 
relevance in mediating other aspects o f drug addiction, in particular cocaine 
reinstatement, remains to be explored.
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CHAPTER 3
The effect of chronic morphine 
administration and naloxone-precipitated 
withdrawal on locomotor behaviour and 
autoradiographic binding of the D2 and 
mGlus receptors in wild-type and A2A 
receptor knockout mice
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3.1 Introduction
Opiates are a class o f drug derived from the opium poppy, o f which the biologically 
active alkaloid morphine is found most abundantly. Opiate drugs such as morphine and 
codeine, or the semi-synthetic opioid drugs like heroin, exert their effects by binding to 
three opioid receptor types: p, ô and k  (Martin et a l ,  1976, Lord et a l ,  1977) and by 
mimicking the actions of the endogenous opioid peptides, the enkephalins and the 
endorphins. The most important therapeutic effect of the opiates is analgesia, exerted 
primarily via actions at the Gj/o protein-coupled p opioid receptor (MOPr) in the spinal 
cord, but also in brain areas such as the anterior cingulate cortex and thalamus (Wang et 
a l,  2009). Due to their powerful analgesic properties, opioids are widely used clinically 
in pain management (see Corbett et a l,  2006), however, a significant proportion of 
patients who are prescribed long-term opioids develop some form of addictive disorder 
(Fields, 2007). This may be in part due to actions of opioids on MOPrs in the VTA, 
which inhibit GAB A release and disinhibit DAergic neurons projecting to the Acb (Di 
Chiara and Imperato, 1988). This causes an increase of accumbal DA concentration, a 
central feature of addictive drugs and as such, opioids are also misused illicitly for their 
powerful euphoric effects.
Prolonged use of opioids leads to an adaptive state of tolerance to their analgesic or 
euphoric properties. Tolerance is defined by the DSM as the need for markedly 
increased amounts of a substance in order to achieve the desired effect and/or a 
markedly diminished effect with continued use of the same amount of substance 
(American Psychiatric Association., 1994). Consequently, repeated exposure to opioids 
results in a diminution of their desirable effects and therefore escalation o f use or dose 
to maintain this response. In addition, prolonged opioid use also causes dependence.
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resulting in the emergence of a withdrawal syndrome upon cessation o f use. Physical 
symptoms of opioid withdrawal include restlessness, muscle and bone pain, diarrhoea, 
tremor and vomiting, which emerge around 6 - 8  hours following last drug use. 
Moreover, acute opioid withdrawal can encompass emotional aspects such as severe 
dysphoria, anhedonia, depression, anxiety and irritability which are hypothesised to be a 
consequence of reduced mesolimbic DAergic neurotransmission and recruitment of 
stress-systems in affective areas of the brain such as the amygdala (Koob, 2003). These 
negative withdrawal symptoms provide a high motivational significance in contributing 
to drug-seeking and relapse (see Koob and Le Moal, 2001). Both physical and somatic 
signs of opioid withdrawal can be precipitated in animal models of opioid addiction via 
administration of the MOPr antagonist, naloxone (Stinus et a l,  1990), which is also 
used clinically to treat opioid overdose.
Early evidence implied a role of the Dz receptor in the Acb as a regulator o f the somatic 
symptoms of opioid withdrawal, as it was shown that D2 receptor activation prevented, 
and antagonism exacerbated, naloxone-precipitated withdrawal in opioid-dependent rats 
(Harris and Aston-Jones, 1994). However, the physical withdrawal symptoms induced 
by opioid withdrawal in D2 receptor KO mice was unaltered from those observed in 
their WT counterparts (Maldonado et a l,  1997). In agreement, although striatal D2 
receptor number was decreased in opioid-dependent subjects, D2 receptor number was 
not altered in these subjects following naloxone-precipitated withdrawal (Wang et a l,  
1997). Yet, recent evidence has shown that D2-containing neurons in the striatum are 
specifically activated following naloxone-precipitated morphine withdrawal in mice 
(Enoksson et a l,  2012) which indicates that the role of the D2 receptor in the mediation 
of opioid withdrawal is unclear. There is however, a role for the D2 receptor in other
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aspects o f opioid addiction. D2 receptor KO mice display a total lack of morphine- 
induced CPP (Maldonado et a l, 1997) and pharmacological antagonism of the D2 
receptor has been shown to reduce morphine self-administration in pre-clinical models 
(David et a l,  2002). Furthermore, antagonism of the D2 receptor inhibits morphine- 
induced locomotor sensitisation (Jeziorski and White, 1995, Serrano et a l,  2002, Yoo et 
a l,  2006), which suggests that there may be a dissociable role of the D2 receptor in 
mediating the different stages of opioid addiction.
As mentioned in Section 1.5.1, a mutual interaction exists between postsynaptic A2A 
and D2 receptors in the stratum, a key area in the modulation of behavioural responses 
to drugs o f abuse. As such, it is hypothesised that manipulation of this relationship may 
be of therapeutic benefit in treating drug addiction. Opioid addiction may be of 
particular relevance given that a wealth of literature exists which documents a link 
between adenosinergic and opioid systems (see Brown and Short, 2008). Administration 
of opioids elevates adenosine levels in the brain and spinal cord (Fredholm and Vemet, 
1978, Phillis et a l,  1980, Sweeney et a l, 1987, Kaplan and Leite-Morris, 1997, Halimi 
et a l,  2000, Brundege and Williams, 2002), and adenosine receptor antagonists have 
been shown to attenuate many of the effects of opioids such as catalepsy (Zarrindast et 
a l, 1997), respiratory depression (Bellville et a l ,  1962), and antinociception 
(Ahlijanian and Takemori, 1985). Therefore, the role of adenosine in opioid addiction 
has been an area o f much interest. Microdialysis studies have shown that during opioid 
withdrawal in rats, significant increases of the adenosine breakdown products 
hypoxanthine and inosine were observed in the Acb, suggesting that the adenosinergic 
system is involved in this response (Salem and Hope, 1999). Moreover, in line with the 
antagonistic A2A-D2 receptor interaction, activation of A2A receptors is effective in
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attenuating morphine withdrawal symptoms in both mice and rats (Kaplan and Sears, 
1996, Salem and Hope, 1997), an effect which is exacerbated by administration of A2A 
antagonists (Kaplan and Sears, 1996, Salem and Hope, 1997). Furthermore, global A2A 
KO mice display augmented physical morphine withdrawal symptoms, such as paw 
tremor and jumping, following naloxone-precipitated withdrawal (Berrendero et a l,  
2003, Bailey et a l ,  2004). Interestingly, in these animals the aversive dysphoric effects 
associated with morphine withdrawal were abolished, suggesting a differential role o f 
the A2A receptor in mediating motivational versus somatic opioid withdrawal symptoms 
(Castané et al., 2008).
A growing body of evidence exists which implies that the A2A-D2 receptor interaction in 
the striatum can be further manipulated by the mGlus receptor (see Section 1.7), 
possibly due to their existence in a functional receptor oligomer in striatopallidal 
neurons (Cabello et a l ,  2009). In addition to both A2A and D2 receptors, a role of the 
mGlus receptor has also been implicated in opioid addiction. Antagonism of the mGlus 
receptor has been shown to reduce the severity of morphine withdrawal symptoms in 
both rats (Rasmussen et a l,  2005) and mice (Palucha et a l ,  2004) and has also been 
shown to be important in preventing cue- and priming-induced morphine reinstatement 
(Brown et a l ,  2011), indicating it may be a potential target for the prevention of relapse 
to morphine administration. Additionally, mGlus receptor antagonism has been shown 
to inhibit the expression of morphine sensitisation to a challenge dose following chronic 
morphine administration in mice (Kotlinska and Bochenski, 2007).
Furthermore, evidence exists showing that either pharmacological antagonism of A2A 
and mGlus receptors, or a combination of genetic deletion (A2A KO) with 
pharmacological antagonism (mGlus), was effective in synergistically attenuating both
115
alcohol self-administration and cue-induced ethanol reinstatement (Adams et a l,  2008) 
and also the reinforcing effects of cocaine (Brown et a l,  2011), suggesting that A2A and 
mGlus receptors can interact to regulate addictive behaviours. However, whether 
interactions between A2A and mGlug receptors comprise a mechanism by which these 
receptors modulate the behavioural effects of opioid addiction is yet to be ascertained.
As documented above, evidence suggests that interactions in adenosinergic, 
glutamatergic, dopaminergic and opioid systems are important in opioid addiction; 
however, the mechanisms by which they interact have not been fully elucidated. A2A, 
mGlus, D2 and MOP receptors are all expressed postsynaptically in GABAergic 
medium spiny neurons (Testa et a l,  1995, Yung et a l ,  1995, Svenningsson et a l,  
1997a, Salio et a l,  2001), suggesting an anatomical substrate for receptor interactions in 
opioid addiction. As has been discussed (Sections 1.5.2 and 1.7), functional A2A-D2 and 
A2A-mGlu$ receptor interactions are evident at this location, yet studies have failed to 
demonstrate receptor level interactions between either M0Pr-D2 receptor (Yoo et a l,  
2010a) or MOP-A2A receptors (Kaplan et a l,  1994, Bailey et a l,  2002b) in the brain. 
However, Bailey et a l (2004) showed that although increased morphine withdrawal 
symptoms in A2A KO mice were not associated with changes in MOPr density, 
morphine-withdrawn A2A KO mice did display a marked upregulation of MOPr- 
mediated [^^SJGTPyS binding in the Acb versus withdrawn WT controls, which 
suggests the presence of an A2A receptor-mediated modulatory control o f MOPr 
activity, rather than density, during morphine withdrawal. In agreement, blockade of 
A2A receptors was shown to attenuate heroin seeking by preventing a facilitatory 
interaction between the striatal MOP and cannabinoid CBi receptors at the second- 
messenger level (Yao et a l ,  2006), suggesting that A2A and MOP receptors interact at a
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signalling level. Furthermore, a functional MOP-mGlus receptor interaction has recently 
been demonstrated in vitro (Schroder et a l,  2009), Avhich may be suggestive of a novel 
mechanism relevant for opioid addiction.
In order to further examine the molecular mechanisms underlying opioid addiction and 
withdrawal, the aim of the present study was to investigate receptor interactions of the 
A2A receptor with mGlus and D2 receptors following either a chronic, intermittent, 
escalating-dose morphine paradigm or naloxone-precipitated morphine withdrawal in 
WT and A2A KG mice. In addition, the role of the A2A receptor in the modulation of 
both the locomotor responses to chronic, intermittent, escalating-dose morphine 
administration and the somatic symptoms of naloxone-precipitated morphine 
withdrawal were assessed in WT and A2A KO mice.
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3.2 Methods
5.2.1 Animals and treatments
Male, 8-15 week old CD-I wild-type and A2A receptor knockout mice derived from a 
heterozygous breeding programme were used in this study as detailed in Section 2.2.1. 
Mice were singularly housed for a period of 7 days prior to the start of the study and 
throughout the whole o f the study period. Mice were habituated to experimenter 
handling for one week before the start of experiment. The home cages were in a 
temperature-controlled environment and on a 12 hour light-dark cycle (lights on 07:00). 
Whilst in home cages, mice had access to food and water ad libitum. All experimental 
procedures were conducted in accordance with the UK Animal Scientific Procedures 
Act (1986).
3.2.2 Chronic, intermittent, escalating-dose morphine administration
Prior to experimental procedure, mice were removed from their home cages and 
allowed to habituate to motility chambers for 1 hour. Following this, mice were treated 
with a chronic, intermittent, escalating-dose morphine paradigm (20 mg/kg on Days 1 
and 2, 40 mg/kg on Days 3 and 4, 80 mg/kg on Days 5 and 6, 100 mg/kg on Days 7 and 
8, i.p., Sigma-Aldrich, Dorset, UK) or saline (4 ml/kg, i.p. each day) twice per day 
(09:00 and 17:00) in order to mimic the human pattern of escalating morphine abuse 
(adapted from Muller and Unterwald, 2004). Horizontal and vertical (rearing) activity 
was recorded for each mouse for 2 hours following morning (09:00) injection 
throughout the duration of the study. Two hours post final injection on Day 8, all 
animals received an injection of saline (4 ml/kg, i.p.) and were left for 30 minutes, after
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which time they were killed via cervical dislocation. All experimentation was carried 
out in a temperature-controlled environment and in dim light.
3.2.3 Motor activity measurements
Motor activity was recorded as detailed in Section 2.2.3, with the exception that beam- 
breaks were recorded continuously every 5 minutes (5 minute bin) for 120 minutes 
immediately following injection (saline or morphine). Mice were returned to their home 
cages each day following completion of the locomotor test.
3.2.4 Naloxone-precipitated morphine withdrawal
WT and A2A KO mice were injected with a chronic, intermittent, escalating-dose 
morphine paradigm as described in Section 3.2.2. To precipitate withdrawal, pre­
weighed morphine-treated animals received an injection of naloxone HCl (1 mg/kg; i.p., 
Sigma-Aldrich, Dorset, UK) 2 hours post final injection on Day 8. WT and A2A KO 
saline control mice were also used for this experiment. Following naloxone injection, 
animals were immediately placed in a clear Perspex observation box (20 cm x 27 cm x 
30 cm) for a period of 30 minutes to assess withdrawal signs (Section 3.2.5). 
Immediately following this, mice were weighed again and then killed by cervical 
dislocation.
3.2.5 Assessment o f  withdrawal signs
Signs of somatic withdrawal behaviour in morphine dependent mice were counted for a 
period of 30 minutes just after naloxone injection (1 mg/kg; i.p.) by trained observers 
blind to genotype, following a measurement protocol modified from Bailey et al. 
(2004). The number of wet-dog shakes, jumping and paw tremors were counted. The
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percentage weight-loss from just before, and 30 minutes following naloxone injection 
was also calculated.
3.2.6 Autoradiographic confirmation o f  adenosine A 2A receptor genotype 
Confirmation of A ia genotype status was carried out as described in Section 2.2.4.
3.2.7 Quantitative receptor autoradiography o f  dopamine D2 and glutamate mGlus
receptors in brains o f  WT and A 2A KO mice following chronic, intermittent,
escalating-dose morphine administration
Tissue preparation, quantitative autoradiographic binding of D2 and mGlug receptors 
and subsequent procedures were carried out in WT and A2A KG mice following chronic 
morphine or saline administration as detailed in Section 2.2.4.
3.2.8 Quantitative receptor autoradiography o f  dopamine D2 and glutamate mGlus
receptors in brains o f  WT and A2A KO mice following naloxone-precipitated
morphine withdrawal
As detailed in Section 2.2.4, tissue preparation, quantitative autoradiographic binding of 
D2 and mGlus receptors and subsequent procedures were carried out in WT and A2A KO 
mice following naloxone-precipitated withdrawal from chronic morphine administration 
or chronic saline administration.
3.2.9 Data analysis
All graphs were produced using GraphPad Prism V5.04 software (GraphPad Software 
Inc., USA). All statistical analysis was carried out using Statistica V I0 software 
(StatSoft Inc., USA).
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3.2.9.1 Motor activity measurement
Basal (treatment-naive) locomotor activity was represented as the mean ± SEM of the 
cumulative total horizontal activity or rearing activity for 1 hour before any treatment 
on Day 1. Comparison of these behaviours was carried out using Student’s unpaired t- 
test. The mean ± SEM of the total horizontal or vertical activity was calculated 
following morning (09:00) injections of saline or morphine for 2 hours every day 
throughout the duration of the study. Comparison of locomotor activities was carried 
out using three-way repeated measures ANOVA for factors genotype, treatment and 
time and significant factors were further analysed with Unequal n Tukey post-hoc test.
3.2.9.2. Naloxone- precipitated morphine withdrawal
The mean ± SEM of the frequency of withdrawal measure was calculated for 30 
minutes following naloxone injection. Comparison of withdrawal severity was carried 
out using Student’s unpaired t-test.
3.2.9.3 Autoradiography o f  dopamine D2 and glutamate mGlus receptors
The mean ± SEM of ligand binding measures (fmol of radioligand bound/mg tissue 
equivalent) was calculated in each brain region for each experimental group. 
Comparison of quantitative measures of autoradiographic binding for the ligand was 
carried out using three-way ANOVA for factors genotype, treatment and brain region. 
Two-way ANOVA was used to assess differences in binding between genotype and 
treatment in each brain region, followed by Duncan’s Multiple Range post-hoc test 
where appropriate.
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3.3 Results
3.3.1 Basal locomotor activity prior to saline or morphine treatment on Day 1 in WT 
and A 2a KO mice
Basal (treatment-naive) horizontal and vertical (rearing) activity, defined as a 
cumulative total number of horizontal or vertical counts for 1 hour prior to any 
treatment injection on Day 1 showed there was no difference between WT and A2A KO 
mice (P>0.05, Figure 3.1 A, B).
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Figure 3.1: Basal locomotor activity in wild-type and adenosine A2A receptor 
knockout mice prior to morphine treatment. Basal horizontal (A) and vertical (rearing) (B) 
locomotor data of wild-type (WT) and adenosine A2A receptor knockout (KO) mice were collected in 5- 
minute bins for 1 hour prior to injection of saline or 20 mg/kg morphine on day 1. The cumulative total of 
horizontal or vertical activity during 1 hour prior injection is represented as mean ± SEM (n=14-15).
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3.3.2 Effect o f  chronic, intermittent, escalating-dose morphine administration on 
locomotor activity in WT and A 2A KO mice
Horizontal and vertical locomotor activity in WT and adenosine A2A KO mice was 
recorded in 5-minute bins for 2 hours post morning (09:00) injection on each day 
throughout the study. Horizontal and vertical activity was measured as number of 
horizontal or vertieal beam-breaks per 5 minutes and a eumulative total was ealculated.
3.3.2.1 Horizontal activity
Three-way repeated-measures ANOVA showed that treatment with ehronic, esealating- 
dose morphine caused an increase in horizontal locomotor activity compared to saline 
controls (treatment effect, F(i,2i) = 78.93, P<0.001; Figure 3.2A). Post-hoc analysis 
showed that compared to saline controls, the horizontal aetivity of WT morphine-treated 
miee was signifieantly inereased on all days (Days 1 and 3-6, P<0.01; Day 2, P<0.05; 
Days 7 and 8, P<0.001). Horizontal activity of morphine-treated A2A KO mice was 
significantly increased from saline eontrols on all days, exeept day 4 (Days 1, 2 and 5-8, 
P<0.05; Day 3, P<0.01). In addition, effects of genotype (genotype effeet, F(i,2i)= 4.83, 
P<0.05) and time (time effeet, F(ij47)= 2.54, P<0.05) were observed. Chronic morphine 
treatment increased the horizontal loeomotor response over the duration of the study in 
a dose-dependent manner (treatment x time interaction, (F(7j 47) = 2.75, P<0.05)), 
however, post-hoc analysis did not show a signifieant difference in either WT or A2A 
KO morphine-treated groups over the duration o f the study (Day 1 versus Day 8, 
f>0.05).
In addition, there was an overall increase of horizontal activity in morphine-treated WT 
mice versus morphine-treated A2A KO miee which was especially prominent at high-
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dose morphine treatment (genotype x treatment interaetion, F(i,2i) = 5.09, P<0.05), 
however, post-hoc analysis did not show a signifieant difference between morphine- 
treated WT and A2A KO miee on any treatment day (P>0.05).
2.2.2.2 Vertical activity
Three-way ANOVA showed that treatment with morphine signifieantly inereased 
rearing behaviour (treatment effeet, F(i,2i) = 7.66, P<0.05) and a significant effect of 
time (F(7,i47) = 2.72, P<0.05), but not genotype (P>0.05) was also observed. There was 
an overall inerease of rearing behaviour in both WT and A2A KO miee over the duration 
of the experiment (time x treatment interaction, F(7, 147) = 3.03, P<0.01; Figure 3.2B), 
however, post-hoc analysis did not reveal any significant differences between morphine 
and saline treated groups on any day (P>0.05), nor between Day 1 and Day 8 in either 
morphine-treated group (P>0.05).
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Figure 3.2: Effect of chronic escalating-dose morphine administration on horizontal 
and vertical locomotor activity in wild-type and adenosine A%A receptor knockout 
mice. Total locomotor activity in wild-type (WT) and adenosine A?A knockout (KO) mice following 
chronic, intermittent administration of escalating-dose morphine (20 mg/kg on Days 1 and 2, 40 mg/kg on 
Days 3 and 4, 80 mg/kg on Days 5 and 6 , 100 mg/kg on Days 7 and 8 , i.p.) or saline twice per day (09:00 
and 17:00). Locomotor data was collected daily in 5-minute bins for 2 hours immediately following 09:00 
injection. The daily cumulative total of locomotor activity during 2 hours post-morning injection is 
represented as mean ± SEM (A) Total horizontal locomotor activity (n = 6-13). Significant effect of 
treatment (f<0.001), genotype (f<0.05) and time (f<0.05) and interactions between genotype x 
treatment (P<0.05) and treatment x time (f<0.05) were identified (3-way repeated measures ANOVA). 
*P<0.05, **P<0.01, ***P<0.001 WT Saline vs. WT Morphine, ^<0.05, ^^ V<0.01 KO Saline vs. KO 
Morphine (Unequal ATukey post-hoc). (B ) Total vertical (rearing) activity (n = 6-13). Significant effects 
of treatment (P<0.05) and time (P<0.05) and a treatment x time interaction (P<0.01) were observed (3- 
way repeated measures ANOVA).
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3.3.3 Autoradiographic binding o f  the adenosine Â 2a receptor fo r  genotype 
confirmation o f  WT and À2a KO mice used in morphine administration and 
withdrawal experiments
Striatal sections from the brains of each experimental animal used in these studies were 
bound with the radiolabelled A2A receptor agonist [^HJCGS 21680 to confirm that the 
genotype determined by PCR and DNA electrophoresis procedure was correct. Overall, 
the genotype of approximately 5% of animals used in this experiment was incorrect. 
Data obtained from these animals were adjusted accordingly.
3.3.4 Effect o f  chronic, intermittent, escalating-dose morphine administration on 
quantitative autoradiographic binding o f  the dopamine D2 receptor in WT and 
À2A KG mice
Quantitative autoradiography of dopamine D2 receptors from coronal sections o f the 
caudate showed extensive binding throughout (Figure 3.3). Binding of [^HJraclopride 
was observed in the Acb, Tu and CPu (region effect, F(3,5i) = 27.72, P<0.001), where 
the highest level of binding was observed (mean specific binding 60.0 -  73.8 fmol/mg 
tissue equivalent). Neither significant effects of genotype (P>0.05) or treatment 
(P>0.05), nor interactions between any factors were observed (P>0.05).
3.3.5 Effect o f  chronic, intermittent, escalating-dose morphine administration on 
quantitative autoradiographic binding o f  the glutamate mGlus receptor in WT 
and À 2A KG mice
Binding of [^HJMPEP in coronal brain sections showed widespread and distinct levels 
of mGlus receptor localisation (region effect, F(i2,224) = 5.40, P<0.001; Figure 3.4). 
Additionally, a significant effect o f genotype was observed across all regions (F( 1,224) =
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4.91, P<0.05). Neither effect of treatment (P>0.05), nor any interactions between 
genotype, region and treatment were observed following 3-way ANOVA (P>0.05).
Analysis of each region via 2-way ANOVA showed a significant treatment effect in the 
thalamus (treatment effect, F(i,i6) = 5.27, P<0.05). Post-hoc analysis showed that in 
comparison to saline controls, chronic morphine administration caused a significant 
increase of mGlu$ receptor binding in the thalamus of A%A KO mice (P<0.05) but not in 
WT (P>0.05). This trend was also observed in the hypothalamus, however, was not 
statistically significant (treatment effect, P=0.08). There was no significant effect o f 
genotype (P>0.05) or treatment (P>0.05), nor genotype x treatment interaction in any 
other brain region (P>0.05). There was no morphine-treatment effect in WT mice in any 
brain region analysed (P>0.05).
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Figure 3.3: Q uantitative autoradiography of Dj receptor binding in coronal brain  
sections from chronically morphine or saline-treated wild-type or adenosine Aza 
receptor knockout mice. Binding of [^ HJraclopride in brains of wild-type (WT) and adenosine Aza 
receptor knockout (KO) mice following administration of chronic, intermittent, escalating-dose morphine 
(20-100 mg/kg, 8 days, i.p.) or saline twice per day. (A) Data are expressed as the mean specific binding 
(fmol/mg tissue equivalent) ± SEM (n=4-5) of [^H]raclopride in brain regions of WT and KO mice 
chronically treated with saline or morphine. Regional determinations were made from both left and right 
sides of the sections. Labelling of the sections was carried out in a completely paired protocol. (B) 
Computer-enhanced autoradiograms of total f  HJraclopride binding of the Di receptor in coronal brain 
sections from WT and KO mice treated with either saline or chronic morphine. The adjacent sections 
shown are from the level of the caudate (Bregma +0.86 mm). The colour bar represents a pseudo-colour 
interpretation of black and white film images in fmol/mg tissue equivalent. Specific binding was -80% of 
total binding in the majority of regions analysed. AcbC, nucleus accumbens core; AchSh, nucleus 
accumbens shell; CPu, caudate putamen; Tu, olfactory tubercule.
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Figure 3.4: Q uantitative autoradiography of mGlus receptor binding in coronal  
brain sections from chronically morphine or saline-treated wild-type or adenosine  
A 2A receptor knockout mice. Binding of ['’HJMPEP in brains of wild-type (WT) and A2A receptor 
knockout (KO) mice following administration of chronic, intermittent, escalating-dose morphine (20-100 
8  days i.p.) or saline twice per day .(A) Data are expressed as the mean specific binding (fmol/mg 
tissue equivalent) ± SEM (n—j-6 ) of [ HJMPEP in brain regions of WT and KG mice chronically treated 
with saline or morphine. Regional determinations were made from both left and right sides of the 
sections. Labelling of the sections was carried out in a completely paired protocol. A significant effect of 
treatment (f<0.05) was observed only in the thalamus (2-way ANOVA). *P<0.05 vs. KO Saline 
(Duncan’s Multiple Range post-hoc test). (B) Computer-enhanced autoradiograms of total [^HJMPEP 
binding of the mGluj receptor in thalamic brain sections from A.a KO mice treated with either saline or 
chronic morphine. The adjacent sections shown are from the level of the thalamus (Bregma -2.30 mm). 
The colour bar represents a pseudo-colour interpretation of black and white film images in fmol/mg tissue 
equivalent. Specific binding was —60% of total binding in the majority of regions analysed. AchC, 
nucleus accumbens core; AcbSh, nucleus accumbens shell; Amy, amygdala; Cg, cingulate cortex; CPu, 
caudate putamen; Hip, hippocampus; Hyp, hypothalamus; LS, lateral septum; Ml, M2, primary and 
secondary motor cortices; MS, medial septum; PrL, prelimbic cortex; Th, Thalamus; VDB, ventral limb of 
the diagonal band of Broca.
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3.3.6 Effect o f  naloxone-precipitated withdrawal from  chronic, intermittent, 
escalating-dose morphine on somatic withdrawal symptoms in WT and A 2A KO 
mice
Opioid withdrawal syndrome was precipitated by the administration of naloxone (1 
mg/kg; i.p.) in mice receiving chronic treatment o f increasing doses o f morphine from 
20 -  100 mg/kg over 8 consecutive days. Prior to injection with naloxone, no somatic 
signs of withdrawal were observed. Following naloxone injection in morphine-treated 
groups, morphine withdrawal symptom was manifested as the presence of a variety of 
somatic signs in both WT and A2A KO mice (Figure 3.5). There was no significant 
genotype effect in any o f the somatic withdrawal signs observed (P>0.05; Figure 3.5A, 
B, C). There was no difference in percentage weight loss as a result o f naloxone 
injection between WT and A2A KO mice (P>0.05; Figure 3.5D).
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Figure 3.5: Quantification of somatic withdrawal signs following naloxone-
precipitated morphine withdrawal in wild-type and adenosine Aza receptor knockout 
mice. Wild-type (WT) and adenosine A2A receptor knockout (KO) mice were treated chronically with an 
escalating-dose morphine paradigm (20 -  100 mg/kg, i.p, 8  days). Naloxone (1 mg/kg, i.p.) was 
administered 2 hour post-final treatment injection to precipitate withdrawal. Withdrawal symptoms were 
measured parametrically over 30 minutes by trained observers blind to genotype. Values represent mean 
± SEM (n = 6 ).
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3.3.7 Effect o f  naloxone-precipitated morphine withdrawal on quantitative 
autoradiographic binding o f  the dopamine D2 receptor in WT and A 2A KO mice
Quantitative autoradiography of dopamine D2 receptors from coronal sections of the 
caudate showed extensive binding throughout (Figure 3.6). Binding of [^HJraclopride 
was limited to the Acb, Tu and CPu (region effect, F(9j 7) = 20.39, P<0.001), where the 
highest level o f binding was observed (mean specific binding 91.2 -  107.1 fmol/mg 
tissue equivalent). Although three-way ANOVA showed a significant effect of genotype 
over all regions (F(i,224) = 6.79, P<0.05), post-hoc analysis showed no differences 
between saline and naloxone-precipitated morphine-withdrawn mice in either genotype 
in any region analysed (P>0.05). Similarly, a genotype effect was observed in the Tu 
(F(i,i9) = 4.98, P<0.05), but there were no significant differences between individual 
groups following post-hoc analysis (P>0.05). No effects of genotype (P>0.05), 
treatment (P>0.05) nor significant treatment x genotype interactions (P>0.05) were 
observed in any other brain regions.
3.3.8 Effect o f  naloxone-precipitated morphine withdrawal on quantitative 
autoradiographic binding o f  the glutamate mGlus receptor in WT and A 2A KO  
mice
Binding of [^HJMPEP in coronal brain sections showed widespread localisation of the 
mGlus receptor (region effect, F(i2,266) = 36.98, P<0.001; Figure 3.7). Additionally, a 
significant effect of treatment was observed across all regions (F(i,266) = 24.36, 
P<0.001). Neither effect of genotype (P>0.05), nor any interactions between genotype, 
region and treatment were observed following 3-way ANOVA (P>0.05).
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However, analysis of each region via 2-way ANOVA showed a significant treatment 
effect in the thalamus (F(i,2i) = 8.97, P<0.01). Post-hoc analysis showed that in 
comparison to saline controls, naloxone-precipitated morphine withdrawal caused a 
significant increase of mGlus receptor binding in the thalamus of A2A KO mice 
(P<0.01), but not WT mice (P>0.05). Additionally, a genotype x treatment interaction 
was observed in the amygdala (F(i,2i) = 4.73, P<0.05), where a significant increase in 
mGlus receptor binding was observed in naloxone-precipitated morphine withdrawn 
A2A KO mice in comparison to naloxone-precipitated morphine withdrawn WT mice 
(P<0.05). Naloxone-precipitated morphine withdrawal did not alter mGlug receptor 
binding in any other brain region analysed (P>0.05). No effects o f genotype (P>0.05), 
treatment (P>0.05) nor significant treatment x genotype interactions (P>0.05) were 
observed in any other brain regions.
133
150-
0) O[U 3
cQ. .2 125-O
O O) 100-re E
o
EI 75-s—
u
S Oc
50-
(Da c 25-
c/3 m
0-
o  WT Saline control 
S  WT Morphine withdrawal 
■  KO Saline control
KO Morphine withdrawal
Brain Region
B finolm e  \M  SALINE C ONTROL W T MORPHINE WIIHDR.VWAL
KO MORPHINE 
WITHDRAWAL
KO SALINE C ONTROL
Figure 3.6: Quantitative autoradiography of D; receptor binding in coronal brain 
sections following naloxone-precipitated morphine withdrawal in wild-type or 
adenosine Aja receptor knockout mice. Binding of [^H]raclopride in brains of wild-type (WT) and 
adenosine Aja receptor knockout (KO) mice following naloxone-precipitated (1 mg/kg, i.p.) withdrawal 
from administration of chronic, intermittent, escalating-dose morphine (20 - 100 mg/kg, 8 days, i.p.) or 
saline twice per day. (A) Data are expressed as the mean specific binding (fmol/mg tissue equivalent) ± 
SEM (n=4-5) of ['’HJraclopride for Di receptors in brain regions of WT and KO mice. Regional 
determinations were made from both left and right sides of the sections. Labelling of the sections was 
carried out in a completely paired protocol. (B) Computer-enhanced autoradiograms of total [^HJraclopride 
binding of the D% receptor in coronal brain sections following chronic saline or naloxone-precipitated 
withdrawal in WT and KO animals. The adjacent sections shown are from the level of the caudate (Bregma 
+0.86 mm). The colour bar represents a pseudo-colour interpretation of black and white film images in 
fmol/mg tissue equivalent. Specific binding was -80% of total binding in the majority of regions analysed. 
AcbC, nucleus accumbens core; AcbSh, nucleus accumbens shell; CPu, caudate putamen; Tu, olfactory 
tubercule.
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Figure 3.7: Quantitative autoradiography of mGlug receptor binding in coronal brain  
sections following naloxone-precipitated morphine withdrawal in wild-type or 
adenosine Aja receptor knockout mice. Binding o f ['hJM PEP in brains o f wild-type (WT) and 
adenosine A,a receptor knockout (KO) mice following naloxone (1 mg/kg, i.p.) precipitated withdrawal from 
administration of chronic, intermittent, escalating-dose morphine (20 - 100 mg/kg, 8 days, i.p.) or saline twice 
per day. (A) Data are expressed as the mean specific binding (fmol/mg tissue equivalent) ± SEM (n=5-6) o f 
[ HJMPEP for mGlus receptors in brain regions of WT and KO mice chronically treated with saline or following 
naloxone-precipitated morphine withdrawal. Regional determinations were made from both left and right sides o f 
the sections. Labelling o f the sections was carried out in a completely paired protocol. A significant effect o f 
treatment was observed m the thalamus (P<0.01) and a significant genotype x treatment interaction (P<0.05) was 
observed in the amygdala (2-way ANOVA). **P<0.01 vs. KO Saline control; "P<0.05 vs. WT Morphine 
withdrawal (Duncan’s Multiple Range post-hoc test). AchC, nucleus accumbens core; AchSh, nucleus accumbens 
shell; amygdala; Cg, cingulate cortex; CPw, caudate putamen; hippocampus; //y;?, hypothalamus; 
lateral septum; M/, M2, primary and secondary motor cortices; M.S, medial septum; RrA, prelimbic cortex; T/r] 
Thalamus; ventral limb of the diagonal band of Broca. (B) Computer-enhanced autoradiograms of total 
[ HJMPEP for mGlus receptor binding in coronal brain sections from saline and naloxone-precipitated morphine- 
withdrawn WT and A,a KO mice. The adjacent sections shown are from the level o f the thalamus (Bregma -1.82 
mm). The colour bar represents a pseudo-colour interpretation o f black and white film images in fmol/mg tissue 
equivalent. Specific binding was -60%  of total binding in the majority o f regions analysed.
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3.4 Discussion
This study aimed to further investigate A%A receptor interactions with mGlus and D2 
receptors following chronic morphine administration and naloxone-precipitated 
morphine withdrawal. In addition, the role of the A2A receptor in the modulation of both 
the locomotor responses to chronic, intermittent, escalating-dose morphine 
administration and the somatic symptoms of naloxone-precipitated morphine 
withdrawal were assessed.
The genotype o f all mice used in this study was confirmed ex vivo by radiolabelling 
striatal brain sections with [^H]CGS 21680. Results were correct in approximately 95% 
of animals and where incorrect, data were reassigned to the correct genotype group. 
These discrepancies contributed to slight variability between the numbers of animals 
used in each experimental group. As discussed in Section 2.4.1, these data indicate that 
perhaps the PCR probes used to genotype the A2A receptor gene were not fully robust, 
and reiterates the great importance of confirming the genotype of transgenic animals 
with other techniques such as autoradiographical binding.
3.4.1 Basal locomotor activity prior to saline or morphine treatment on Day 1 in WT 
and A 2A KO mice
In order to assess treatment-naive basal activity, horizontal and vertical activities o f WT 
and A2A k g  mice were measured 1 hour prior to any treatment on Day 1. The data 
showed no significant genotype difference in either locomotor parameter (Figure 3.1 A 
and B), which is consistent with findings observed in the previous study (Figure 2.2) 
and in agreement with Soria et al. (2006) and Castafié et al. (2008). However, as 
discussed in Section 2.4.1, these findings are in contrast to the original hypolocomotor
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phenotype of A2A KO mice demonstrated by Ledent et a l  (1997). This may be 
attributable to differences in enrichment factors which affect anxiety-like responses, as 
A2A KO mice are phenotypically more anxiogenic (Ledent et a l ,  1997).
3.4.2 Effect o f  chronic, intermittent, escalating-dose morphine treatment on locomotor 
activity in WT and A 2A KO mice
The present study examined the effects o f chronic, intermittent, escalating-dose 
morphine administration on locomotor activity in WT and A2A KO mice. Over the 
duration o f the study, administration of escalating-dose morphine increased horizontal 
and vertical activity in a dose-dependent manner in both WT and A2A KO mice (Figure 
3.2), which was in agreement with evidence from a similar escalating-dose protocol of 
heroin (precursor o f morphine) administration in C57BL/6J mice (Bailey et a l ,  2010).
Acute administration of morphine induced the same level o f locomotor activity in both 
WT and A2A KO mice (Figure 3.2A, Day 1), which was in agreement with other studies 
(Castané et al., 2008, Brown et al., 2009). However, there was an overall reduction of 
locomotor activity in morphine-treated A2A KO mice versus WT (genotype x treatment 
interaction), which suggests that A2A receptors are at least partly responsible for the 
chronic locomotor effects of morphine, especially at high dose (100 mg/kg). Chronic 
morphine administration increases levels o f adenosine in the brain which is thought to 
be attributable to morphine-induced inhibition of adenosine uptake (Sweeney et a l ,  
1993, Halimi et a l ,  2000). As such, activation of adenosine receptors is likely increased 
following chronic morphine administration. In line with the A2A-D2 antagonistic 
interaction, it would be hypothesised that increased activation of A2A receptors (i.e. in 
WT mice) would antagonise D2 function to reduce the locomotor response to morphine 
administration (Zarrindast and Zarghi, 1992). However, the opposite response is
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observed, whereby an apparent tolerance to the locomotor activating effects of 
morphine displayed by A%A KO mice at high dose. This suggests that a direct effect in 
the form of removal o f A2A receptor antagonism of D2 receptor-mediated effects is 
unlikely to be the mechanism by which A2A receptor deletion modulates chronic 
morphine-induced locomotor activity. In agreement, D2 receptor binding levels were not 
altered following chronic morphine administration in either genotype (Figure 3.3). 
Importantly, a genotypic difference in morphine-stimulated horizontal activity was most 
prominent with very high dose morphine, which has been shown to influence multiple 
neurotransmitter systems independent of MOPr activation (Montel et a l ,  1974, Yaksh 
et a l,  1986). As such, it is likely that the effects observed here may be attributable to 
non-opioid effects, which may also have influence on regulation of the adenosinergic 
system.
In agreement with a reduced locomotor effect o f chronic morphine administration in 
A2A KO mice observed in the present study, these mice also display reduced morphine 
reward (Castafié et al., 2008) and morphine self-administration (Brown et a l,  2009), 
suggesting that perhaps that A2A KO mice represent a phenotype of low vulnerability to 
opioid addiction.
3.4.3 Effect o f  chronic, intermittent, escalating-dose morphine treatment on 
quantitative autoradiographic binding o f  the dopamine D2 receptor in WT and 
A 2A KO mice
Treatment with chronic, escalating-dose morphine in CD-I mice did not alter the 
surface level binding of D2 receptors in comparison with saline controls (Figure 3.3). 
This is in agreement with Bailey et al. (2010) who, using a similar paradigm of 
escalating heroin administration, observed no differences in D2 receptor binding
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between heroin and saline treated C57BL/6J mice, suggesting that D2 receptor levels are 
generally unaffected in mice following chronic opioid administration regardless of 
strain. However, the present data are in disagreement with Navarro et a l (1992), who 
showed a decreased number of D2 receptors in mice which received continuous 
morphine administration via implantation o f morphine pellet, which suggests that the 
protocol of morphine administration differentially alters D2 receptor binding. Although 
no changes were observed at the receptor level in the present study, this does not rule 
out alterations in D2 second-messenger systems. Indeed, it has been shown that chronic 
morphine administration causes super-sensitivity of DA receptors as demonstrated via 
increased locomotor hyperactivity to direct-acting DA agonists (Eidelberg and 
Erspamer, 1975, Woo and Kim, 2001).
Despite observing a genotype difference in the locomotor response to chronic morphine, 
A2A receptor deletion had no effect on D2 receptor binding. Therefore, if  there is a 
DAergic component in mediating this response, it does not occur at the D2 receptor 
level. Lack of genotype effect was in agreement with earlier data from treatment-naive 
(Figure 2.6) and chronically cocaine-treated (Figure 2.8) WT and A2A KO mice and 
suggests that the A2A receptor does not have a role in regulating the surface level of D2 
receptors either physiologically or in response to chronic cocaine or morphine 
administration.
3.4.4 Effect o f  chronic, intermittent, escalating-dose morphine treatment on 
quantitative autoradiographic binding o f  the glutamate mGlus receptor in WT 
and A 2A KO mice
Following chronic escalating-dose administration with morphine, there was no 
upregulation of mGlug receptor binding in WT mice in any brain region (Figure 3.4).
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This is in contrast with work from our lab which showed increased mGlug binding 
following chronic escalating-dose morphine administration in brains regions of 
C57BL/6J mice (Bailey et a l,  2009), which suggests a strain-specific effect of 
morphine administration in mGlus receptor upregulation.
However, chronic, escalating-dose morphine administration significantly increased 
thalamic mGlus receptor binding in A%A KG mice compared to A2A KG saline controls, 
which suggests a role for A2A in modulating opioid-induced mGlus receptor 
upregulation specifically in the thalamus. This may be due to the presence of an A2A- 
mGlus receptor interaction in the thalamus or an indirect effect occurring elsewhere in 
the CNS. mGlus and MGP receptors are highly expressed in the thalamus of mice (Abe 
et a l,  1992, Ding et a l,  1996) and there is also evidence of immunolabelling of 
thalamic A2A receptors (Rosin et a l ,  1998), although they are not readily observed using 
autoradiographical techniques (Fredholm et a l,  1998, DeMet and Chicz-DeMet, 2002). 
Although A2A-mGlu5 receptor interactions have not been reported in the thalamus, 
mGlus-MGP receptor interactions have been identified in vitro (Schroder et a l,  2009) 
and functional A2A-mGlu5 receptor interactions have been demonstrated in the striatum 
(Section 1.7.2) and hippocampus (Tebano et a l ,  2005). The present results therefore 
give reason to suggest that MGPr activation via morphine administration can modulate 
thalamic mGlus receptor levels via an A2A-dependent mechanism, indicating a complex 
interplay between A2A, mGlus and MGP receptors directly in this region.
However, due to low density of A2A receptors in the thalamus (Fredholm et a l,  1998, 
DeMet and Chicz-DeMet, 2002), it is likely that thalamic mGlus receptors might be 
modulated by A2A receptors elsewhere in the CNS. For example, an indirect regulation 
by A2A receptors has also been demonstrated in the VTA, whereby A2A KG mice had
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increased Di-receptor mediated desensitisation in VTA DAergic neurons despite no 
autoradiographical confirmation of VTA A%A receptors (Al-Hasani et a l ,  2011). A2A 
receptors are expressed in the peripheral sensory neurons (Kaelin-Lang et a l,  1998), 
where MOPr are also expressed (Fields et a l,  1980) and these neurons carry pain 
stimuli to the spinal cord which are then transmitted to the sensory cortex via thalamic 
processing. As a result, it is possible that A2A receptors on peripheral sensory neurons, 
rather than central A2A receptors, may modulate a MOPr-mGlus interaction in the 
thalamus.
The functional significance of an A2A-mediated mGlus receptor upregulation in the 
thalamus following chronic morphine administration is unknown, however, it appears 
that this interaction is likely more important in the antinociceptive effects o f morphine 
rather than its addictive properties. It is well known that chronic morphine 
administration causes tolerance to its antinociceptive effects and that the thalamus is a 
key structure in the nociceptive circuitry, processing and relaying signals from sensory 
neurons to and from the periphery. There are high densities of both MOP and mGlus 
receptors in the thalamus and these receptors are known to have central roles in opioid- 
mediated pain regulation (Matthes et a l,  1996, Xu et a l, 2008, Picker et al., 2011). For 
example, mGlus receptors have been implicated in the development of morphine 
antinociceptive tolerance (Kozela et a l, 2003, Smith et a l,  2004, Xu et a l ,  2008) and 
chronic morphine treatment has been shown to increase mGlus receptor levels in the 
spinal cord (Narita et a l ,  2005). As a result, it is plausible that A2A receptors could 
further modulate morphine analgesic tolerance by regulating mGlug receptor expression 
in the thalamus via a peripheral A2A-M0Pr interaction. Indeed, it has been suggested 
that peripheral, rather than supraspinal A2A receptors are more important in the
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mediation of opioid-induced antinociception (Bailey et a l,  2002a). Although studies in 
A2A KO mice have shown that, acutely, the A2A receptor is not involved in mediating 
either spinal (Bailey et a l, 2002a) or supra-spinal morphine-induced antinociceptive 
responses (Castané et al., 2008), the antinociceptive responses o f these mice following a 
chronic morphine administration paradigm remain to be investigated.
Interestingly, following morphine administration there was a lack of effect o f A2A 
deletion on regulation of the mGlug receptor in the striatum, an area of high A2A 
receptor density, which was in agreement with earlier findings following chronic 
cocaine administration (Figure 2.9). Lack of striatal mGlus alteration in morphine- 
treated A2A KO mice suggests that it is an unlikely mechanism responsible for the 
genotype effect observed morphine-induced horizontal activity (Figure 3.2A), as 
changes in mGlu$ receptor binding were not observed in regions of the brain which are 
known to govern motor function (Acb, CPu).
3.4.5 Effect o f  naloxone-precipitated withdrawal from  chronic, intermittent, 
escalating-dose morphine on somatic withdrawal symptoms in WT and A 2A KO 
mice
The present study assessed the severity of certain physical withdrawal symptoms (paw 
tremor, jumping, wet-dog shakes and percentage weight loss) following naloxone- 
precipitated withdrawal from a chronic, intermittent, escalating-dose morphine 
administration paradigm in WT and A2A KO mice. The data showed that there was no 
significant genotype difference in any of the parameters analysed (Figure 3.5A-D). This 
is in agreement with observations from Berrendero et al. (2003) who also observed no 
genotype difference between WT and A2A KO mice in paw tremor, wet-dog shakes and 
jumping following naloxone-precipitated withdrawal from a similar paradigm of
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chronic, intermittent morphine administration. Interestingly, the study by Berrendero et 
a l  (2003) showed that A2A KO mice did score higher in withdrawal-induced sniffing 
and diarrhoea compared to WT mice, which suggests that the A2A receptor may play a 
differential role in mediating types o f somatic withdrawal symptoms (Berrendero et a l, 
2003). This is in accordance with evidence showing that pharmacological antagonism of 
A2A receptors increased the incidence of some, but not all, somatic symptoms following 
naloxone-precipitated morphine withdrawal (Kaplan and Sears, 1996, Salem and Hope, 
1997). In contrast to the present data, Bailey et a l (2004) observed increased 
withdrawal-induced jumping, writhing and paw tremors in A2A KO mice following 
naloxone injection in morphine-dependent mice. However, this may be due to 
difference in paradigm, as Bailey et a l (2004) used implanted subcutaneous mini­
pumps to deliver continuous morphine infusion and this is known to cause significant 
differences to morphine-induced responses, such as analgesic tolerance (Kumar et a l, 
2008, Sirohi et a l ,  2008, Dighe et a l, 2009).
The present data indicate that following naloxone-precipitated withdrawal from a 
pattern of morphine administration relevant to human use, the A2A receptor does not 
have a role in mediating the somatic signs of morphine withdrawal as analysed in this 
study. However, there does appear to be a role for A2A receptors in mediating the 
aversive dysphoric effects associated with morphine withdrawal, as these symptoms 
were abolished in A2A KO mice (Castané et al., 2008). This suggests a differential role 
of the A2A receptor in mediating motivational versus somatic opioid withdrawal 
symptoms.
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3.4.6 Effect o f  naloxone-precipitated morphine withdrawal on quantitative 
autoradiographic binding o f  the dopamine D2 receptor in WT and A 2A KO mice
Although there was a tendency for higher [^HJraclopride binding in A2A KO mice 
irrespective of treatment (genotype effect), naloxone-precipitated withdrawal from 
chronic morphine treatment did not significantly alter D2 receptor binding levels in 
either WT or A2A KO mice (Figure 3.6). This finding is in agreement with observations 
from Bailey et al. (2004), who also observed no changes in D2 receptor levels following 
naloxone-precipitated withdrawal in WT and A2A KO mice, despite differences in 
morphine administration paradigm (osmotic mini-pump versus intermittent injection). 
Furthermore, these data concur with the lack of effect of the A2A receptor on the specific 
physical naloxone-precipitated morphine withdrawal symptoms that were assessed in 
this study (Figure 3.5), which suggests that they are not mediated by an A2A-D2 
interaction at the receptor level.
A role for D2 receptor however, has been implicated in the manifestation of naloxone- 
precipitated opioid withdrawal symptoms (Harris and Aston-Jones, 1994), yet the 
present data indicate that a mechanism other than alterations of D2 receptor levels may 
be involved. It is likely that the contribution of D2 in mediating responses to opiate
I
administration and withdrawal may be due to D2 receptor-mediated second-messenger 
system alterations (Piepponen et a l,  1996).
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3.4.7 Effect o f  naloxone-precipitated morphine withdrawal on quantitative 
autoradiographic binding o f  the glutamate mGlus receptor in WT and A 2A KO 
mice
In accordance with our previous data in chronically morphine-treated animals (Figure 
3.4), following naloxone-precipitated morphine withdrawal a significant increase in 
mGlus receptor binding was also evident in the thalamus of A2A KG mice compared to 
A2A KG saline controls (Figure 3.7). The persistence of this finding indicates that a 
regulatory role o f A2A on a MGPr-mGlus interaction is dependent on MGPr activation 
and not withdrawal. This reinforces our earlier indication for possible direct thalamic 
A2A-mGlu5-MGP receptor interaction, or an indirect action of A2A in the pain circuitry 
following morphine administration (Section 3.4.4).
In addition, following naloxone-precipitated morphine withdrawal, a significant 
upregulation o f mGlus receptors was observed in the amygdala o f A2A KG mice 
compared to WT. The amygdala is a forebrain structure composed of several distinct 
nuclei, such as the central, basolateral and medial nuclei and has important roles in the 
mediation of emotional responses such as fear and anxiety (see Gallagher and Chiba, 
1996). Like the thalamus, the amygdala is rich in mGlus (Rodrigues et a l ,  2002) and 
MGP (Ding et a l,  1996) receptors and there is evidence for amygdalar A2A 
immunolabelling (Rosin et a l,  1998), but again these receptors are not readily observed 
via receptor autoradiography (Fredholm et a l,  1998, DeMet and Chicz-DeMet, 2002). 
Similarly, it is unknown whether these receptors are co-localised in the amygdala or 
whether this upregulation is a result of an indirect action of A2A receptors elsewhere.
The functional significance of an A2A-dependent regulation of amygdalar mGlus 
expression during naloxone-precipitated withdrawal is unclear. However, glutamate
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transmission in the amygdala is involved in the emotional-affective component of both 
pain (Bellgowan and Helmstetter, 1996, McGaraughty and Heinricher, 2002, 
Neugebauer and Li, 2003) and morphine withdrawal (Watanabe et a l ,  2002). 
Furthermore, amygdalar mGlus receptors are involved in both nociceptive processing 
and anxiety (Perez de la Mora et a l,  2006, Kolber et a l,  2010, Li et a/., 2011, Crock et 
a l, 2012), indicating that it is plausible that this upregulation might be involved in 
mediating the negative affective component of naloxone-precipitated morphine 
withdrawal. However, in contrast to this, it has been shown that the aversive effects of 
naloxone-precipitated morphine withdrawal are actually abolished in A2A KO mice 
(Castané et al., 2008). This indicates that causal effect of a novel A2A-mGlu5 interaction 
in the amygdala following naloxone-precipitated morphine withdrawal clearly requires 
further investigation.
3.4. 8  Chapter summary
The present data show that A2A KO mice have reduced hyperactivity to chronic, 
intermittent, escalating-dose morphine administration, which was prominent at high 
doses. This suggests, like others, that A2A KO mice have reduced behavioural responses 
to morphine administration (Castané et al., 2008, Brown et al., 2009). Chronic morphine 
administration caused a significant upregulation of mGlug receptors in the thalamus of 
A2A KO mice, suggesting that in the presence o f morphine (i.e. via MOPr activation), 
A2A receptors can regulate the expression of thalamic mGlug receptors possibly via a 
MOPr-A2A-mGlu5 receptor interaction. Although the functional significance o f this is 
unclear, it may be linked to mediation of the nociceptive circuitry in response to chronic 
morphine administration. The somatic withdrawal symptoms precipitated by naloxone 
injection in morphine-dependent WT and A2A KO mice were not significantly different.
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which was in agreement with the literature (Berrendero et a l ,  2003). In addition to the 
persistent upregulation o f thalamic mGlus receptors observed in morphine-withdrawn 
A2A KO mice, binding of the mGlus receptor in these mice were also significantly 
increased from WT in the amygdala, however, the functional significance of this 
regulation remains to be elucidated.
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CHAPTER 4
The effect of chronic methamphetamine 
administration on locomotor behaviour and 
autoradiographic binding of the D2 and 
mGlus receptors in wild-type and A2A 
receptor knockout mice
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4.1 Introduction
Methylamphetamine, more commonly referred to as methamphetamine (MAP), is the 
A-methylated analogue of the psychostimulant amphetamine and both drugs share 
similar pharmacodynamics and pharmacokinetic properties (Melega et a l,  1995). 
Despite this, it is commonly accepted that MAP is a more addictive and more potent 
psychostimulant than amphetamine, which is most likely attributable to differing 
neurochemical effects (see Shoblock et a l,  2003). MAP readily crosses the blood-brain 
barrier where it interacts with nerve terminals to increase levels of DA, NA and 5-HT 
via either amine redistribution from synaptic vesicles to the cytoplasm, or by causing 
reverse action of monoamine transporters (see Sulzer et a l,  2005). Acute actions of 
MAP at DA nerve terminals in the striatum are thought to account for its initial euphoric 
and stimulatory actions (Vollm et a l,  2004).
In the UK, prevalence of MAP use is low, with around 0.1% of the population 
indicating they had used MAP in 2010/2011 (Smith and Flatley, 2011). However, the 
relatively easy clandestine manufacture and consequently low street cost o f MAP has 
meant that its use has reached near-epidemic proportions in the United States (see 
Gonzales et a l,  2010) and multiple bouts of epidemic MAP use in Japan have been 
reported (see Wada, 2011). Furthermore, MAP is a known neurotoxic agent, causing 
damage of nigrostriatal DAergic neurons (Wagner et a l,  1980) via DA oxidation and 
the formation of reactive oxygen species (O'Dell et a l,  1991, Cubells et a l ,  1994, 
Yamamoto and Zhu, 1998, LaVoie and Hastings, 1999), and also via glutamate 
excitotoxicity as a consequence of MAP-induced glutamate release in the striatum 
(Nash and Yamamoto, 1992, Abekawa et a l ,  1994, Stephans and Yamamoto, 1994). 
Clinically, this MAP-induced DA neurotoxicity can increase the risk of Parkinson’s
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disease in MAP users as they age (Callaghan et a l,  2010). In light of this, and to 
attempt to control emergent problems of MAP in the UK, it was reclassified from a 
Class B to a Class A drug in 2007 under the Misuse of Drugs Act (1971).
As described in Section 1.1.5, repeated psychostimulant administration causes the 
development of sensitisation, the augmentation of behavioural responses following 
repeated drug administration (Robinson and Berridge, 1993). Behavioural sensitisation 
can also be expressed by a ‘challenge’ low-dose psychostimulant injection following a 
period of abstinence/withdrawal from chronic psychostimulant administration (Pierce 
and Kalivas, 1997). Psychostimulant-induced sensitisation in animal models is 
hypothesised to have face validity for schizophrenic-like psychosis, due to parallels of 
this behaviour in human psychostimulant users (Robinson and Berridge, 1993). 
Psychosis is defined by the DSM as an abnormal state of the mind whereby the subject 
has a ‘loss o f contact with reality’, manifesting as hallucinations, delusions and 
disturbed or confused thought (American Psychiatric Association., 1994). This is 
thought to be measured by deficits in sensorimotor gating which, in animals, is 
measured by pre-pulse inhibition (Geyer and Moghaddam, 2002). Like psychosis, 
stereotypic behaviour is a positive symptom of schizophrenia (American Psychiatric 
Association., 1994) and can be induced by psychostimulant administration in both 
humans and animal models (Creese and Iversen, 1972). Stereotypies are thought to 
represent a process of cognitive inflexibility which distract from normal goal-directed 
behaviours, such as eating and sleeping and which can interfere with learning and social 
behaviours (see Cunningham and Schreibman, 2008).
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In animal models, amphetamine-sensitised behaviour often manifests as escalated 
locomotor and/or stereotyped repetitive responses, such as rearing, grooming, biting or 
circling (see Creese and Iversen, 1972, Scheel-Krüger, 1972). Although the neural 
mechanisms underlying stereotypic behaviour are not fully elucidated, it is thought to be 
related to the part of the striatal complex stimulated as a consequence of 
psychostimulant-induced increased striatal DAergic transmission (Costall et a l,  1977). 
For example, it has been shown that the Acb is essential for control o f hyperactivity 
(Koob et a l ,  1981), whereas the CPu appears to have a more prominent role in 
mediating stereotypic responses (Cho et a l, 1999). Stereotypies induced by the 
amphetamines are resultant of complex changes in the activity o f striatal neurons which 
are thought to be behaviourally distinct (Rebec et a l,  1997). Specifically, in response to 
MAP administration, the CPu appears to have a prominent role in mediating rearing 
behaviour (al-Kdiatib et a l,  1995). Rearing and climbing behaviours in rodents, similar 
to those elicited with psychostimulants, can be induced via administration o f the non- 
selective DA agonist apomorphine and reversed by pre-treatment with antipsychotic 
drugs such as haloperidol (Protais et a l,  1976, Costall et a l,  1978), leading to 
associations o f this behaviour with psychotic symptoms. Consistent with this finding, 
pre-treatment of D% receptor antagonists which are known to possess antipsychotic 
ability, reduced MAP-induced behavioural sensitisation and attenuated the 
augmentation of DA release following MAP challenge (Ujike et a l,  1989). Moreover, 
MAP-induced stereotypic responses are directly linked to D2 receptor function 
(Feldman et a l,  1997, Glickstein and Schmauss, 2004). Unsurprisingly, 
psychostimulant abuse (Persico et a l,  1996, see Noble, 2000) and clinical phenotypes 
of MAP psychosis (Ujike et a l,  2009) are associated with polymorphisms of the D2 
receptor gene, DRD2.
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There is a body of evidence suggesting a role o f the A2A receptor in MAP addiction and 
MAP-induced psychosis. For example, MAP dependence and MAP-induced psychosis 
in the Japanese population are associated with polymorphisms in the AD0RA2A  gene 
(Kobayashi et a l,  2010), which may be attributable to the presence of an A2A-D2 
receptor interaction. In agreement with the well-documented antagonistic nature of this 
relationship, it has been shown that A2A receptor agonism counteracts MAP-induced 
elevations in DA output in the striatum following a neurotoxic regimen of MAP 
administration (Golembiowska and Zylewska, 1998). Furthermore, the A2A agonist CGS 
21680 dose-dependently reduced MAP-induced hyperactivity after ‘challenge’ dose of 
MAP administered following cessation from chronic MAP treatment (Shimazoe et a l,  
2000). These findings suggest that A2A receptor agonism may be beneficial in reducing 
MAP-induced locomotor responses, possibly due to its ability to antagonise D2-receptor 
meditated effects.
To date, there has been no investigation into the effect of MAP administration in A2A 
KG mice, however, studies o f amphetamine administration in both global and 
conditional-forebrain A2A receptor KG mice have shown that, in contrast with the above 
pharmacological data, A2A KG mice have reduced amphetamine-induced hyperactivity 
and development of behavioural sensitisation to amphetamine challenge (Chen et a l ,  
2003, Bastia et a l ,  2005). Moreover, these behaviours were reproduced in WT mice 
pre-treated with A2A antagonists (Bastia et a l,  2005) suggesting again that, in contrast 
with the above data, A2A receptor antagonism or deletion reduces amphetamine-induced 
locomotor behaviours. As discussed in Section 1.5.2, these discrepancies may be 
explained by recent evidence showing that selective inactivation of striatal A2A 
receptors enhances, while forebrain A2A deletion reduces cocaine-induced hyperactivity
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(Shen et a l ,  2008) and which suggested a preferential postsynaptic (striatal) mechanism 
of action for some A%A receptor antagonists (see Orru et a l ,  2011).
Indeed, activation of cortical presynaptic A2A receptors can positively modulate 
glutamate input to the Acb through a synergistic effect with mGlus receptors (Rodrigues 
et a l, 2005) which may have implications on the regulation of psychomotor 
sensitisation behaviour, especially as it has been shown that prefrontal glutamate 
transmission is increased in both cocaine and MAP/amphetamine sensitised animals 
(Stephans and Yamamoto, 1996, Li et a l,  1999, Peterson et a l, 2000). Furthermore, 
administration of mGlus receptor antagonists have shown to reduce amphetamine- 
induced horizontal locomotion (Pietraszek et a l,  2004, McGeehan et a l,  2004, Gormley 
and Rompre, 2011).
As mentioned previously (see Section 1.7), there is a growing body of literature which 
suggests that the A2A and mGlug receptors are co-expressed postsynaptically in 
GABAergic striatopallidal efferent neurons. Further, evidence has demonstrated an 
mGlu5-A2A-D2 receptor oligomer in both HEK-293 cells and rat striatal homogenate 
(Cabello et a l,  2009). The presence of an mGlu5-A2A-D2 receptor complex is further 
supported by evidence showing an A2A-mGlu5 interaction can modulate D2 receptor 
function at molecular, transmission and behavioural levels (see Section 1.7). Recently, 
an A2A-mGlu5 receptor interaction has been shown to exist which can synergistically 
attenuate both alcohol self-administration and cue-induced ethanol reinstatement 
(Adams et a l,  2008) and also the reinforcing effects o f cocaine (Brown et a l ,  2011), 
however, no study to date has investigated the relevance of an A2A-mGlu5 receptor 
interaction in models of MAP addiction.
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Therefore, the aim of the present study was to further investigate the role of the A%A 
receptor in modulating the locomotor and stereotypic responses induced by chronic 
MAP treatment with the use o f WT and A2A KO mice. Using quantitative receptor 
autoradiography, we also aimed to identify if  A2A plays a role in the regulation of D2 
and mGlus receptor binding following chronic methamphetamine administration in WT 
and A2A KO mice. In addition, to confirm a role of the A2A receptor in the modulation of 
locomotor and stereotypic responses to methamphetamine, the effect of A2A antagonist 
pre-treatment on methamphetamine-induced horizontal and vertical activity in WT mice 
was investigated. Furthermore, to determine if an A2A-mGlu5 receptor interaction was 
involved in the locomotor and stereotypic effects of methamphetamine, the effect of 
sub-threshold doses o f A2A and mGlug receptor antagonists on methamphetamine- 
induced horizontal and vertical activity in WT mice was examined.
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4.2 Methods
4.2.1 Animals and treatments
Male, 8-15 week old CD-I wild-type and Aia receptor knockout mice, derived from a 
heterozygous breeding programme were used in this study, as detailed in Section 2.2.1. 
Mice were singularly housed for a period o f 7 days prior to the start o f the study and 
throughout the whole of the study period. Mice were habituated to home cages and 
experimenter handling for one week before the start o f experiment. The home cages 
were in a temperature-controlled environment and on a 12 hour light-dark cycle (lights 
on 07:00). Whilst in home cages, mice had access to food and water ad libitum. All 
experimental procedures were conducted in accordance with the UK Animal Scientific 
Procedures Act (1986).
Prior to experimental procedure, mice were removed from their home cages at 10:00 
and allowed to habituate to the motility chambers for 1 hour. At 11:00, mice were 
treated with methamphetamine (MAP; 1 mg/kg; i.p., Sigma-Aldrich, Dorset, UK) or 
saline (4 ml/kg; i.p.) each day for 10 days. Horizontal and vertical (rearing) activity 
behaviours were recorded for each mouse throughout the duration o f the study. All 
experimentation was carried out in a temperature-controlled environment and in dim 
light.
4.2.2 Motor activity measurements
Motor activity for the habituation (pre-injection) period and following saline or 
methamphetamine injection was recorded as detailed in Section 2.2.3, with the 
exception that beam-breaks were recorded continuously every 5 minutes (5 minute bin)
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for 180 minutes immediately following injection. Mice were returned to their home 
cages each day following completion of the locomotor test.
4.2.3 Autoradiographic confirmation o f  adenosine A 2A receptor genotype 
Confirmation of A2A genotype status was carried out as described in Section 2.2.4.
4.2.4 Quantitative receptor autoradiography o f  dopamine D2 and glutamate mGlus 
receptors following chronic methamphetamine administration in brains o f  WT 
and A 2A KO mice
As detailed in Section 2.2.4, tissue preparation, quantitative autoradiographic binding of 
D2 and mGlus receptors and subsequent procedures were carried out in WT and A2A KO 
mice following chronic MAP or saline administration.
4.2.5 Effect o f  A 2A receptor antagonist (SCH 58261) on methamphetamine-induced 
locomotor responses in WT mice
This experiment was carried out to confirm the role of A2A in the locomotor effects of 
MAP with the use of an A2A receptor antagonist, SCH 58261 (SCH, Tocris Biosciences, 
Bristol, UK) in WT mice. Dose-response experiments with SCH (1, 0.25, 0.1 or 0.01 
mg/kg; i.p.) followed by 1 mg/kg (i.p.) MAP injection were carried out in CD-I male 
WT mice (8-12 weeks). SCH was dissolved in DMSO and diluted to the required 
concentration using saline solution with a final concentration of 20% DMSO (see 
Hussey et a l ,  2007). All experimentation was carried out in a temperature-controlled 
environment and in dim light.
Prior to experimental start on each day, mice were removed from their home cages at
9.30 am and allowed to habituate to the motility chambers for 1 hour. Following this.
156
mice were treated with either vehicle (20% DMSO-saline) or SCH (1, 0.25, 0.1 or 0.01 
mg/kg; i.p.) and placed back into motility chambers for a further 30 minutes. At 
11:00am mice received an acute injection of either MAP (1 mg/kg; i.p.) or saline (4 
ml/kg; i.p.) and placed back into the motility chamber. Horizontal and vertical (rearing) 
activity behaviours were recorded for each mouse immediately following MAP or saline 
injection for a period of 3 hours, as described in Section 2.2.3. All experimentation was 
carried out in a temperature-controlled environment and in dim light. From these data 
we identified that a dose of 0.01 mg/kg of SCH was sub-threshold for reducing MAP- 
induced rearing.
4.2.6 Effect o f  co-administration o f  sub-threshold dose o f  A 2A cind mGlus receptor 
antagonist (MTEP) on methamphetamine-induced rearing in WT mice
This experiment was conducted to test the hypothesis of the existence of a functional 
role of A2A and mGlus receptors in regulating the locomotor effects of MAP. Sub­
threshold doses o f A2A antagonist, SCH 58261 and mGlug antagonist, MTEP (Tocris 
Biosciences, Bristol, UK) were administered prior to MAP injection in WT mice. 
MTEP was dissolved in DMSO and diluted to the required concentration using saline 
solution with a final concentration of 20% DMSO. To identify sub-threshold doses of 
A2A and mGlus antagonists, a dose-response study with SCH 58261 (see Section 4.2.5) 
and MTEP (see Section 4.2.6.1) was carried out in male CD-I WT mice (8-12 weeks) 
tested acutely with MAP (1 mg/kg, i.p.).
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4.2.6.1 Effect o f  mGlus receptor antagonist (MTEP) on
methamphetamine-induced locomotor responses in WT mice
Prior to experimental start on each day, mice were removed from their home cages at
9.30 am and allowed to habituate to the motility chambers for 1 hour. Following this, 
mice were treated with either vehicle (20% DMSO-saline) or MTEP (0.5, 0.25, 0.1 or 
0.01 mg/kg; i.p.) and placed back into motility chambers for a further 30 minutes. At 
11:00 am mice received an acute injection of either MAP (1 mg/kg; i.p.) or saline (4 
ml/kg; i.p.) and placed back into the motility chamber. Horizontal and vertical (rearing) 
activity behaviours were recorded for each mouse immediately following injection of 
MAP or saline for a period of 3 hours, as described in Section 2.2.3. All 
experimentation was carried out in a temperature-controlled environment and in dim 
light. From these data we identified that a dose of 0.01 mg/kg of MTEP was sub­
threshold for reducing MAP-induced rearing.
4.2.6.2 Effect o f  co-administration o f  sub-threshold dose o f  A 2A receptor
antagonist (SCH 58261) and mGlus receptor antagonist (MTEP) 
on methamphetamine-induced rearing in WT mice
Prior to experimental start on each day, mice were removed from their home cages at
9.30 am and allowed to habituate to the motility chambers for 1 hour. Following this, 
mice were treated with vehicle (20% DMSO-saline), a sub-threshold dose of SCH (0.01 
mg/kg; i.p.), a sub-threshold dose of MTEP (0.01 mg/kg; i.p.), or a combination of both 
ligands at sub-threshold dose (SCH, 0.01 mg/kg and MTEP 0.01 mg/kg; i.p) and placed 
back into motility chambers and left for a further 30 minutes. At 11:00 am mice 
received an acute injection of either MAP (1 mg/kg; i.p.) or saline (4 ml/kg; i.p.) and
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placed back into the motility chamber. Horizontal and vertical (rearing) activity were 
recorded for each mouse immediately following injection o f MAP or saline for a period 
of 3 hours, as described in Section 2.2.3. All experimentation was carried out in a 
temperature-controlled environment and in dim light.
4.2.7 Data analysis
All graphs were produced using GraphPad Prism V5.04 software (GraphPad Software 
Inc., USA). All statistical analysis was carried out using Statistica V I0 software 
(StatSoft Inc., USA).
4.2.7.1 Motor activity measurement
Basal (treatment-naive) locomotor activity was represented as the mean ± SEM of the 
cumulative total horizontal activity or vertical (rearing) activity for 1 hour before any 
treatment on Day 1. Comparison of these behaviours was carried out using Student’s 
unpaired t-test. The mean ± SEM of the cumulative pre- (1 hour) and post-injection (3 
hour) total horizontal or vertical activity was calculated for each experimental group 
every day throughout the duration of the study. Comparison of locomotor activities was 
carried out using three-way repeated measures ANOVA for factors genotype, treatment 
and time and significant factors were further analysed with Unequal n Tukey post-hoc 
or Tukey post-hoc test where appropriate.
4.2.7.2 Autoradiography o f  dopamine D2 and glutamate mGlus receptors
The mean ± SEM of each ligand binding measures (fmol of radioligand bound/mg 
tissue equivalent) was calculated in each brain region for each experimental group. 
Comparison of quantitative measures of autoradiographic binding for the ligand was
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carried out using three-way ANOVA for factors genotype, treatment and brain region. 
Two-way ANOVA was used to assess differences in binding between genotype and 
treatment in each brain region, followed by Duncan’s Multiple Range post-hoc test 
where appropriate.
4.2.7.3 Effect o f  co-administration o f  A 2A antagonist (SCH 58261) and
mGlus antagonist (MTEP) on methamphetamine-induced 
locomotor responses in WT mice
For the dose-response experiments, the mean ± SEM of the total horizontal or vertical 
activity for 3 hours following MAP injection was calculated for each experimental 
group. Comparison of locomotor activity was made for pre-treatment with each ligand 
(SCH or MTEP) using one-way ANOVA and compared to the Vehicle-MAP control 
group via post-hoc analysis with Dunnett’s Multiple Comparison test.
For the co-administration experiment, the mean ± SEM of the cumulative stimulated (3 
hour) total horizontal or vertical activity following MAP or saline injection was 
calculated for each experimental group. Comparison of locomotor activities was carried 
out using two-way ANOVA for factors of treatment (MAP, saline) and pre-treatment 
(vehicle, SCH, MTEP, SCH + MTEP). Significant effects were further analysed with 
Unequal n Tukey post-hoc test.
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4.3 Results
4.3.1 Basal locomotor activity prior to treatment with methamphetamine on Day 1 in 
WT and A 2A KO mice
Basal (treatment-naïve) locomotion, defined as total number of horizontal or vertical 
beam-breaks for 1 hour prior to either treatment injection on Day 1, showed there was 
no difference in either the horizontal or vertical activity of WT and A%A KO mice 
(P>0.05, Figure 4.1 A, B).
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Figure 4.1: Basal locom otor activ ity  prior to m etham phetam ine adm inistration  in 
w ild-type and adenosine A2A receptor knockout mice. Basal locomotor data were collected in 
5-minute bins for 1 hour prior to injection of saline or 1 mg/kg methamphetamine in wild-type (WT) and 
adenosine A2A receptor knockout (KO) mice on Day 1. (A) The cumulative total of horizontal activity 
during 1 hour prior injection is represented as mean ± SEM (n = 9). (B) The cumulative total of vertical 
activity during 1 hour prior injection is represented as mean ± SEM (n = 9).
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4.3.2 Horizontal locomotion pre- and post-methamphetamine administration in WT 
and À 2A KO mice
Horizontal locomotor activity in WT and adenosine A2A KO mice was recorded in 5- 
minute bins for 1 hour prior to injections of either saline or MAP (pre-injection basal 
activity) or 3 hours post-injection each day throughout the study. Horizontal activity 
was measured as the number of horizontal beam-breaks per bin and a cumulative total 
was calculated. To assess MAP-induced effects on basal horizontal activity (MAP pre­
treatment), this was recorded for 1 hour prior to first injection on each day (Figure 
4.2A). All groups showed a decrease in basal (pre-injection) activity over time (time 
effect, F(7,56) = 16.97, P<0.001) and post-hoc analysis in the factor o f time showed that 
in comparison to Day 2, this decrease was significantly different on Day 3 (P<0.05) and 
all subsequent days (P<0.001). In addition, pre-treatment with MAP significantly 
elevated the basal (pre-injection) horizontal activity o f mice in comparison to saline pre­
treated animals irrespective of genotype (treatment effect, F(i,g) = 7.07, P<0.05), 
although this was not significant on any day following post-hoc analysis. No effect of 
genotype (P>0.05), nor any interactions between treatment, genotype or time were 
observed (P>0.05).
Three-way repeated measures ANOVA showed that chronic treatment with MAP 
caused a significant increase in horizontal activity compared to saline controls 
(treatment effect, F(i^ 20) = 69.14, P<0.001). MAP-induced elevations in horizontal 
activity were significantly different from saline controls on all days in WT (Days 1, 6- 
10: P<0.001, Days 2-4: P<0.01) and A2A KO mice (Days 1-9, P<0.01; Day 10, 
P<0.001). MAP-induced horizontal activity did not significantly alter over time
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(treatment x time interaction, P>0.05) and there was no significant genotype effect in 
saline or MAP-treated animals (genotype effect, P>0.05).
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Figure 4.2: Effect of chronic methamphetamine administration on pre- and post­
injection horizontal locomotor activity in wild-type and adenosine A2A receptor 
knockout mice. (A) Pre-injection (basal) horizontal locomotor activity in wild-type (WT) and 
adenosine A2A receptor knockout (KG) mice following saline or methamphetamine (MAP, 1 mg/kg, i.p.) 
treatment throughout the duration of the study. Locomotor data was collected daily in 5-minute bins for 1 
hour prior to injection of saline or MAP. The cumulative total of horizontal activity during 1 hour prior 
injection is represented per day as mean ± SEM (n = 3-6). Significant effects of treatment (P<0.05) and 
time (P<0.001) were observed (3-way repeated measures ANOVA). *P<0.05, ***P<0.001 vs. Day 2 over 
all treatment groups. ). Data for Day 1 is omitted as it is represented in Figure 4.1. (B) Total horizontal 
locomotor activity in WT and KG mice following an injection of saline or MAP (1 mg/kg, i.p.). 
Locomotor data were collected daily in 5-minute bins for 3 hours immediately following injection. The 
cumulative total of horizontal activity during 3 hours post-injection is represented per day as mean ± 
SEM (n = 6 ). A significant effect of treatment (P<0.001) was observed (3-way repeated measures 
ANOVA). **f<0.01, <0.001 vs. WT Saline, "''f<0.01, <0.001 vs. KG Saline (Tukey post-hoc
test). Data for day 5 are absent due to irretrievable software failure.
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4.3.3 Vertical locomotion pre- and post-methamphetamine administration in WT and 
A 2A KO mice
Vertical activity in WT and KO mice was recorded in 5-minute bins for 1 hour prior to 
injections of either saline or MAP (pre-injection basal activity) or 3 hours post-injection 
each day throughout the study. Vertical (rearing) activity was measured as number of 
vertical beam-breaks per bin and a cumulative total was calculated. To assess MAP- 
induced effects on basal vertical activity (MAP pre-treatment), this was recorded for 1 
hour prior to injection on each day (Figure 4.3A). All groups showed a decrease in basal 
vertical activity over time (time effect, F(?,56) = 14.32; P<0.001) and post-hoc analysis in 
the factor o f time revealed that in comparison to Day 2 this decrease was statistically 
significant on Day 3 (P<0.05), Day 4 (P<0.01), and all subsequent days (F<0.001). 
Neither significant effects of treatment (P>0.05) or genotype (P>0.05) nor any 
significant interactions between time, treatment and genotype were observed (P>0.05).
In WT mice treatment with chronic MAP (post-injection) caused a significant increase 
in rearing behaviour (treatment effect, F(i,20) = 25.58, P<0.001) which did not alter over 
time (time effect, P>0.05). Post-hoc analysis showed that in comparison with WT 
Saline controls, vertical activity of WT MAP-treated mice was significantly elevated on 
almost all days (Days 1,6-10, f  <0.001; Day 2, ?<0.01 and Day 3, P<0.05). In addition 
to an observed effect of genotype (F(i,20) = 6.29, P<0.05), MAP-induced rearing 
behaviour was completely attenuated in MAP-treated A2A KO mice (treatment x 
genotype interaction, F(i,20) = 12.27, P<0.01; Figure 4.3B). In fact, MAP-induced 
rearing behaviour in A2A KO mice was not significantly different from rearing 
behaviour in A2A KO saline controls on any day (P>0.05) and was significantly reduced 
from WT MAP rearing on most days (Day 1, 7 and 9, P<0.01; Days 6 and 8, P<0.001).
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Figure 4.3: Effect of chronic methamphetamine administration on pre- and post­
injection vertical locomotor activity in wild-type and adenosine A2A receptor 
knockout mice. (A) Pre-injection (basal) vertical activity in wild-type (WT) and adenosine A2A 
receptor knockout (KO) mice was collected daily in 5-minute bins for 1 hour prior to injection of saline or 
1 mg/kg methamphetamine (MAP). The daily cumulative total of vertical activity during 1 hour prior 
injection is represented mean ± SEM. (n=3-6). A significant effect of time (P<0.001) was observed (3- 
way repeated measures ANOVA). *P<0.05, **P<0.01, ***P<0.001 vs. Day 2 over all treatment groups 
(Unequal n Tukey post-hoc test). Data for Day 1 is omitted as it is represented in Figure 4.1. (B) Total 
rearing activity in WT and KO mice following an injection of saline or MAP. Locomotor data were 
collected daily in 5-minute bins for 3 hours immediately following injection. The daily cumulative total 
of vertical activity during 3 hours post-injection is represented as mean ± SEM (n = 6). Significant effects 
of genotype (P<0.05), treatment (P<0.001) and a genotype x treatment interaction (P<0.01) were 
observed (3-way repeated measures ANOVA). *P<0.05, **P<0.01, ***P<0.001 WT MAP vs. WT 
Saline, ^^ /*<0.01, f  <0.001 WT MAP vs. KO MAP (Tukey post-hoc test). Data for day 5 are absent due 
to irretrievable software failure.
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4.3.4 Autoradiographic binding o f  the adenosine À 2a receptor fo r  genotype 
confirmation in WT and À 2a KO mice used in methamphetamine experiments
Striatal sections from the brains of each experimental animal were bound with the 
radiolabelled A2A receptor agonist [^HJCGS 21680 to confirm that the genotype 
determined by the PCR and DNA electrophoresis procedures were correct. In this 
experiment, autoradiographic binding confirmed genotyping was correct in all animals.
4.3.5 Effect o f  chronic methamphetamine treatment on quantitative autoradiographic 
binding o f  the dopamine D2 receptor in WT and À 2a KO mice
Quantitative autoradiography of dopamine D2 receptors from coronal sections of the 
caudate showed extensive binding throughout (Figure 4.4). Binding of [^HJraclopride 
was limited to the Acb, Tu and the CPu (region effect, F(3j 2) = 69.17, f<0.001), where 
the highest level of binding was observed (mean specific binding 108.1 -119.2 fmol/mg 
tissue equivalent). No significant effects of genotype (P>0.05) or treatment (P>0.05) or 
interactions between those factors were observed (P>0.05).
4.3.6 Effect o f  chronic methamphetamine treatment on quantitative autoradiographic 
binding o f  the glutamate mGlus receptor in WT and À 2a KO mice
Binding of [^HJMPEP in coronal brain sections showed widespread and distinct levels 
of mGlus receptor localisation (region effect, F(i2,230) = 11.40, P<0.001; Figure 4.5). 
While chronic MAP treatment caused a region-specific upregulation of mGlug receptors 
in WT (treatment effect, F(i,23o) = 6.25, P<0.05), this was completely abolished in the 
brains of A2A KO mice (genotype x treatment interaction, F(i,230) = 39.48, P<0.001). 
When analysed by region, significant genotype x treatment interactions were observed 
in the AcbC (F(i,i8) =7.65, P<0.05), AcbSh (F(i,i7) = 5.61, P<0.05), CPu (F(i,i9) = 5.73,
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P<0.05) and hypothalamus (Hyp, F (ij9) = 5.73, P<0.05). A significant effect of 
genotype was observed in the motor cortex (M l, M2, F(ijg) = 5.28, P<0.05).
Post-hoc analysis showed that MAP-treated WT mice had significantly increased mGlug 
receptor binding in comparison with WT saline controls in AcbC, AcbSh and CPu (all 
P<0.05), which did not occur in A2A KG mice (P>0.05). Additionally, MAP-treated A2A 
KG mice showed a general decrease in [^HJMPEP binding compared to MAP-treated 
WT mice, a finding which was significant in the ventral striatum (AcbC, P<0.05; 
AcbSh, P<0.05), motor cortex (M l,M2, P<0.01) and hypothalamus (Hyp, P<0.05).
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Figure 4.4: Q uantitative autoradiography of D; receptor binding in coronal brain  
sections from chronically  m etham phetam ine or saline-treated  w ild-type or 
adenosine A 2 A receptor knockout mice. W ild-type (W T) and adenosine A 2A receptor knockout 
(KO) mice were treated with either m etham phetam ine (M A P , 1 m g /k g /d a y ; i .p .)  o r s a l in e  (4 
m l/k g , i .p .)  e a ch  d ay  fo r  10 d ay s . (A) Data are expressed as the mean specific binding (fm ol/m g 
tissue equivalent) ± SEM (n=4-6) o f  [^H]raclopride for D2 receptors in brain regions o f  W T and KO 
mice chronically treated with saline or MAP. Regional determ inations were made from both left and 
right sides o f  the sections. Labelling o f the sections was carried out in a com pletely paired protocol. No 
significant effects were observed (3-way ANOVA). (B) Com puter-enhanced autoradiogram s o f  coronal 
brain sections from W T and KO mice treated with either saline or chronic MAP. The adjacent sections 
shown are from the level o f  the caudate (Bregm a +0.86 mm). The colour bar represents a pseudo­
colour interpretation o f  black and white film images in fmol/m g tissue equivalent. Specific binding was 
-8 0 %  o f  total binding in the m ajority o f  regions analysed. AcbC, nucleus accum bens core; AcbSh, 
nucleus accumbens shell; CPu, caudate putamen; Tu, olfactory tubercule.
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Figure 4.5: Q uantitative autoradiography of mGlus receptor binding in coronal 
brain sections from chronically  m etham phetam ine or sa line-treated  vrild-type or 
adenosine A 2 A receptor knockout mice. W ild-type (W T) and adenosine A 2A receptor 
knockout (KO) mice were treated with either m etham phetam ine (M AP, 1 mg/kg/day; i.p.) or saline (4 
ml/kg, i.p.) each day for 10 days. (A) Data are expressed as the mean specific binding (fm ol/m g tissue 
equivalent) ± SEM (n=4-6) o f [^HJMPEP for m Gluj receptors in brain regions o f  W T and KO mice 
chronically treated with saline or MAP. Regional determ inations were made from both left and right 
sides o f  the sections. Labelling o f  the sections was carried out in a com pletely paired protocol. A 
significant effect o f treatm ent (F<0.05) and a significant genotype x treatm ent interaction (P<0.001) 
was observed over all regions (3-way ANOVA). *P<0.05 vs. WT saline; V < 0 .05 ; ^^P<0.01 vs. W T 
MAP (D uncan’s M ultiple Range post-hoc test). AcbC, nucleus accum bens core; AcbSh, nucleus 
accumbens shell; Amy, amygdala; Cg, cingulate cortex; CPu, caudate putamen; Hip, hippocam pus; 
Hyp, hypothalam us; LS, lateral septum; Ml, M2, primary and secondary motor cortices; MS, medial 
septum; PrL, prelim bic cortex; Th, Thalamus; VDB, ventral limb o f  the diagonal band o f  Broca. (B) 
Com puter-enhanced autoradiogram s o f  coronal brain sections from brains o f  WT and KO mice treated 
with saline or MAP. The adjacent sections shown are from the level o f  the caudate (Bregm a +0.86 
mm). The colour bar represents a pseudo-colour interpretation o f  black and white film images in 
finol/m g tissue equivalent. Specific binding was -6 0 %  o f total binding in the majority o f  regions 
analysed.
170
4.3.7 Effect o f  A 2A antagonist SCH 58261 on methamphetamine-induced locomotor 
responses in WT mice
There was a significant effect of pre-treatment with SCH 58261 to reduce MAP- 
induced horizontal activity (F(4,2i) = 7.35, P<0.001, Figure 4.6A) but when analysed by 
post-hoc comparison, no dose was statistically significant in this respect (P>0.05 vs. 
Vehicle-MAP). However, pre-treatment with SCH 58261 significantly reduced MAP- 
induced rearing (F(4,i9) = 9.81, P<0.001, Figure 4.6C) at doses of 1 mg/kg, 0.25 mg/kg 
and 0.1 mg/kg (all P<0.01). Pre-treatment with SCH 58261 at a dose of 0.01 mg/kg 
was ineffective (i.e. sub-threshold) at reducing MAP-induced rearing (P>0.05).
4.3.8 Effect o f  co-administration o f  sub-threshold doses o f  À 2a antagonist (SCH  
58261) and mGlus antagonist (MTEP) on methamphetamine-induced 
locomotor responses in WT mice
Sub-threshold doses of A%A antagonist SCH 58261, and mGlu$ antagonist MTEP were 
administered prior to MAP injection in WT mice (see Section 4.3.8.2). To identify 
sub-threshold doses of A%A and mGlug antagonists, a dose-response study with SCH 
58261 (see Section 4.3.7) and MTEP (see Section 4.3.8.1) prior to MAP (1 mg/kg, 
i.p.) administration were carried out.
4.3.8.1 Effect o f  mGlus receptor antagonist MTEP on
methamphetamine-induced locomotor responses in WT mice
There was a significant effect of pre-treatment with MTEP to reduce MAP-induced 
horizontal activity (F(4,2i) = 3.53, P<0.05; Figure 4.6B), but, no dose was statistically 
significant in this respect when analysed by post-hoc comparison (P>0.05 vs. Vehicle-
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MAP). However, pre-treatment with MTEP significant reduced MAP-induced rearing 
(F(4,i9) = 5.86, P<0.01; Figure 4.6D) at doses of 0.5 mg/kg (P<0.01), 0.25 mg/kg 
(?<0.05) and 0.1 mg/kg (P<0.05). Pre-treatment with MTEP at a dose of 0.01 mg/kg 
was ineffective at reducing MAP-induced rearing (P>0.05).
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Figure 4.6: D eterm ination  o f a sub-threshold  dose o f A 2A an tagon ist, SCH 58261 
and mGIus receptor antagonist, MTEP on m etham phetam ine-induced rearing  
behaviour in w ild-type mice. The effect of pre-treatment with Aja receptor antagonist SCH 
58261 (1, 0.25, 0.1 or 0.01 mg/kg, i.p.) or mGluj receptor antagonist MTEP (0.5, 0.25, 0.1 or 0.01 
mg/kgj i-p.) on methamphetamine (MAP, 1 mg/kg, i.p.) induced horizontal and vertical (rearing) 
locomotor activity was assessed in wild-type mice. Locomotor data for horizontal activity and vertical 
activity was collected in 5-minute bins for 3 hours immediately following injection of MAP. The 
cumulative total of either horizontal or vertical activity during 3 hours post-injection is represented as 
mean ± SEM (n = 3-8). Significant effects of pre-treatment with SCH 58261 on horizontal (A, P<0.001) 
and vertical (C, P<0.001) activity and MTEP on horizontal (B, P<0.05) and vertical (D, P<0.01) 
activity were observed (one-way ANOVA). *P<0.05 **?<0.01 vs. Vehicle-MAP (Dunnetfs Multiple 
Comparisons post-hoc test).
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4.3.8 .2 Co-administration -  effect o f  sub-threshold dose o f  MTEP and
SCH 58261 administration on methamphetamine-induced 
locomotion in WT mice
A  dose of 0.01 mg/kg for both MTEP and SCH 58261 (SCH) was determined as sub­
threshold for efficacy in reversing MAP-induced rearing based on dose-response 
studies (Figure 4.6C and D). Single or co-administration of sub-threshold dose of 
MTEP (0.01 mg/kg) and SCH (0.01 mg/kg) were injected 30 minutes before saline or 
MAP (1 mg/kg, i.p.) injection to measure the effect o f mGlus and A2A receptor co­
antagonism on MAP-induced rearing behaviour.
Administration of MAP (1 mg/kg; i.p.) significantly increased both horizontal 
(treatment effect, F(i^2) = 104.65, P<0.001; Figure 4.7A) and vertical (treatment effect, 
F(i,32) = 55.92, P<0.001; Figure 4.7B) activity compared to saline-treated WT mice. 
There was no significant effect of SCH and/or MTEP pre-treatment on either 
horizontal (P>0.05) or vertical (P>0.05) activity and no significant interactions 
between factors were observed (P>0.05).
As expected, pre-treatment of a sub-threshold dose of SCH 58261 (0.01 mg/kg) did 
not prevent MAP-induced locomotor activity, as both horizontal (P<0.001) and 
vertical (P<0.01) activities were significantly elevated from respective saline controls. 
In agreement, pre-treatment of a sub-threshold dose of MTEP (0.01 mg/kg) did not 
prevent MAP-induced locomotor activity, as both horizontal (P<0.001) and vertical 
(P<0.05) activities were also significantly elevated from respective saline controls.
However, MAP-induced elevations in vertical activity, but not horizontal activity, 
were prevented by combined SCH 58261 (0.01 mg/kg) and MTEP (0.01 mg/kg) pre­
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treatment, as this response was not significantly different from the respective saline 
control. Further, when compared to MAP administration with vehicle pre-treatment 
(Vehicle-MAP), co-administration of SCH 58261 (0.01 mg/kg) and MTEP (0.01 
mg/kg) produced a significant -60%  decrease in MAP-induced vertical activity 
(P<0.05). Although co-administration of these ligands (MTEP 0.01 mg/kg + SCH 
58261 0.01 mg/kg) reduced MAP-induced horizontal activity by approximately 25%, 
this decrease was not statistically significant from MAP administration with vehicle 
pre-treatment (Vehicle-MAP, P>0.05).
Pre-treatment o f either MTEP (0.01 mg/kg) or SCH 58261 (0.01 mg/kg) alone, or in 
combination, did not affect the horizontal or vertical locomotor response in saline 
treated animals (P>0.05).
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Figure 4.7: The effect o f either single or co-adm inistration  of sub-threshold  doses 
of A 2A antagon ist SCH 58261 and/or mGlug receptor antagonist MTEP on 
m etham phetam ine-induced locom otor activ ity  in w ild-type mice. The effect of pre­
treatment with sub-threshold doses of A2A antagonist SCH 58261 (SCH, 0.01 mg/kg, i.p.), mGlug 
receptor antagonist MTEP (0.01 mg/kg, i.p.) or a combination of both (SCH 0.01 mg/kg + MTEP 0.01 
mg/kg, i.p.) on methamphetamine (MAP, 1 mg/kg) induced horizontal and vertical (rearing) locomotor 
activity was assessed in wild-type mice and paired with saline controls. Locomotor data for (A) 
horizontal activity and (B) vertical activity was collected in 5-minute bins for 3 hours immediately 
following injection of saline or MAP. The cumulative total of either horizontal or vertical activity 
during 3 hours post-injection is represented as mean ± SEM (n = 4-6). Significant effects of treatment 
(P<0.05) were observed for both horizontal and vertical activity (2-way ANOVA). *P<0.05, **P<0.01, 
<0.001 vs. respective saline control group, <0.05 (Unequal A^Tukey/?o5?-/?oc test).
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4.4 Discussion
This study aimed to further investigate the role of the A%A receptor in MAP-induced 
locomotor responses and neurochemical effects, and was the first of its kind to do so in 
A2A KO mice. The genotype o f all mice used in this study was confirmed ex vivo by 
radiolabelling striatal brain sections with [^HJCGS 21680. In this experiment, receptor 
autoradiography showed that the genotypes of all animals determined by PGR were 
correct.
4.4.1 Basal locomotor activity prior to treatment with methamphetamine on Day 1 in 
WT and A 2A KO mice
In order to assess treatment-naïve basal activity, horizontal and vertical activities of WT 
and A2A KO mice were measured 1 hour prior to any treatment on Day 1. The data 
showed no significant genotype difference in either locomotor parameter (Figure 4.1), 
which is consistent with findings observed in the previous studies (Figures 2.2 and 3.1) 
and is in agreement with Soria et al. (2006) and Castané et al. (2008). However, as 
discussed in Section 2.4.1, these findings are in contrast to the original hypolocomotor 
phenotype o f A2A KO mice demonstrated by Ledent et al. (1997). This may be 
attributable to differences in enrichment factors which affect anxiety-like responses, as 
A2A KO mice are phenotypically more anxiogenic (Ledent et a l ,  1997).
4.4.2 Effect o f  chronic methamphetamine pre-treatment on basal locomotor activity in 
WT and À 2a KO mice
In order to determine if treatment with MAP affected the basal (pre-injection) 
locomotor responses of WT and A2A KO mice, horizontal and vertical activity was 
recorded for one hour prior to injection of saline or MAP on each day. All groups
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showed a significant decrease in the total daily basal horizontal (Figure 4.2A) and 
vertical (Figure 4.3A) activities over time, an effect attributed to behavioural 
habituation to the test environment (see Section 2.4.2). However, in comparison to 
saline controls, MAP pre-treated groups showed significantly elevated levels of basal 
horizontal, but not vertical, activity suggesting that MAP pre-exposure in CD-I mice 
increased their basal locomotor response to an open-field environment. It is plausible 
that this could reflect cue-induced expectation of drug reward when mice were placed 
into the motility chambers, as context-specific sensitisation has been associated with 
administration of amphetamines (Tirelli and Terry, 1998).
4.4.3 Methamphetamine-stimulated horizontal locomotion in WT and A 2A KO mice
The present data examined the effects of chronic MAP administration on locomotor 
activity in the CD-I mouse strain, which has as yet has remained unexplored. The data 
showed that MAP administration produced a significant elevation in horizontal activity, 
which persisted to the same level throughout the 10-day duration of the study in both 
WT and A2A KO mice (Figure 4.2B). In contrast to the present study, other studies 
which have used inbred mice strains (C57BL/6J, ICR) to examine the effects of low 
dose (1-3 mg/kg) MAP or amphetamine administration have observed the development 
of a locomotor sensitisation response over the duration of the study (Chen et a l ,  2003, 
Bastia et a l,  2005, Yoo et a l,  2010b). This suggests a strain difference in the locomotor 
effects induced by MAP administration and is in agreement with the lack of behavioural 
sensitisation observed in our chronic cocaine study (Figures 2.3B, 2.4B). In addition, in 
contrast with C57BL/6J mice where amphetamine-induced neurotoxicity was shown to 
be much more severe, CD-I mice displayed milder responses (Krasnova et a l ,  2001).
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Together, these findings suggest that the CD-I mouse strain is less sensitive to at least 
some of the effects o f psychostimulants.
The present data also indicate that A2A receptors are not involved in the modulation of 
the acute and persistent MAP-induced elevations in horizontal activity, as a similar 
locomotor response to WT was observed in A2A KO mice. However, attenuated 
locomotor responses to amphetamine administration have been observed in C57BL/6J 
global A2A KO mice (Chen et a l, 2000, Chen et a l,  2003), thereby implicating a role of 
the A2A receptor in mediating amphetamine-induced locomotor behaviours. Again, this 
suggests that either the effect of strain may be confounding the role o f the A2A receptor 
in psychostimulant addiction (similar to our observations for cocaine, see Section 2.4.4) 
or that there are specific differences between the responses to amphetamine and MAP in 
A2A KO mice.
4.4.4 Methamphetamine-stimulated vertical locomotion in WT and A 2A KO mice
Acute and chronic MAP administration caused a persistent and significant increase in 
rearing behaviour in WT mice (Figure 4.3B). However, this behaviour was completely 
abolished in A2A KO mice, thereby indicating a pivotal role of the A2A receptor in 
mediating MAP-induced rearing. Classically, rearing behaviour in untreated rodents is 
considered an exploratory response (Holmes, 2003), however, its prominence following 
psychostimulant administration (Creese and Iversen, 1972, Kelly et a l,  1975) and the 
observation that psychostimulant-induced rearing is far higher than levels observed in 
saline control animals (Figure 4.3B), suggest either that distinct mechanisms are 
mediating this behaviour, or that the exploratory response is dysregulated by 
psychostimulant administration.
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As described in Sections 1.1.5 and 1.3.3, psychostimulant-induced rearing is a type of 
stereotypic behaviour. Stereotyped behaviour is thought to reflect cognitive inflexibility, 
resulting in the disruption of normal goal-directed behaviours and is a common feature 
of the neuropsychiatrie disorders schizophrenia and autism (American Psychiatric 
Association., 1994). However, the pathophysiology and neurobiology o f stereotypic 
behaviour is poorly understood. Psychostimulant-induced stereotypies are hypothesised 
to result from dysregulation o f the basal ganglia and frontal cortex (see Ridley, 1994), 
in particular, altered DAergic transmission in discrete subregions of the striatum (Staton 
and Solomon, 1984, Kuczenski et a l, 1991, Segal and Kuczenski, 1992). The 
anatomical specificity and modulation of this behaviour by other systems, however, is 
relatively unknown.
Microdialysis studies in intact rats show that MAP administered at a dose o f 1 mg/kg 
(i.p.) induces large extracellular DA release in the striatum, with baseline increases of 
-125 % and -200%  in the Acb and CPu, respectively (Zhang et a l,  2001). This is in 
contrast with a -70%  and 170% (Acb and CPu) increase o f striatal DA release induced 
by 10 mg/kg (i.p.) cocaine (Zhang et a l,  2001), which may partly explain why 
differences are observed between MAP-rearing and that observed in the earlier cocaine 
study (Figure 2.4B). The fact that the A%A receptor has such a profound modulatory 
effect on psychostimulant-induced rearing, without having an effect on horizontal 
locomotor behaviour is consistent with studies investigating the role of 5-HT2c and 
GABAb receptors in these behaviours, which appear to point toward modulation of 
striatal DAergic transmission in governing this response. Indeed, intra-mPFC 
administration of a 5-HT2c antagonist, which is known to block behaviours dependent 
on the activation of the mesoaccumbens DAergic circuitry (Filip and Cunningham,
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2003), specifically attenuated MAP-induced rearing, but not horizontal locomotion 
(Hall et a l,  2009a). In agreement, direct administration of GABAb receptor agonist, 
baclofen, into the VTA or SN, which is known to block striatal DA release (Klitenick et 
a l, 1992), significantly attenuated amphetamine-induced rearing without altering 
horizontal behaviour in rats (Zhou et a l,  2005). Although it is unclear what 
neuroanatomical striatal regions are involved in mediating MAP-induced rearing 
behaviour, based on the above evidence, it is plausible that high DAergic stimulation in 
specific regions of the striatum are responsible for MAP-induced rearing and that this is 
distinct from brain regions which govern horizontal behaviour.
The lack of MAP-induced rearing in A2A KO mice suggests deletion o f the A2A receptor 
may also be acting to reduce DA transmission in the striatum in response to MAP 
administration. This is supported by evidence showing that administration o f an A2A 
receptor antagonist (DMPX) was effective in countering amphetamine (2 mg/kg; i.v.) 
induced increases in striatal DAergic transmission (Chen et a l,  2005). However, others 
have shown that conversely, A2A receptor agonism in rats reduced MAP-evoked DA 
release following a neurotoxic ( 3 x 5  mg/kg) MAP-administration regimen 
(Golembiowska and Zylewska, 1998). The mechanism by which A2A modulates DA 
release has not been fully elucidated. Striatal presynaptic A2A receptors are not 
expressed on DAergic terminals (Hettinger et a l,  2001), which eliminate a direct action 
of A2A antagonism on DA release. However, A2A receptors are located presynaptically 
in striatal glutamatergic terminals (Hettinger et a l,  2001) and activation of these 
receptors facilitates striatal glutamate release (Golembiowska and Zylewska, 1997, 
Quarta et a l ,  2004, Rodrigues et a l ,  2005). It has been shown that glutamate release 
and activation of glutamate receptors in the striatum can facilitate extracellular DA
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release (Shimizu et a l ,  1990, Segovia et a l ,  1997, see David et a l ,  2005), thereby 
implicating an indirect role o f A2A receptors in striatal DA modulation. However, 
additional studies are required to further investigate the mechanism by which A2A 
receptor deletion prevents MAP-induced rearing. For example, freely-moving 
microdialysis in the striatum of MAP-treated WT and A2A KO mice may confirm 
whether alterations in glutamate and DAergic transmission do indeed contribute to 
rearing behaviour.
In addition to providing novel evidence for the targeting of A2A receptors in the 
management of the stereotypic effects associated with MAP addiction, these data may 
also be indicative of a relevant target for the treatment o f the stereotypic symptomology 
of other neuropsychiatrie disorders such as schizophrenia, autism and OCD.
4.4.5 Effect o f  chronic methamphetamine administration on quantitative 
autoradiographic binding o f  the dopamine D2 receptor in WT and A 2A KO mice
The present data showed that treatment with chronic MAP did not alter D2 receptor 
binding levels when compared to saline controls (Figure 4.4) and is in agreement with 
others showing that D2 receptor density was also unaltered following treatment with 
chronic MAP ( 2 x 1  mg/kg per day, 7 days; i.p.) (Yoo et a l ,  2010b) or amphetamine (2 
X 5 mg/kg per day, 6 days; i.p.) (Bonhomme et a l ,  1995). This indicates that chronic 
MAP treatment does not alter levels of the D2 receptor in animal models of 
amphetamine/MAP sensitisation.
Yet, there is clear evidence for a role o f D2 receptors in MAP-induced behaviours. 
MAP-induced stereotypic responses are directly linked to D2 receptor function 
(Feldman et a l,  1997, Glickstein and Schmauss, 2004) and sensitisation of the DAergic
182
system, in particular the D2 receptor, is hypothesised to be necessary for the 
development of psychostimulant-induced psychosis (Seeman et a l ,  2006). In fact, 
chronic MAP treatment has been shown to cause super-sensitivity o f D2 receptors, as 
demonstrated by an augmented locomotor and stereotypic response to D2 receptor 
agonist administration in rats following prolonged abstinence from chronic MAP 
treatment (Ujike et a l,  1990). The lack of D2 receptor density modulation by MAP as 
observed in this study and by others suggest that changes in D2 receptor binding do not 
underpin the neurobiological mechanism underlying MAP-induced locomotor 
behaviour, but possibly changes in D2 mediated signalling. In support of this, there is 
some evidence to suggest that downstream D2 receptor mediated effects are involved in 
mediating amphetamine behavioural responses, such as hyperactivity and sensitisation 
(Beaulieu et a l ,  2004, Enman and Unterwald, 2012).
In addition, deletion of the A2A receptor had no effect on the regulation of D2 receptor 
binding in response to chronic MAP treatment, and again is consistent with data from 
other drugs o f abuse (see Figures 2.8 and 3.6). This suggests that the deletion o f the A2A 
receptor does not alter the expression of D2 receptors following chronic MAP 
administration.. However, further work is required to elucidate whether there is a role of 
A2A in the modulation of both striatal DAergic transmission and D2 receptor-mediated 
effects in models of MAP addiction.
4.4.6 Effect o f  chronic methamphetamine administration on quantitative 
autoradiographic binding o f  the glutamate mGlus receptor in WT and A 2A KO 
mice
To date, no study has assessed the changes in mGlus receptor binding levels, nor the 
effect of A2A receptor deletion on the regulation of these receptors following chronic
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MAP administration. The present data showed that in response to chronic MAP 
administration, WT mice showed a significant striatal-specific upregulation of mGlus 
receptors (Figure 4.5) and that this upregulation was absent in A2A KO mice. This 
showed for the first time a direct regulatory role of the A2A receptor in modulating 
receptor levels o f mGlu$ receptors in response to chronic MAP treatment and suggests 
that MAP-induced mGlug receptor upregulation in WT mice is A2A receptor dependent.
Others investigating the regulation of mGlus receptors in response to amphetamine 
treatment have shown that acute amphetamine treatment (5 mg/kg) transiently 
decreased striatal mGlug receptor protein levels, as assessed by Western blot (Shaffer et 
a l, 2010), and striatal mGlug receptor mRNA was decreased in rats behaviourally 
sensitised to amphetamine (Mao and Wang, 2001). However, mRNA levels do not 
necessarily represent changes in receptor binding levels and differences in other factors 
such as drug administration (amphetamine vs. MAP) and paradigm (i.e. acute, chronic 
and sensitisation), which are known to vary over the stages of psychostimulant 
addiction (see Kalivas et a l,  2009), may explain the inconsistency o f these studies with 
the present results.
The mechanism by which deletion of the A2A receptor prevents upregulation of the 
mGlus receptor in response to MAP treatment is unknown, but is in support of earlier 
data which showed decreased mGlus receptor binding in the striatum of treatment-naïve 
A2A KO mice versus WT (Figure 2.7). Together, these data suggest the presence of a 
close modulatory role o f A2A on striatal mGlug receptor expression in vivo. Indeed, 
mGlus and A2A receptors are co-localised in both presynaptic glutamatergic terminals of 
the striatum (Rodrigues et a l ,  2005) and postsynaptically in striatopallidal GABAergic 
neurons (Testa et a l ,  1995, Hettinger et a l,  2001), however, the present
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autoradiographical technique is unable to distinguish between pre- and postsynaptic 
receptors. The fact that the abolition of MAP-induced mGlus receptor activation is 
associated with the lack of MAP-induced rearing in A%A KO mice suggests that an Aia- 
mGlus receptor interaction might be at least partly implicated in the molecular 
mechanism underpinning this behaviour. As mentioned in Section 4.4.4, the MAP- 
induced rearing response in WT mice is thought to be attributed to high DAergic 
stimulation in the striatum. This may be linked to an indirect mechanism of A2A- 
mediated glutamate release, which has been shown to be facilitated by a presynaptic 
A2A-mGlu5 receptor interaction in glutamatergic striatal terminals (Rodrigues et a l ,  
2005). Therefore, the present data support an A2A receptor-dependent mechanism of 
MAP-induced striatal mGlus receptor upregulation, possibly at a presynaptic locus, 
which may be involved in mediating MAP-induced rearing in WT mice. However, 
further work in this area is required to fully understand the causal effect o f MAP- 
induced striatal mGlug upregulation and the role of the A2A receptor in mediating this 
response.
It is plausible that MAP-induced A2A-dependent upregulation of striatal mGlug receptors 
may also contribute to a mechanism of neurotoxicity, as administration of MAP is 
known to cause significant neurotoxicity of DA nerve endings terminating in the 
striatum (Lorez, 1981). Moreover, endogenous activation of mGlus receptors enables 
the development of MAP-induced neurotoxicity (Battaglia et a l,  2002, Shah et a l ,  
2012) and blockade of astroglial mGlus receptors was shown to be protective from 
MAP-induced increases in pro-inflammatory cytokines (Shah et a l,  2012). Although it 
is unclear whether chronic treatment with 1 mg/kg MAP, as used in the present study, 
induced neuroinflammation or neurotoxicity in CD-I mice, the increased striatal mGlug
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receptor levels observed in WT animals could contribute to this. This appears to be in 
accordance with evidence suggesting that A2A receptor deletion is protective against the 
neurotoxic effects of the amphetamine-derivative, MDMA, whereby the striatal 
inflammatory response induced by MDMA was attenuated in A2A KO mice, despite 
having identical total locomotor activity (Ruiz-Medina et a l,  2011). Therefore, the 
present data, which show A2A receptor deletion prevents mGlus receptor upregulation, 
may reflect a role of A2A in mediating MAP-induced neurotoxicity via an mGlug- 
dependent mechanism; however, additional work would be necessary to investigate this 
further.
4.4.7 Effect o f  acute sub-threshold co-administration o f  A2A antagonist (SCH 58261) 
and mGlus antagonist (MTEP) on methamphetamine-induced locomotor 
responses in WT mice
As detailed in Section 4.1, both the A2A and mGlug receptors have been shown to be 
implicated in modulating MAP/amphetamine-induced locomotor behaviours. It has 
been shown that both A2A KO mice and administration of A2A receptor antagonist SCH 
58261 in WT mice reduced amphetamine-induced hyperactivity and development of 
behavioural sensitisation to amphetamine challenge (Chen et a l,  2003, Bastia et a l,  
2005). In agreement, pharmacological antagonism of mGlu$ receptors with MPEP over 
a dose range of 1 -  30 mg/kg significantly reduces amphetamine-induced locomotor 
behaviour (Pietraszek et a l ,  2004, McGeehan et a l ,  2004, Gormley and Rompre, 2011). 
Despite emerging evidence for a functional A2A-mGlu5 interaction, which has been 
shown to synergistically modulate addictive behaviours (Adams et a l ,  2008, Brown et 
a l, 2011), no evidence exists with regards to this receptor interaction in a model of 
MAP administration.
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In light of our earlier findings, which showed that both MAP-induced rearing (Figure 
4.3B) and upregulation of mGlus receptors (Figure 4.5) were abolished in A2A KO mice, 
it was hypothesised that an A2A-IÏ1GIU5 receptor interaction may be involved in 
mediating the MAP-induced rearing response. As such, the effect of either singular or 
co-pharmacological antagonism of these receptors on MAP-induced locomotor 
behaviours was investigated in WT mice. The results from a dose-response experiment 
showed that pharmacological antagonism of A2A receptors was effective at reducing 
MAP-induced rearing at higher doses (Figure 4.6C), demonstrating that 
pharmacological antagonism of A2A was akin to genetic A2A deletion in producing this 
response. Additionally, pharmacological antagonism of mGlug receptors was also able 
to reduce MAP-induced rearing at higher doses (Figure 4.6D), suggesting that the 
mGlus receptor was also involved in mediating this response. When administered 
singularly at doses of 0.01 mg/kg, neither the A2A antagonist, SCH 58261, nor the 
mGlus receptor antagonist, MTEP, were effective in reducing MAP-induced horizontal 
or locomotor activity, indicating that these doses were sub-threshold for efficacy in this 
parameter. Additionally, pre-treatment of SCH 58261 or MTEP at any dose (data not 
shown), nor their co-administration (SCH 58261, 0.01 mg/kg + MTEP, 0.01 mg/kg. 
Figure 4.7) did not cause motor impairments in saline-treated animals, suggesting the 
effects were specific for MAP administration and not a consequence of altered motor 
ability.
Co-administration of SCH 58261 and MTEP at sub-threshold dose (0.01 mg/kg) elicited 
a striking 60% reduction in MAP-induced rearing behaviour (Figure 4.7B) without 
significantly reducing MAP-induced horizontal hyperactivity (Figure 4.7A), which is in 
complete agreement with the locomotor data observed in MAP-treated A2A KO mice
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(Figures 4.2 and 4.3). This suggests that the reduction in MAP-induced rearing in A2A 
KO mice must involve an interaction with the mGlus receptor and gives support to our 
earlier findings that MAP-induced upregulation of mGlug receptors is A2A-receptor 
dependent (Figure 4.5). These data adds to the growing body of literature which 
indicates that A2A and mGlug receptors can interact to regulate drug-induced behaviours 
and is in agreement with evidence from Adams et al. (2008) who demonstrated that co­
administration of sub-threshold doses of SCH (0.5 mg/kg) and MTEP (0.25 mg/kg) 
were effective in reducing ethanol self-administration and cue-induced reinstatement of 
ethanol seeking in rats.
The fact that co-administration of A2A and mGlus antagonists reduced rearing behaviour 
at doses which were ineffective when administered alone means that lower doses of 
these drugs are required to elicit this response. In fact, the present work showed that co­
administration of both SCH 58261 and MTEP were able to elicit a striking reduction in 
MAP-induced rearing at doses even greater than 10-fold lower than those reported in 
the literature (Coccurello et a l ,  2004, Adams et a l,  2008). As such, this has the 
potential to minimalise off-target effects o f these drugs which are observed when used 
at higher doses. For example, higher doses of both MTEP (10 mg/kg) and SCH 58261 
(3.75 mg/kg) have been shown to increase basal motor activity in rodents 
(Svenningsson et a l ,  1997b, Martin-Fardon and Weiss, 2012), an effect omitted at 
much lower doses (present study). Moreover, designing novel pharmaceuticals to 
specifically target co-localised A2A and mGlus receptors, which may be interacting in a 
receptor heteromer in the striatum, could prevent non-specific activation of these 
receptors at other sites which could lead to undesirable side effects.
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Therefore, the present data suggests that the efficacy and selectivity o f A2A receptor 
antagonists can be improved via co-antagonism with mGlus receptor ligands and this 
may have important implications in the development of more specific, novel bivalent 
therapeutics (e.g. Soriano et a l,  2009). Specifically, this has relevance in the 
management o f the stereotypic effects associated with MAP addiction, however, as 
previously mentioned, A2A antagonism in the treatment of stereotypic behaviours 
associated with other neuropsychiatrie disorders, such as schizophrenia, autism and 
OCD may also be improved via co-administration with mGlus receptor antagonists.
4.4.8 Chapter summary
The present data show for the first time that global deletion or pharmacological 
antagonism of the A2A receptor completely abolished MAP-induced rearing behaviour. 
The genotype-specific effect on MAP-induced vertical, but not horizontal, activity 
indicates a specific role of A2A in mediating MAP-induced stereotypic, but not 
horizontal locomotor activity in CD-I mice. Psychostimulant-induced stereotypic 
behaviour has been shown to implicate the D2 receptor (Feldman et a l,  1997, Glickstein 
and Schmauss, 2004) and although MAP administration did not alter D2 receptor 
density in either genotype, alterations in D2 signalling are plausible. The synergistic 
reduction in MAP-induced rearing behaviour upon co-administration of sub-threshold 
doses of A2A and mGlus receptor antagonists in WT mice, akin to observations o f MAP 
administration in A2A KG mice, provide direct evidence for a functional role of an A2A- 
mGlus receptor interaction in modulating specific behavioural effects of MAP 
administration. This appears to be further supported by the abolition of MAP-induced 
striatal upregulation of the mGlug receptor in A2A KG mice, demonstrating that MAP 
increases mGlus receptors via an A2A-dependent mechanism in the striatum. In short,
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this is the first study to demonstrate that a functional A2A-mGlu5 receptor interaction 
modulates MAP-induced stereotypic behaviour in a model of MAP addiction in vivo. 
The present data therefore, provide a novel target for pharmacotherapy to manage not 
only MAP-induced stereotypic behaviours, but possibly for the management of 
stereotypy in other neuropsychiatrie disorders such as schizophrenia, autism and OCD.
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CHAPTER 5
I n  v i v o  dopamine release following chronic 
‘binge’ cocaine administration in wild-type 
and adenosine A2A receptor knockout mice
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5.1 Introduction
A role of DA in drug addiction was established by early microdialysis studies showing 
that administration o f addictive drugs caused an increase of DA release in the Acb 
(Hernandez and Hoebel, 1988, Carboni et a l,  1989, Mifsud et a l ,  1989, Rada et a l, 
1991). As mentioned in Chapter 2, the mechanism by which cocaine increases the 
synaptic concentration o f DA in the Acb is via blockade o f DA reuptake into 
presynaptic VTA mesolimbic neurons projecting to the Acb. Self-administration of 
cocaine has been shown to increase extracellular DA concentrations in the Acb (Pettit 
and Justice, 1989, Di Ciano et a l,  1995, Pontieri et a l, 1995), indicating that increased 
DAergic release in the Acb drives the positive reinforcement for cocaine-seeking. In 
agreement, self-administration of cocaine was significantly attenuated upon 
administration of DA receptor antagonists (Woolverton, 1986, Richardson et a l,  1994), 
or via 6-OHDA lesioning o f the accumbal DAergic pathways (Roberts et a l,  1980, 
Pettit et a l ,  1984, Zito et a l ,  1985).
In addition, locomotor responses to cocaine are also reported to result in part from drug- 
induced elevations in DA concentrations in the mesocorticolimbic system (Kalivas and 
Stewart, 1991, Kalivas and Duffy, 1993, Robinson and Berridge, 1993, Neisewander et 
a l, 1995). Indeed, blockade of DA receptors in the Acb was shown to decrease the 
locomotor stimulant response to cocaine (Neisewander et a l,  1995, Baker et a l ,  1996), 
and 6-OHDA lesions of the mesocortical DAergic system was shown to enhance both 
cocaine-induced DA concentrations in the Acb and the motor-stimulant response to 
cocaine (Beyer and Steketee, 1999). Furthermore, it is widely accepted that the 
initiation and expression of behavioural sensitisation, the enhancement of locomotor 
activity upon repeated administration of psychostimulants such as cocaine (see Section
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1.1.4), results from drug-induced alterations in DA transmission in the VTA and Acb 
(see Kalivas and Stewart, 1991, Vanderschuren and Kalivas, 2000).
Tonically, adenosine acts as a neuromodulator o f DA transmission in the Acb by acting 
on Ai receptors and A2A receptors to inhibit or stimulate neurotransmitter release 
respectively (Popoli et a l ,  1995, Okada et a l,  1996, Golembiowska and Zylewska, 
1997, Quarta et a l ,  2004). In agreement, microdialysis studies have shown a 
hypoDAergic striatal profile in treatment-naïve A2A KO (Dassesse et a l, 2001), which 
is hypothesised to result from a lack of tonic A2A-mediated extracellular DA release in 
the striatum (Golembiowska and Zylewska, 1997). As such, adenosinergic receptor 
manipulation could influence the effects of addictive drugs via modulation of striatal 
DA neurotransmission. Indeed, it has been shown that pharmacological antagonism of 
the A2A receptor reduced the drug-induced increase in striatal DAergic transmission 
following acute administration of amphetamine (Chen et a l,  2005) and delta-9- 
tetrahydrocannabinol (Justinova et a l, 2011). Moreover, the work of Wells et a l  (2012) 
within our laboratory showed that acute single-dose cocaine (20 mg/kg, s.c.) 
administration in A2A KO mice significantly decreased accumbal DA release compared 
to WT at 100 minutes post-injection, indicating A2A receptors have a role in the 
modulation o f cocaine-induced DA release via a downstream mechanism.
As discussed previously (see Section 1.5.2, Tables 1.2 and 1.3), there is significant 
evidence for a role o f the adenosine A2A receptor in many aspects o f cocaine addiction; 
however, its role in cocaine-induced locomotor sensitisation is not clear. 
Pharmacological evidence has shown that A2A receptor agonism decreased locomotor 
sensitisation to cocaine in rats, an effect which is augmented upon A2A receptor 
antagonism (Filip et a l ,  2006). Conversely, studies in A2A KO mice have shown that the
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development and expression of locomotor sensitisation to cocaine in these mice was 
unaltered (Soria et a l ,  2006), despite having attenuated sensitisation responses to 
amphetamine (Chen et a l,  2003). One reason for the lack of the behavioural 
sensitisation to cocaine observed by Soria et a l  (2006) may be attributable to the 
protocol of cocaine administration. Single daily doses of cocaine, such as those used by 
Soria et a l  (2006), have been considered to lack relevance to the human pattern of 
cocaine administration due to its short, 30-minute half-life. Cocaine users often engage 
in a ‘binge’ pattern of administration, using multiple doses of cocaine over a relatively 
short period of time, and this pattern of administration has been modelled in the chronic 
‘binge’ cocaine administration paradigm (Maisonneuve and Kreek, 1994, Maisonneuve 
et a l,  1995). This administration paradigm, which consists of 3 x 15 mg/kg cocaine 
injections at 1 hour intervals over a 14 day period, has been shown to acutely maintain 
increased DAergic transmission in the striatum, which may contribute to sustaining 
initial cocaine reward (Maisonneuve and Kreek, 1994). Moreover, this paradigm of 
administration has been shown to induce behavioural sensitisation to cocaine in 
C57BL/6J mice (Bailey et a l,  2008, Metaxas et a l,  2012).
Given that the work of Wells et a l (2012), demonstrated a role for the A ia receptor in 
regulating acute cocaine-induced DAergic transmission in the Acb, the aim of the 
present study was to further assess its role in mediating accumbal DA release following 
a paradigm of chronic cocaine administration designed to induce behavioural 
sensitisation. The accumbal DA release following chronic saline or ‘binge’ cocaine 
administration was measured via freely-moving in vivo microdialysis in WT and A%A 
KO mice. Dialysate was analysed for the detection of DA and its metabolites using high
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performance liquid chromatography (HLPC) with electrochemical detection (EC) as 
previously described (Castané et ah, 2008, Wells et ah, 2012).
The work described in Chapter 5 represents a substantial body o f work which was 
undertaken during the first 18 months of this Ph.D., which, due to unforeseen technical 
problems in the dialysate analysis stage has meant that a limited output of results is 
presented.
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5.2 Methods
5.2.1 Animals and treatments
Male, 8-15 week old CD-I wild-type and A2A receptor knockout mice, derived from a 
heterozygous breeding programme were used in this study, as detailed in Section 2.2.1. 
Mice were singularly housed for a period of 7 days prior to study start and throughout 
the whole duration of the study. Mice were habituated to home cages and experimenter 
handling for one week before the start o f experiment. The home cages were in a 
temperature-controlled environment and on a 12 hour light-dark cycle (lights on 07:00). 
Whilst in home cages, mice had access to food and water ad libitum. All experimental 
procedures were conducted in accordance with the UK Animal Scientific Procedures 
Act (1986).
Prior to experimental procedure on each day, mice were removed from their home cages 
at 10:00 am and allowed to habituate to a specially-adapted chamber for 1 hour. The 
chamber was specially-adapted with a freely-moving arm, connected to a dialysate 
fraction collector, to enable the conductance of freely-moving microdialysis on Day 14. 
Following this, mice were treated with a chronic steady-dose ‘binge’ cocaine 
administration paradigm as first described by Maisonneuve et al. (1994). This consisted 
of 3 injections per day at 1-hourly intervals (at 11.00, 12.00 and 13.00 hours) of either 
cocaine (15 mg/kg, s.c.. Sigma-Aldrich, Dorset, UK) or saline (4 ml/kg, s.c.) for 13 days 
prior to surgical procedure on Day 13 to insert a cannula for microdialysis 
measurements. For 1 hour post each injection, mice were placed back into the specially- 
adapted chamber. On Day 14, cannulated mice were habituated for 1 hour to the 
chamber prior to a subsequent 3 injections at 1-hourly intervals (at 11.00, 12.00 and 
13.00) of the same treatment, either cocaine (15 mg/kg, s.c.) or saline (4 ml/kg, s.c.).
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Following each injection, mice were then placed into the adapted chamber and dialysate 
samples were collected throughout. All experimentation was carried out in a 
temperature-controlled environment and in dim light.
5.2.2 Implantation o f  the cannulae fo r  microdialysis
All surgical tools were sterilised in a heated bead steriliser prior to surgery: pointed- 
dissecting scissors, straight graefe forceps, #3 scalpel handle with a #10 scalpel blade, 2 
mm flat-head screw-driver and needle holders (World Precision Instruments Ltd, FL. 
USA). The drill, 4 mm x 0.75 mm jaw vessel clips and 2 mm M l anchor screws 
(Royem Scientific, Bedfordshire, UK) were swabbed or placed in 100% ethanol and 
disposable items, such as cotton buds, were autoclaved.
Approximately 1 hour following completion of cocaine or saline administration on day 
13, mice were anaesthetised with a volatile isofluorane anaesthetic (3.0%) (IsoFlo, 
Abbott Laboratories Ltd, Kent, UK) vaporised in 95% O2 / 5% CO2, with a flow rate of 
-450 ml/min delivered by a U400 anaesthetic unit (Univentor, Royem Scientific, UK). 
The mouse was placed in the anaesthetic unit for 3 -  4 minutes until all righting reflex 
was lost, ensuring the mouse was anaesthetised. The mouse was weighed before transfer 
to the stereotaxic frame and anaesthesia was maintained while in the stereotaxic frame 
and throughout surgery by mask for approximately 45 minutes using (2.5%-2.9%) 
isofluorane at a flow rate of -360 ml/min.
The mouse was placed on a homeothermic blanket with a rectal probe (CMA/150, CMA 
microdialysis, Sweden) to maintain the mouse’s core body temperature at 37.5°C. The 
upper incisors of the mouse were hooked into the tooth-bar allowing the anaesthetic 
mask to be placed over the face. The tooth-bar was adjusted so the dorsal surface of the
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skull was horizontal to the bench, ensuring accuracy and a paw pinch was administered 
to check the required depth of anaesthesia was maintained. The head of the mouse was 
supported in the stereotaxic frame by gentle insertion of ear bars into the ear canals 
either side of the mouse’s head (Figure 5.1). No less than 3.5 mm was left on either side 
of the head to ensure stability whilst avoiding haemorrhage or strangulation due to 
increased pressure from the ear bars.
tereotaxic frame I
Ear bar
Anaesthetic mask
iïÆ ïeat mat
Figure 5.1: Surgical set-up for guide cannula implantation for the facilitation of 
freely-moving microdialysis. Photo courtesy of Ream Al-Hasani.
The eyes of the mouse were protected throughout surgery using tissue dampened with 
sterile water. The head of the mouse was then shaved, the fur was removed and the 
scalp was swabbed with disinfectant to remove any remaining fur and to sterilise the
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area. EMLA cream (5% lidocaine and prilocaine. Vet-tech solutions limited, Cheshire, 
UK) was also applied to the scalp to mildly anaesthetise the area. A 6-10 mm saggital- 
midline incision was made in the scalp with one stroke through the skin exposing the 
coronal and transverse (sagittal) sutures of the skull and their point intersection, the 
Bregma. The periosteum was cleared using sterile cotton buds, allowing the Bregma 
point to be clearly visible. The skin surrounding the incision was secured using vessel 
clips and a small mark was made above the Bregma point. The tip of the drill bit was 
then positioned slightly above the Bregma mark by use of the stereotaxic arms. This 
established the reference point from which ‘zero’ coordinates were ascertained.
The right stereotaxic arm allowed the drill to be moved in the direction of three planes, 
the anterior-posterior plane, the lateral plane, and the vertical plane. The co-ordinates of 
the position of the drill tip were read from the Vernier scales on the anterior-posterior 
and lateral arms of the stereotaxic frame. Vernier scales allowed positioning to an 
accuracy of 0.1 mm. Once the Bregma co-ordinates were determined it was possible to 
target the region of interest, the Acb, at the co-ordinates calculated from a mouse brain 
atlas (Franklin and Paxinos, 1997). The drill was repositioned at the calculated co­
ordinates above the Acb and a small borehole was drilled through the skull to the level 
of the dura. The drill tip was then moved to a clear area of the skull, well below the bore 
hole and used to create a small furrow into which an anchor screw was placed, ensuring 
that the screw did not penetrate the depth of the skull.
The microdialysis MAB4 probe guide cannula (Microbiotech, Royem Scientific, UK) 
was placed into the probe clip positioned on the left stereotaxic arm. The probe was 
aligned with the Bregma point, the co-ordinates were recalculated from the Bregma 
using the left stereotaxic arm and the probe was placed over the target area. The probe
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was then lowered to the level of the dura, the depth was read from the vertical plane and 
the probe was lowered to the required depth. The probe and anchor screws were fixed 
to the skull using cyanoacrylate superglue and fixing agent (RS Components, South 
Africa). Once set, the probe was carefully released from the clip and a further layer of 
glue was applied to secure it. The skin surrounding the probe was pulled over the glue 
and sutured if  necessary.
Upon completion o f the surgical procedure the ear bars were released and the level of 
anaesthesia was reduced (-2.1%  isofiuorane, 215 ml/min air flow). The mouse was 
allowed to recover in a heated recovery chamber until its righting reflex returned. The 
mouse was closely monitored post-surgery and microdialysis did not commence until 
the following day, ensuring the mouse was fully recovered
5.2.3 Conductance o f  freely-moving microdialysis
On the morning of experimentation (day 14), a vial of aCSF and K''’aCSF (Section 
5.2.4) were defrosted and degassed by sonification for 15 minutes. Two 1 ml gas-tight 
microdialysis syringes (Royem Scientific, UK) were flushed three times, and then filled 
to 1 ml with aCSF. One 1 ml gas-tight microdialysis syringe was flushed three times 
and then filled to 1 ml with K^aCSF. All visible air bubbles were expelled. The syringes 
were then mounted on a microinjection pump (CMA/400, CMA microdialysis, 
Stockholm, Sweden) and one syringe of aCSF was used to flush the fiuorinated ethylene 
propylene (FEF) tubing and a liquid switch (Microbiotech, Royem Scientific, UK) at a 
flow rate o f 1 pi per minute to remove any debris or air bubbles. Using FEP tubing, the 
liquid switch was connected via one outlet to the second syringe containing aCSF and 
via another outlet to the syringe containing K^aCSF ready to deliver either solution as 
appropriate.
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FEP tubing was also connected to the inlet of the MAB4 probe (1 mm cuprophane 
membrane with a 6 kDa cut-off and outer diameter o f 0.24 mm), the membrane of 
which was submerged in a vial containing ethanol at a high flow rate (5 -  10 pi per 
minute) for 5 minutes, to remove the protective glycerol coating. The vial of ethanol 
was replaced with a vial of filtered aCSF and perfused with aCSF for a further 5 
minutes to remove any traces of glycerol and air. The probe remained submerged until 
needed. Additional sections of FEP tubing were prepared to connect the liquid switch to 
the swivel on the freely-moving arm for the transport o f aCSF to the mouse and to 
connect the probe to the swivel, and then from the swivel to a microfraction collector 
(CMA/470, CMA microdialysis, Stockholm, Sweden).
The mouse was briefly anaesthetised with isofiuorane inhalation anaesthesia (3% in 
95% 0 2 /5 % CO2 gas mix for 3-4 minutes) so the probe could be inserted into the guide 
cannulae. The animal was placed back in the motility chamber and attached to the 
freely-moving arm via their collar and all FEP tubing was connected accordingly. The 
probe was perfused with aCSF at a flow rate of 1 pl/minute; dialysate was collected for 
2 hours and discarded to ensure a stable basal DA level. Five consecutive dialysate 
fractions were collected at 20 minute intervals to monitor basal DA release. The animal 
was injected with saline or 15 mg/kg cocaine at 11.00, 12.00 and 13.00 hours whilst in 
the motility chamber. Sample fractions were collected at 20 minute intervals 
throughout. The liquid switch was then set to deliver high K^aCSF and a further 5 
sample fractions were collected. All dialysate fractions were collected into polypropene 
sample vials that contained 35 pi of mobile phase and frozen immediately in dry ice. 
The samples were kept frozen at -80°C until analysed by HPLC-EC.
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Upon completion of the experiment the mouse was killed by cervical dislocation and 
trypan blue solution (0.4% Sigma-Aldrich, Dorset, UK) was immediately flushed 
through the probe to aid the location o f the guide cannula and probe tracts. The brain 
was removed and frozen in isopentane with dry ice (-20°C to -30°C) for verification of 
probe placement. All components of the freely-moving microdialysis equipment were 
flushed with sterile water and dried with a bolus of air.
5.2.4 Preparation o f  reagents
The aCSF contained 145 mM NaCl, 2.8 mM KCl, 1.3 mM CaCl and 1.2 mM MgCb 
and was prepared and filtered with a 0.2 pm syringe filter. A further solution of aCSF 
was adjusted to contain a high concentration o f potassium (K^aCSF), which contained
77.5 mM NaCl, 50 mM KCl, 1.3 mM CaCl and 1.2 mM MgCl% and also filtered with a 
0.2 pm syringe filter. Both solutions were prepared in advance of experimentation, 
aliquoted into 10 ml vials and stored at -20°C.
5.2.5 Analysis o f  dopamine levels in microdialysis dialysate by high performance 
liquid chromatography with electrochemical detection
Analysis of DA in dialysate samples were attempted as per the methodology below 
(Section 5.2.5.1 and 5.2.5.2). However, major failure of the HPLC-EC analysis 
attempted both at the University of Surrey and the University o f Roehampton meant that 
dialysate samples were unable to be processed in this way and no results from HPLC- 
EC analysis were achieved. Samples were collected over a period of 18 months and 
stored at -80°C whilst attempting to rectify this problem. Due to the sensitive nature of 
DA, degradation of samples had likely occurred during this time rending the samples 
effectively incomparable. As an alternative, brain DA content analysis via HPLC-EC
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was performed in association with a collaborator at the University of Sao Paulo (see 
Section 5.2.6).
5.2.5.1 High performance liquid chromatography with electrochemical 
detection methodology
HPLC-EC was used to measure the concentration of DA in the dialysate samples 
collected during freely-moving microdialysis. The HPLC system consisted of a pump, 
refrigerated automatic autosampler (set at 4°C, injection volume 50 pi) supplied by 
JASCO (Essex, UK). The pulse dampener and dual potential coloumetric microdialysis 
cell were housed in a separate unit supplied by Presearch (Hampshire, UK) along with a 
GeminiNX C l8 3 pm x 100 mm x 2 mm analytic column (Phenomenex, Cheshire, UK)
and a guard column (Phenomenex, Cheshire, UK). The mobile phase was made of
sodium phosphate, 0.05 M octyl sodium sulphate, 0.8 mM EDTA, 0.1 mM methanol 
10% (v/v), adjusted to pH 3.3 with orthophosphoric acid, filtered through a 0.2 pm 
nylon membrane and degassed with helium before use. The pH of the mobile phase was 
low as DA is easily oxidised in solution. All reagents used for the mobile phase were of 
analytical or electrochemical grade (Fischer Scientific, Leicestershire, UK). The mobile 
phase was allowed to circulate through the HPLC machine at a flow rate o f 0.2 
ml/minute for 2 days prior to use. DA was detected on a dual porous graphite electrode 
system.
5.2.5.2 Preparation and calibration o f  standards
External DA standards were used to calibrate the HPLC-EC application. DA 
hydrochloride (Sigma-Aldrich, Dorset, UK) was dissolved in 10 ml 0.1 M HCl to make
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a 5 mM solution. The flask was protected from light with aluminium foil, vortexed, and 
left to stand at 4°C overnight. The stock solution was filtered through a 0.2 pm 
membrane and divided into 1 ml aliquots which were also protected from light with foil 
and frozen at -80°C until required. Further dilutions were made in ice-cold mobile phase 
when preparing the standard curve. Current-voltage curves were used to determine the 
optimal potential to be applied across the cell to produce a maximal response from DA 
oxidation.
5.2.6 Analysis o f  dopamine content following chronic ‘binge’ cocaine administration 
in brains o f  WT and A 2A KO mice as assessed by high performance liquid 
chromatography with electrochemical detection
Previously stored frozen brains of WT and Aia KO mice used in the present study were 
allowed to slightly defrost on dry-ice. The striatum (Acb and CPu) was dissected from 
the right hemisphere (without microdialysis probe) of each brain. These tissues were 
homogenized in an appropriate volume of 0.1 M perchloric acid, 0.02% EDTA, 0.02% 
sodium metabisulfite using an ultrasonic cell disrupter (Cole-Parmer, Vernon Hills, IE, 
USA). Samples were then centrifuged (45 min, 4°C, 14,000 r.p.m.) and passed through 
a 0.22 pm syringe filter.
Samples were then transported on dry-ice to a collaborative laboratory in Brazil 
(University of Sao Paulo) for HPLC-EC analysis. Dopamine was separated by a mC18 
column (250 mm length x 4.5 mm diameter and 5 mm particle size shim-pack; CLC- 
ODS, Shimadzu) with an isocratic gradient using a HPLC system (Shimadzu Co., 
Japan, model LC-IOVP) coupled to an electrochemical detector (Hewlett Packard, 
Germany, model 1049A) with a glass-carbon electrode set at 0.65V versus a solid-state
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Ag/AgCl reference electrode. The mobile phase consisted of 50 mM Na2HP0 4 , 1.2 mM 
heptane-1-sulfonic acid, 0.2 mM EDTA and methanol (5% v/v in deionized water), pH 
2.6. Peaks were identified by comparison with the retention time of injected standards. 
The amount of DA in each sample was estimated by measuring the peak area relative to 
the peak areas obtained with known picogram amounts o f the standards. Standards were 
purchased from Sigma-Aldrich, and other HPLC-graded reagents were purchased from 
Merck (Sao Paulo, Brazil).
5.2.7 Autoradiographic confirmation o f  adenosine A 2A receptor genotype in WT and 
A 2A KO mice used in microdialysis experiments
Confirmation of A2A genotype status was carried out as described in Section 2.2.4 on 
striatal sections cut from the remaining left hemisphere (containing microdialysis probe) 
of each brain.
5.2.8 Data analysis
All graphs were produced using GraphPad Prism V5.04 software (GraphPad Software 
Inc., USA). All statistical analysis was carried out using Statistica V I0 software 
(StatSoft Inc., USA). The mean ± SEM of DA concentration (ng DA/mg protein) was 
calculated in each treatment group in both genotypes. Two-way ANOVA was used to 
assess differences between genotype and treatment, followed by Unequal N  Tukey post- 
hoc test where appropriate.
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5.3 Results
5.3.1 Autoradiographic binding o f  the adenosine A 2A receptor in WT and A 2A KO mice 
used in microdialysis experiments
Striatal sections from the brains of each experimental animal were bound with the 
radiolabelled A2A receptor agonist [^H]CGS 21680 to confirm that the genotype 
determined by the PGR and DNA electrophoresis procedures were correct. In this 
experiment, the genotype of all animals determined by PGR was correct when validated 
with receptor autoradiography.
5.3.2 Analysis o f  dopamine content in striatum following chronic ‘binge’ cocaine 
administration in WT and A 2A KO mice
Analysis of the data by 2-way ANOVA showed that in comparison to WT, A2A KO 
mice tended to have higher striatal DA concentration (genotype effect, F (ij2) = 11.94, 
P<0.01, Figure 5.2) and this was higher in saline-treated A2A KO mice compared to WT 
(genotype x treatment interaction, F(i,i2) = 5.53, P<0.05). No effect o f treatment was 
observed (P>0.05). Post-hoc analysis showed that in comparison with WT saline treated 
animals, striatal DA content was significantly higher in saline-treated A2A KO mice 
(P<0.05) although no difference in genotype was observed following cocaine treatment 
(P>0.05).
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Figure 5.2: Brain concentration of dopamine following chronic saline or chronic 
‘binge’ cocaine administration in wild-type and adenosine Aia receptor knockout 
mice. Striatal dopamine (DA) concentration expressed as mean ± SEM [DA] ng/mg protein content 
(n=3-4) in homogenated striatal brain samples in wild-type (WT) or adenosine A2A receptor knockout 
(KO) mice treated with injections of either chronic saline or cocaine (3x15 mg/kg, s.c.) for 14 days. A 
significant effect of genotype (P<0.01) and a significant genotype x treatment interaction (f<0.05) were 
observed (2-way ANOVA). *f<0.05 vs. WT Chronic saline (Unequal A Tukey post-hoc test).
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5.4 Discussion
The genotype o f all mice used in this study was confirmed ex vivo by radiolabelling 
striatal brain sections with [^H]CGS 21680. In this experiment, receptor 
autoradiography showed that the genotypes of all animals determined by PGR were 
correct.
5.4.1 Analysis o f  striatal dopamine content following chronic ‘hinge’ cocaine
administration in WT and A 2A KO mice
Originally, the present study was designed to assess the difference in extracellular 
striatal DA in response to a chronic ‘binge’ cocaine paradigm in WT and A2A KO mice 
using in vivo freely-moving microdialysis. Due to unforeseen technical difficulties over 
a period of 18 months, analysis o f dialysate samples was not possible. As an alternative 
measure, the striatum of these mice were homogenised and analysis o f DA content was 
determined by HPLG-EG analysis in a collaborative laboratory.
The present data showed the DA content of saline-treated A2A KO mice was 
significantly higher than in the striatum of saline-treated WT mice (Figure 5.2). It has 
been shown that extracellular levels of DA were significantly lower in the striatum of 
A2A KO mice compared to WT, as assessed by freely-moving microdialysis (Dassesse 
et al., 2001). This suggests that the increased DA content observed in the striatum of 
A2A KO mice in the present study is likely to be intracellular. The mechanism for this 
appears not to be due to either deficits in DA reuptake or synthesis, as both DA 
transporters (Ghen et al., 2000) and the level of tyrosine hydroxylase, an enzyme 
involved in DA synthesis (Dassesse et al., 2001) are not significantly altered in A2A KO 
mice compared to WT. Instead, it is likely that the deletion of the A2A receptor produces
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a deficit in DA release leading to increased intracellular DA storage. Microdialysis 
studies have shown that striatal DA release is mediated by A2A receptors as 
pharmacological antagonism of the A2A receptor reduces, and agonism increases, striatal 
DA release (Zetterstrom and Fillenz, 1990, Okada et ah, 1996, Golembiowska and 
Zylewska, 1997). This is also in agreement with the striatal hypoDAergic phenotype of 
A2A KO mice (Dassesse et a l ,  2001). However, the mechanism by which A2A receptors 
modulate DA release has not been fully elucidated. As mentioned in Section 4.4.4, A2A 
receptors are not expressed presynaptically in DAergic terminals (Hettinger et a l,  
2001), therefore do not have a direct modulatory function on DA release. However, A2A 
receptors are located presynaptically in glutamatergic terminals (Hettinger et a l ,  2001) 
and endogenous glutamate release has been shown to increase extracellular DA release 
(Segovia et a l,  1997). In agreement, perfusion of CGS 21680 in the striatum also 
causes an increase in striatal glutamate release (Golembiowska and Zylewska, 1997, 
Quarta et a l ,  2004, Rodrigues et a l ,  2005), suggesting modulation o f glutamate by A2A 
could indirectly affect DA release in the striatum.
Acute cocaine administration elevates extracellular DA in the striatum (Di Chiara and 
Imperato, 1988) and it has been shown that following an identical pattern o f chronic 
‘binge’ cocaine administration in C57BL/6J and 129/J mice striatal DA release 
(expressed as percentage of baseline) is further elevated (Zhang et a l ,  2003). In the 
present study however, there was no significant treatment effect on the striatal DA 
content following chronic cocaine administration, which is in agreement with Zahniser 
et al. (1988). Although chronic cocaine administration appeared to reduce striatal DA 
content in A2A KO mice, this was not statistically significant. Moreover, following 
cocaine treatment, there was no significant difference in striatal DA content between
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A2A KO and WT mice. This is in agreement with the lack of genotype effect on cocaine- 
induced locomotor activity in these mice as shown in Chapter 2 (Figures 2.3B and 
2.4B), which is generally thought to be at least partly driven by DA release (see Section 
1.3.3). Additionally, this also appears to be in agreement with data from our laboratory, 
which showed that acute cocaine-induced (20 mg/kg, s.c.) elevations in striatal DA were 
not altered between A2A KO and WT mice during the first 60 minutes post injection 
(Wells et a l,  2012), at which point a subsequent injection of cocaine was administered 
in the present ‘binge’ paradigm.
In summary, the present data are in accordance with the literature, supporting a role of 
A2A in the mediation o f tonic striatal DA release. However, following chronic cocaine 
administration, which is known to alter striatal DAergic transmission (Maisonneuve et 
a l, 1995, Pierce et a l,  1996, Zhang et a l,  2003), the ability of A2A to mediate DA 
release is probably diminished. This supports our earlier conclusion that A2A receptors 
are not involved in mediating the locomotor response to cocaine ‘binge’ cocaine 
administration in CD-I mice.
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CHAPTER 6
General Discussion
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6.1 General discussion
The nucleoside purine, adenosine, has an important role in drug addiction. In particular, 
actions of adenosine at the A2A receptor have been identified as significant in the 
behavioural responses to drugs of abuse, such as cocaine, morphine and 
methamphetamine (MAP), which is likely attributable to the high density of A2A 
receptors in the striatum. Over the last ten years, evidence has emerged identifying that 
in addition to the well-documented A2A-D2 receptor interaction in the striatum, a 
functional interaction exists between striatal A2A and mGlu$ receptors, whereby they are 
hypothesised to act synergistically to overcome D2 receptor mediated responses. In 
physiological models, an A2A-mGlu5 receptor interaction has been demonstrated at both 
the molecular (Popoli et a l ,  2001, Ferre et a l,  2002, Nishi et a l ,  2003) and 
transmission levels (Diaz-Cabiale et al., 2002, Rodrigues et al., 2005) and has shown to 
be significant at the behavioural level in pathophysiological disorders of the basal 
ganglia, such as Parkinson’s disease (Coccurello et a l,  2004, Kachroo et a l,  2005). 
More recently, evidence has emerged indicating these receptors can also synergistically 
interact to regulate both alcohol-seeking and cue-induced reinstatement to alcohol 
(Adams et a l,  2008) and also the conditioned effects of cocaine (Brown et a l ,  2011), 
implying that an A2A-mGlu5 interaction is relevant in drug addiction. However, little is 
knovm about the mechanism underlying the A2A-mGlu5 receptor interaction and how it 
may be altered in the process of drug addiction. Furthermore, the findings of Adams et 
a l (2008) and Brovm et a l (2011) raise questions regarding the nature of an A2A-mGlu5 
receptor interaction in other types of drug addiction, and at which stages o f addiction its 
contribution may be relevant.
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Therefore, the aim of the present work was to test the hypothesis that adenosine A2A 
receptors modulate the behavioural and neurochemical responses to chronic 
administration o f several addictive drugs by means of A2A receptor interactions with D2 
and mGlus receptors.
6.1.1 Evidence fo r  a physiological A 2A-mGlu5 receptor interaction
The present work demonstrated for the first time that an A2A-IÏ1GIU5 interaction exists at 
the receptor level, as deletion of the A2A receptor in treatment-naive mice caused a 
decrease in mGlus receptor binding specifically in the ventral striatum, an area rich in 
both A2A and mGlus receptors. This adds to evidence which shows that A2A and mGlus 
receptors can interact to regulate actions of the striatum, such as DAergic transmission 
and motor control and therefore has implications for the regulation of physiological 
processes involving the basal ganglia.
Moreover, the specificity of this interaction in the striatum could lead to increased 
selectivity o f drug action for basal ganglia disorders such as Parkinson’s disease, where 
A2A receptor antagonism has been shown to be of therapeutic benefit due to blockade of 
A2A receptors in the striatum. Taking advantage of the specific striatal co-localisation of 
A2A and mGlus receptors could lead to the development of novel bivalent ligands (e.g. 
Soriano et a l, 2009) to reduce unwanted side effects associated with pharmacological 
global targeting of A2A receptors, particularly given their prominent location also in the 
periphery.
6.1.2 A 2A receptor modulation o f  mGlus receptor expression
The most striking finding of this work was the drug-specific modulatory effect o f the 
A2A receptor on the regulation of brain mGlus receptors, suggesting that the mechanism
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of action of these drugs has a discernible effect on an AiA-mGlus receptor interaction. 
Chronic administration of MAP, but not cocaine or morphine, modulated striatal mGlu$ 
receptor expression via an AiA-dependent mechanism, as MAP-induced increases in 
WT striatal mGlus receptor binding Avere completely abolished in A2A KO mice. In 
addition to further emphasising a role of the A2A receptor in mediating striatal mGlus 
receptor expression, this finding supports a growing body of evidence for an A2A-mGlu5 
receptor interaction in modulating the chronic effects of drugs o f abuse and 
demonstrates for the first time the existence of an A2A-mGlu5 receptor interaction in a 
model of MAP addiction.
Although there were no changes in the striatal modulation of mGlug receptors following 
chronic morphine administration in A2A KO mice, increases in receptor binding were 
observed in the thalamus, which was not observed following cocaine or MAP 
administration. This clearly points towards the antinociceptive actions of chronic 
morphine administration and tentatively implies that an A2A-niGlu5 interaction may 
have relevance in the management of morphine antinociceptive tolerance. The present 
study was not designed to assess the nociceptive responses of these mice following 
chronic morphine administration, but it would be interesting to see whether an A2A- 
mGlus receptor interaction has a role in mediating such behaviour, particularly given 
recent evidence of a direct mGlug-MOPr interaction in vitro (Schroder et ah, 2009).
6.1.3 The stereotypic effects o f  chronic methamphetamine, but not cocaine or 
morphine administration is A2A receptor dependent
The present work identified that stereotypic behaviour induced by chronic 
administration of MAP, but not cocaine or morphine, was A2A receptor dependent, as 
the MAP-induced rearing behaviour evident in WT mice was completely abolished in
214
Aia KOs. Notably, A2A KO mice displayed no differences in cocaine-induced rearing, 
nor the hyperactive responses to cocaine or MAP administration. This provides further 
support for a role of the A2A receptor in modulating the behavioural responses to drug of 
abuse and suggests its action is drug-dependant.
It is likely that the striking difference in the stereotypic rearing response to the 
psychostimulants cocaine and MAP in A2A KO mice is attributable to a role o f A2A 
receptor in the facilitation of DA release in the striatum (Okada et a l ,  1996, Sebastiao 
and Ribeiro, 1996, Dassesse et a l,  2001), as we hypothesised that high DAergic 
stimulation at a specific anatomical location in the striatum is responsible for the 
manifestation of MAP-induced rearing. The difference in behaviour elicited between 
MAP and cocaine may therefore be related to the magnitude of DA release. Cocaine 
increases extracellular striatal DA by blocking DA transporters, thereby preventing DA 
reuptake. However, MAP can facilitate DA release not only by blockade of the DAT 
but also through facilitation of vesicular DA release (Sulzer et a l,  2005). Microdialysis 
studies have shown that administration of cocaine and MAP differentially affects DA 
release in the striatum, whereby MAP almost doubles the percentage increase in 
accumbal DA in comparison to cocaine (Zhang et a l,  2001). The present studies 
identified that following cocaine administration the striatal DA content, likely 
intracellular, was not significantly different between WT and A2A KO mice, which was 
in agreement with the lack of genotype effect on cocaine-induced locomotor responses. 
Further work, however, is required to investigate the underlying neurobiological 
mechanisms responsible for MAP-induced rearing in CD-I mice and the role of A2A and 
mGlus receptors in modulating this response. In particular, the effect of A2A and mGlus
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receptor antagonism and co-antagonism on MAP-induced DAergic and glutamatergic 
transmission in both the ventral and dorsal striatum of CD-I mice would be of interest.
The present study used rearing behaviour as an indicator of stereotypy; however, further 
work is required to fully understand the translational meaning of this behaviour. 
Chronic MAP administration can also cause the emergence of a persistent psychotic 
syndrome in humans and amphetamine-sensitisation is a widely used animal model for 
psychosis (Robinson and Becker, 1986). Indeed, polymorphisms in the A2A receptor 
gene have been associated with increased vulnerability to MAP-induced psychosis 
(Kobayashi et a l,  2010). Although, whilst there is no direct evidence which has 
investigated a link between rearing behaviour in mice with psychosis, a similar 
rearing/climbing behaviour is elicited upon administration o f the Di and D2 receptor 
agonist, apomorphine, in rodents. This behaviour is thought to be mediated by the 
mesolimbic DA system and the ability of a drug to antagonise apomorphine-induced 
climbing has been correlated with antipsychotic potential (Protais et a l ,  1976). Thus, it 
is plausible that the MAP-rearing behaviour presently observed is linked with a 
psychotic-like state. As such, it would be interesting to utilise the apomorphine 
climbing assay following MAP-administration in WT and A2A KO mice and to assess 
the effect of administration of a typical antipsychotic, such as the D2 antagonist 
haloperidol, on mediating this behaviour. This is of particular relevance given the 
proposed A2A-D2-mGlus receptor oligomer (Cabello et a l ,  2009) and the demonstration 
of an A2A-mGlu5 interaction in modulating D2-mediated effects (Ferre et al., 2002, 
Diaz-Cabiale et al., 2002).
In short, these findings indicate a therapeutic relevance for the use of A2A receptor 
antagonists in the management of stereotypic effects of MAP addiction and possibly
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MAP-induced psychosis. In addition, A2A antagonism may also be of benefit in the 
treatment of similar repetitive behaviours which emerge in neuropsychiatrie disorders 
such as autism, OCD and schizophrenia.
6.1.4 An A 2A~fnGlu5 receptor interaction modulates methamphetamine-induced 
stereotypic rearing
The suppression of both MAP-induced striatal-specific mGlus upregulation and rearing 
behaviour in A2A KO mice pointed toward a striatal A2A-mGlu5 receptor interaction in 
the mediation of this response. This was confirmed by observations that 
pharmacological antagonism of either the A2A or mGlug receptor in WT mice was able 
to reduce the MAP-induced rearing response. More importantly, co-administration of 
these ligands at doses pharmacologically ineffective at reducing rearing behaviour 
caused a significant 60% reduction in MAP-induced rearing. Although the anatomical 
substrate of this interaction can only be confirmed via intracerebroventricular A2A and 
mGlus antagonist administration, the present autoradiographical evidence, high density 
of striatal A2A and mGlug receptors and the prominent role of the striatum in the 
regulation of motor behaviour, strongly suggest that MAP-induced rearing is dependent 
on a striatal A2A-mGlu5 receptor interaction.
Taken together, the present work has shown that use of A2A antagonists may be 
beneficial in the management of MAP addiction, and suggests they may also be relevant 
for the treatment of stereotypic behaviours which are symptomatic o f neuropsychiatrie 
disorders such as autism, OCD and schizophrenia. More importantly, we have shown 
that co-antagonism with mGlus receptors could improve both the efficacy and 
selectivity o f A2A antagonists in such treatments, due to selective striatal targeting of 
these receptors at sub-threshold doses. Again, improving the selectivity and efficacy of
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A%A antagonists via their co-administration with mGlus receptor antagonists has 
particular relevance for the development of more effective anti-Parkinsonian 
pharmacotherapy with fewer o f f  target effects.
6.1.5 Overall conclusion
Collectively, the results described in this thesis show that the contribution of the A2A 
receptor in mediating the stereotypic response to chronic drug administration is drug 
specific, as is the ability of A2A to regulate mGlug receptor binding. Specifically, the 
therapeutic relevance o f the novel A2A-mGlu5 interaction identified following chronic 
MAP treatment merits further investigation as it adds to a growing body o f evidence 
which infers that simultaneous targeting of A2A and mGlus receptors has implications 
for the improved efficacy of treatments for basal ganglia disorders.
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